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Abstract 
Mucosal surfaces offer a potential for non-invasive delivery of proteins. The role of 
these surfaces, however, is to limit the movement of material from the external 
environment (mucosal lumen) into systemic circulation. Mucosal absorption of 
protein therapeutics is constrained through several physiological barriers such as 
mucus and mucociliary clearance, protease enzymes, epithelial tight junctions (TJs) 
and cellular membranes. This work explores different strategies with the view to 
improving the transport of macromolecules (proteins and protein drug models) across 
polarised epithelial cell layers in vitro, which could potentially be a reflection of 
improved mucosal absorption and bioavailability in vivo. The Calu-3 cell line was 
used in this work to produce such layers, serving as an in vitro model of the airway 
epithelium. Following growth of Calu-3 cells on filters under air-interface culture 
conditions polarised layers of closely packed cells were formed. The cell layers 
exhibited a TEER ≥500 Ωcm
2
 and cells showed structural features similar to the 
native epithelium, including the TJs, the microvilli and the secretory granules. Cell 
layers presented a barrier to the permeability of FITC-dextrans (FDs, paracellular 
markers) and nanoparticles (NPs). 
 
The first class of tested compounds, namely alkylglycoside (AG) surfactants, 
exhibited severe toxicity at concentrations considerably lower than those used in the 
literature. Data indicated that the cellular toxicity of AGs possibly results from a 
membrane effect. Investigation of calcium depletion as a proposed strategy to 
improve mucosal absorption of protein therapeutics, revealed that calcium depletion 
on the apical side produced limited TJ opening, as demonstrated by reversible 
decrease in transepithelial electrical resistance (TEER) and modest enhancement of 
 ii 
permeability of macromolecules. Although combined apical and basolateral calcium
 
exhaustion produced significant effects on TJs, this scenario becomes irrelevant in an 
in vivo situation. Application of chitosan in the form of solution and NPs to Calu-3 
layers demonstrated that chitosan NPs formulated by the ionic gelation method, 
exhibit a similar TJ-opening effect to solution. This was shown by similarities in 
measurable indicators of TJ opening such as reduction in TEER and enhancement of 
dextran permeability across the cell layers. Furthermore, chitosan NP and solution 
exhibited similar effects on the TJ protein, Zonula Occludens-1. These results 
therefore indicated that chitosan NPs could potentially be used to carry and protect 
fragile therapeutic proteins to the mucosal surface(s) of interest and at the same time 
promote their absorption through TJ opening.  
 
TJ opening as a strategy to improve mucosal absorption of macromolecular 
therapeutics is rather inefficient for larger proteins such as antibodies, or for nano-
sized drug carriers following their mucosal administration; this led to investigation of 
the IgG/neonatal Fc receptor (FcRn) transcytotic pathway. Immunostaining data 
demonstrated that Calu-3 cells express FcRn. IgG was shown to traverse the Calu-3 
layers and studies characterizing this transport indicated FcRn involvement in this 
process. Confocal microscopy revealed that IgG- or Fc-adsorbed NPs were taken up 
by Calu-3 cells. Adsorption of Fc on the surface of NPs was seen to promote their 
cellular uptake and transport across the cell layers. Characterisation of cell uptake and 
transport of Fc-NPs revealed data that strongly suggested FcRn involvement in these 
processes.  
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Chapter 1 
Mucosal Delivery of Protein Therapeutics  
 
1.1 Why deliver protein therapeutics mucosally? 
The development of drugs based on biotechnology products is a rapidly expanding 
area within the pharmaceutical industry. A recent report by the Pharmaceutical 
Research and Manufacturers of America (PhRMA) states that in 2008 there were 633 
biotechnology medicines ('biologics') in development, for more than 100 diseases (1). 
A large proportion of these are therapeutics based on different proteins, including 
monoclonal antibodies and recombinant hormones (Figure 1.1). The United States 
Food and Drug Administration (FDA) has so far approved more than 130 proteins and 
peptides for therapeutic purposes (2). The growth in protein drugs (and biologics in 
general) is unfortunately not matched by developments of effective and convenient 
delivery systems for this class of therapeutics. Currently, protein drugs are 
predominantly administered parenterally. This is due to their high molar mass, 
hydrophilicity and their inability to withstand the environment in the gastrointestinal 
tract, resulting in an inadequate absorption and hence poor bioavailability following 
oral administration. However, disadvantages associated with the parenteral route, 
including patient discomfort and high cost, necessitate research into alternative ways 
of administering this class of therapeutics. 
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Figure 1.1. Different classes of biologics in development in 2008. Adopted (and modified) from 
PhRMA [1]. 
 
Arguably, the withdrawal of the pulmonary-delivered insulin, Exubera
¨
, from the 
market in 2008 resulted in the shutdown of many research projects on pulmonary 
delivery of proteins in the pharmaceutical industry (3). However, as will be discussed 
later, non-parenteral delivery of protein drugs is still being explored by researchers in 
academia and the pharmaceutical industry and many interesting developments have 
been made. Examples of technologies, their associated companies and therapeutic 
proteins/peptides under development are listed in Table 1.1. 
44 
23 
38 
5 
16 
10 
192 
66 
223 
16 
Others 
Cell Therapy 
Gene Therapy 
Growth Factors 
Interferons 
Interleukins 
Monoclonal Antibodies (mAb) 
Recombinant Hormones/Proteins 
Vaccines 
Antisense 
Biologics in Development: Product Category 
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Delivery pathway Oral Pulmonary Nasal Buccal 
Technologies 
(associated companies) 
Eligen
¨
 (Emisphere) 
LPM
TM
 (DOR Biopharma) 
Spheromers
TM 
PIN
TM
 (Spherics) 
Polymer/Bioadhesive 
platform (Coremed Inc.) 
Promaxx (Baxter Healthcare 
Corporation) 
Technosphere
¨
 (MannKind 
Corporation) 
MicroDose Electronic dry 
powder inhaler (MicroDose 
Therapeutx) 
Polymer/Bioadhesive 
platform (Coremed Inc.) 
CPE-215
¨
 (CPEX 
Pharmaceuticals) 
Intravail
¨
 (Aegis Therapeutics) 
Thiomers (ThioMatrix) 
Rapidmist
TM
 
(Generex) 
Thiomers 
(ThioMatrix) 
 
Therapeutic 
proteins under 
investigation 
(associated companies) 
 
Insulin (Oramed) 
Salmon calcitonin, heparin, 
glucagon-like peptide-1 
(GLP-1), insulin, human 
growth hormone (Emisphere) 
Insulin (Extrawell) 
Insulin (Diabetology Ltd.) 
Leuprolide (DOR Biopharma) 
Nodlin and Nodexen (NOD 
Pharmaceuticals Inc.) 
 
Insulin, PTH, salmon 
calcitonin, GLP-1 
(MannKind Corporation) 
Insulin (Microdose 
Therapeutx) 
Insulin (Coremed Inc.) 
 
Insulin (CPEX Pharmaceuticals, 
Inc.) 
Insulin, GLP-1 (MDRNA) 
Insulin, salmon calcitonin, PTH, 
and desmopressin (Unigene) 
GLP-1 (Amylin) 
 
Insulin (Biodel Inc) 
 
Marketed products 
(associated companies) 
 
Minirin
¨
 (Ferring) 
Nocutil
¨
 (Gebro Pharma) 
 
None known 
 
Miacalcin
¨
 (calcitonin, Novartis) 
Minirin
¨
 (desmopressin, Ferring) 
Suprecur
¨
 (Sanofi-Aventis) 
Fortical
¨
 (Unigene) 
 
 
Oral-lyn
TM
 (India) 
(Generex) 
 
Table 1.1 Examples of delivery technologies and therapeutic proteins currently being investigated/marketed for mucosal administration by the Pharmaceutical Industry. 
For more information the reader is referred to companies' websites. Table modified from Moeller et al. (3)  
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1.2 Crossing the mucosal barriers: possible pathways  
While some small, amphipathic molecules have the ability to partition into and out of 
lipid bilayer membranes (apical and basolateral) allowing them to readily enter and 
leave the epithelial cells without a specific transport system (Figure 1.2a), the 
transport of smaller hydrophilic macromolecules is limited to the paracellular route 
(i.e. between adjacent cells; Figure 1.2b). Larger macromolecules and nano-sized 
particles can also be transported across the cells via transcytosis route through a series 
of vesicular structures (Figure 1.2c). However, the organization and movement of 
these vesicles is highly regulated to minimize the non-selective transport of 
macromolecules into and out of the body (4).  
 
Figure 1.2. Possible pathways for translocation of molecules and nanoparticles across the mucosal 
surfaces. a) Trancellular route, applicable to small, lipophilic molecules, b) Paracellular (between 
cells) route, relevant to relatively small, hydrophilic macromolecules, and c) Transcytosis (which 
may be receptor mediated), through which large macromolecules and nanoparticles can potentially 
traverse the mucosal surfaces. 
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1.3 Barriers to mucosal absorption 
Successful delivery and systemic absorption of protein therapeutics following 
mucosal administration requires several biological barriers to be overcome. Using the 
airway mucosa as an example, these barriers are presented schematically in Figure 
1.3. 
 
Figure 1.3. Barriers to mucosal drug absorption. In mucosal surfaces such as nasal and bronchial, 
columnar ciliated epithelial cells are interconnected by tight junctions. Cells are covered by a layer 
of mucus, which is normally secreted by goblet cells (not included in the schematic). Cilia beat in a 
synchronized fashion, resulting in unidirectional movement of mucus (represented by the gray 
arrow). This mucociliary clearance mechanism clears the mucus-trapped material (which may 
include administered drugs) from the mucosal surfaces. 
 
Drug absorption across the mucosal surfaces is in some cases affected by mucus (5) 
and a functional mucociliary clearance mechanism. For example, in the nasal mucosa 
the mucociliary mechanism clears 50% of the administered dose (applied as a spray) 
from its ciliated respiratory mucosa within 15-20 minutes (6). The presence of 
proteases that may degrade the administered protein drug is also an important barrier 
limiting the availability of peptides and proteins at the mucosal surface and hence 
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their absorption (7). Finally, the existence of tight junctions (TJs) between adjacent 
epithelial cells, limits the permeability of macromolecules larger than approximately 
1000 Da (8, 9). Transcellular movement (i.e. through individual epithelial cells) of 
hydrophilic macromolecules on the other hand is severely limited due to the physico-
chemical nature of epithelial cell plasma membranes (5). The restriction of drug 
movement and mucosal absorption presented by mucus and the TJs is discussed in 
detail below.  
 
1.3.1 The mucus barrier 
The mucus barrier is essential in protecting vulnerable surfaces in the respiratory, 
intestinal, eye and reproductive tissues from invasion by foreign agents including 
bacteria, viruses, allergens and irritants. Furthermore, mucus also acts as a lubricant, 
aiding functions such as blinking and movement of food through the digestive system. 
 
The mucus gel is mainly composed of linear, glycosylated mucin fibers entangled into 
a dense network (10, 11). The combination of mucin fiber composition and its 
architecture results in strong interactions between mucus and foreign molecules, 
severely inhibiting or hindering their movement through the gel (12, 13). 
 
Factors affecting the rate of drug diffusion through mucus include the relative size of 
the drug molecule, the effective mesh size of the mucus gel and interactions between 
the drug and the components of mucus (14). It was long thought that the mucus 
barrier prevents the uptake of large molecules primarily by hindering their diffusion, 
with an inverse relationship between molecular weight and diffusion coefficient of the 
drug frequently reported (14). However, it is now known that most proteins, including 
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large antibodies diffuse easily through mucus (15). For example, Saltzman et al. (16) 
found that the diffusion of antibodies through human cervical mucus is relatively 
unimpeded, with antibodies diffusing through the mucus almost as readily as in water. 
This is thought to be because the mesh size of mucin fibres within mucus 
(approximately 1 µm) is much larger than most proteins (16). 
 
In contrast to macromolecules, there is strong evidence that mucus presents a 
considerable barrier to the movement of nanoparticles (NPs) (17). In an attempt to 
improve their transport through mucus, Wang et al. (18) recently attached PEG on the 
surface of NPs and measured their diffusion rate in cervicovaginal mucus. The 
authors coated the surface of negatively charged 220 nm diameter polystyrene 
particles, which normally exhibit poor diffusion in mucus, with differently sized PEG, 
at different densities. Coating of the particles with short-length PEG at high density 
resulted in neutralisation of the particlesÕ negative surface charge, which afforded 
diffusion in mucus gel at a rate just ten times slower than in water. Reduction of PEG 
coating density on the surface of particles decreased the rate of particle transport, 
which was explained by less effective screening of the negative charge of the particle 
surface resulting in binding of particles to mucin fibres. The results of this study 
therefore suggested that particle transport in mucus could potentially be improved by 
a net neutral surface to avoid binding, and a small radius to avoid entanglement with 
the mucin network.  
 
Lai et al. (17) further demonstrated that large NPs, if properly coated, can rapidly 
penetrate human mucus. In this study the authors used high-speed multiple particle 
tracking to quantify transport rates of different particles in samples of fresh human 
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cervicovaginal mucus. PEGylated NPs of 500 nm and 200 nm in diameter were found 
to diffuse through mucus with an effective diffusion coefficient only 4- and 6-fold 
lower than that for the same particles in water (the diffusion coefficient of uncoated 
particles of 100Ð500 nm diameter was 2,400- to 40,000-fold lower in mucus than in 
water). Interestingly, the rate of particle diffusion in mucus was enhanced more for 
larger PEGylated NPs of 200 nm and 500 nm than for smaller, 100 nm particles. 
 
In another study, Cu et al. (19) examined the effect of immobilization of PEG with 
different molecular weight (2, 5 and 10 kDa) onto the surface of poly(lactic-co-
glycolic)acid (PLGA) NPs (170 nm diameter) at a range of densities from 5-100% on 
diffusion in cervical mucus. The reported observations indicated that incorporation of 
PEG onto the surface of particles enhanced the diffusion of particles in cervical 
mucus (diffusion of PEGylated particles was 3- to 10-fold higher than that of 
unmodified particles), in addition to improving particle dispersion and neutralizing 
the surface charge. Particle diffusion in mucus was strongly dependent on the 
molecular weight of PEG and the coating density.  
 
While the studies discussed above demonstrated that PEGylation improved the 
transport of NPs through mucus, Huang et al. (20) have shown that grafting of PEG 
increases the mucoadhesiveness of acrylic-based hydrogels, sticking to mucus strands 
in a way that would inhibit transport. Whether PEGylation facilitates transport 
through the mucus gel or provides mucoadhesion seems to be an effect of its 
molecular weight, coating density and the structure to which it is attached (e.g. 
nanoparticle versus polymeric hydrogels).   
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1.3.2 Intercellular Tight Junctions 
The intercellular tight junctions (TJ) encircle the epithelial cells in a belt-like manner 
at the apical cellular borders (21), separating the membrane surfaces of these cells into 
the apical and basolateral regions. The homotypic contact made by TJs across the 
intercellular spaces between the adjoining epithelial cells (22, 23) provides a 
structural barrier against paracellular permeation (24, 25), maintaining the restrictive 
barrier of the mucosae. The TJs regulate the passage of ions, water and molecules 
through the paracellular pathway (26). Furthermore the TJs limit the diffusion of 
proteins and lipids between the apical and basolateral domains of the plasma 
membrane (27) and recruit cytoskeletal and signaling molecules involved in cell 
polarity, growth, differentiation and apoptosis (28). 
 
TJs are observed by Electron Microscopy as a series of fusion points (sometimes 
referred to as 'kissing points') between the outer leaflets of the membrane of the 
adjacent cells. Structural components of the TJs include the transmembrane proteins 
such as claudins, occludin and junction adhesion proteins, as well as cytoplasmic 
plaque proteins including zonula occludens-1/2/3, cingulin and 7H6 (29). Both 
claudin and occludin are tetra-span (four-pass) proteins consisting of four 
transmembrane regions and two extracellular domains, which are capable of 
interactions with complementary molecules on adjacent cells forming adhesion points 
and through lateral copolymerization forming continuous strands (26). Cytoplasmic 
plaque proteins are thought to link claudin and occludin to the actin cytoskeleton 
through PDZ domains and cross-link the transmembrane junction proteins (28). 
Furthermore the cytoplasmic plaque proteins may have a role in vesicular trafficking 
to the TJ and cell signaling through their associated kinases and other less 
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characterized functions such as gene expression (28). A TJ inter-connecting adjacent 
nasal epithelial cells of excised porcine mucosa (respiratory region), imaged using 
Electron Microscopy by our group is presented in Figure 1.4. 
 
Figure 1.4. Nasal epithelial cells interconnected by a tight junction. Transmission Electron 
Microscopy (TEM) micrograph of epithelial cells obtained from tissue samples from excised porcine 
nasal mucosa (respiratory region). Arrow indicates a tight junction between the cells. 
 
TJs comprise a major barrier towards the paracellular transport of larger solutes (30). 
The dimensions of the paracellular space lie between 10 and 30Ð50 , suggesting that 
solutes having a molecular radius exceeding 15  (3.5 kDa) will be excluded from 
this route (31): this includes most therapeutic proteins. 
 
1.4 Mucosal administration of protein drugs: potential routes  
1.4.1 Oral route 
The oral route is the preferred way of drug administration due to the ease of self-
administration, convenience and lower costs (32). However, the gastrointestinal tract 
is a complicated system of organs designed primarily to break down food and absorb 
nutrient molecules. Following their oral administration, many peptides and proteins 
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will be destroyed before absorption can take place in the small intestine. This is 
because of the presence of proteolytic enzymes (2) and an unfavorable acidic 
environment (33). In vivo studies with native insulin in a murine model have shown 
bioavailabilities of less than 1% following administration via the oral route (34). This 
low level of bioavailability is generally not acceptable, as unlike small chemical 
entities, with protein pharmaceuticals the cost of goods is generally high. 
Consequently, a drug product having a relatively low bioavailability requires a high 
dose to achieve the desired therapeutic effects, which presents problems with regards 
to its cost effectiveness. 
 
Therapeutic proteins/peptides intended for oral administration under development by 
the pharmaceutical industry include Glucagon-like peptide-1 (GLP-1, a gut hormone 
possessing physiological properties, including stimulation of insulin secretion, that 
make it a potentially useful compound for treatment of diabetes) by Emisphere, which 
is currently in phase I clinical trials. Oral insulin is also under development by 
Emisphere, Oramed, Diabetology, Extrawell and most likely by other companies. The 
oral insulin product by Diabetology, called Capsulin, incorporates absorption 
enhancers and exhibits a reported bioavailability of 6-10% relative to injected insulin 
(35). 
 
1.4.2 Pulmonary route 
The respiratory system can be separated anatomically into the conducting regions, 
consisting of the air-transmitting passages of the nose, nasopharynx, larynx, trachea, 
bronchi and bronchioles (36), and respiratory regions (where exchange of gases 
occurs) comprising of alveolar ducts and saccules. The structure of the conducting 
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airways changes gradually as the diameter of the respiratory tubes becomes smaller 
(37), with the pseudostratified, columnar and ciliated epithelium with goblet cells and 
submucosal glands changing into a flattened squamous organization lacking in goblet 
cells or glands. The change in structural features of the airways is presented 
schematically in Figure 1.5. 
 
Figure 1.5. Structural features of the respiratory tube wall throughout the system, starting from 
trachea to alveoli. Adopted from (38). 
 
In the upper airways mucus functions to clear entrapped particulates entering the lung. 
The ciliated epithelial cells move the tracheal mucus sheet (containing inhaled, 
trapped particles) in an escalator-like fashion to its juncture with the esophagus, 
following which the trapped material is swallowed and cleared from the airway; this 
mucocilliary clearance mechanism provides an important host innate defense 
mechanism against invading organisms and exogenous particulate material. 
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Pulmonary administration is attractive for non-invasive drug delivery because of the 
very large surface area (approximately 140 m2) for drug absorption (39), thin alveolar 
epithelial cells presenting minimal barriers to transport, avoidance of the first-pass 
metabolism and minimal enzymatic activity within the lungs (2). On the other hand, 
factors that may limit the use of the pulmonary route for delivery of protein drugs 
include lung disease, smoking and the necessity to control the breathing rate (39). 
 
In terms of developments in the pharmaceutical industry, MannKind Corp. is actively 
seeking to market pulmonary insulin (Afrezza), with the company filing for FDA 
approval in 2009. Furthermore, an unnamed inhaled insulin product by MicroDose 
Therapeutx has completed its phase I clinical trial, while Alveairª (produced by 
Coremed Inc.) and an unnamed product (both insulin formulations designed for 
inhalation) made by Baxter are both in phase I trials (40).  
 
1.4.3 Nasal route 
Some of the characteristics of the nasal cavity that make the delivery of therapeutics 
through the nasal mucosa attractive, include the relatively large surface area available 
for absorption (approximately 150 cm2), the highly vascularised submucosa, and the 
avoidance of both gastric and first pass metabolism (8). Furthermore, the nasal 
mucosa exhibits a lower enzymatic activity when compared to the gastrointestinal 
tract (41). The nasal epithelial layer is covered by a mucus blanket, synthesized by the 
goblet cells, nasal and lacrimal glands, and plasma transudate. The mucus blanket, 
which traps particles larger than 4 µm, consists of two layers: an underlying sol 
(water) layer close to the epithelium and a superficial gel layer. Mucus is 90-95% 
water, 1-2% salt, 2-3% mucin and proteins. The pH of nasal secretions in adults is 
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5.5-6.5 (42).   
 
Of the three different regions of the nose (vestibular, respiratory and olfactory), the 
respiratory region is important for nasal delivery due to its large surface area and rich 
vasculature. Nasal mucosal epithelium consists of ciliated, non-ciliated, goblet and 
basal cells. The respiratory region is lined with pseudostratified columnar epithelium 
and within this region the ciliated columnar cell is the predominant type. Each ciliated 
cell contains around 100 cilia each about 5 µm long. The cilia beat in a synchronised 
fashion to clear the covering mucus layer (mucociliary clearance) at a rate of 6 
mm/min (43).  
 
Potential problems associated with the use of the nasal route for drug delivery include 
filtration of foreign particulates and rapid mucociliary clearance, which may affect the 
absorption of macromolecules (44). Other factors such as nasal secretions and the pH 
of the nasal cavity must be considered, as it is important to preserve the physiological 
functions and conditions of the nasal cavity (45). Nasal mucosa exhibits a low 
molecular weight (MW) cut-off (approximately 1000 Da) for macromolecular 
absorption (41) and therefore absorption enhancers have been extensively investigated 
as a possible solution to this problem. 
 
Marketed nasal formulations are restricted to peptides such as desmopressin 
(Minirin¨, Ferring) and buserelin (Suprecur¨, Sanofi-Aventis). These formulations are 
plain peptide solutions with no absorption enhancers, which explains their relatively 
modest bioavailabilities of approximately 3Ð10% (3). An unnamed insulin nasal spray 
developed by MDRNA and a nasal liquid emulsion spray (Nasulin) by CPEX 
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Pharmaceuticals are both in phase II clinical studies. Nasal formulations of the GLP-1 
analogue exenatide are also in development by Amylin Pharmaceuticals and MDRNA 
(both in phase II trials) (40). 
 
1.4.4 Buccal route 
Delivery through the buccal cavity offers avoidance of first pass metabolism as the 
blood vessels of the oral mucosa drain directly into the jugular vein. Furthermore, the 
oral cavity is highly vascularized (2) and provides an environment almost free from 
the acidity and protease activity encountered elsewhere in the mucosa (46). The 
surface of the buccal mucosa consists of a stratified squamous epithelium composed 
of 40Ð50 cell layers (47). While the cells of the intestinal and nasal epithelia are 
joined by TJs, the presence of these structures is rare in the oral mucosa (48), where 
the membranes of the epithelial cells are surrounded by a hydrophilic intercellular 
matrix composed of relatively polar lipids (47). However, the presence and variable 
flow rate of saliva acts as a barrier to drug transport (2). Furthermore, observed 
regional variation in drug permeability in the buccal mucosa (49) gives rise to 
challenges for reproducible delivery and maximal bioavailability. Many buccal 
delivery systems based on bioadhesion have been described for numerous therapeutics 
based on peptides or proteins (50). For example, buccal delivery of calcitonin and 
GLP-1 using an adhesive tablet showed 37% (51) and 41% (52) bioavailabilities, 
respectively.  
 
A sublingual tablet formulation of Desmopressin (Minirin¨) has been developed and 
marketed by Ferring Pharmaceuticals, but has a low bioavailability of 0.25% (3). 
Some of the technologies under development contain mucoadhesive excipients like 
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thiomers developed by ThioMatrix, while others, such as insulin product Oral-lynª 
contain absorption enhancers to help the drug cross the epithelial barrier. With regards 
to the latter product, relative bioavailabilities of 7Ð9% have been reported by its 
manufacturer (Generex). Biodel Inc. is also developing an oral formulation of insulin 
designed for sublingual administration (VIAtabª), which is currently in phase I 
studies.  
 
1.4.5 Other mucosal routes  
Other sites that have been explored for delivery of protein therapeutics include rectal, 
vaginal and ocular mucosas. Rectal delivery of proteins provides a greater systemic 
bioavailability compared to the oral route of administration (53) and also avoidance of 
enzymatic degradation as there may be protein absorption by the lymphatic system 
(39). However, limitations with this approach include bacterial activity, interference 
from fecal material, and longer disintegration and dissolution times in the colon 
environment (54). Furthermore, rectal administration of drugs has poor cultural 
acceptance in some countries (2).  
 
Ocular absorption occurs predominantly through the nasolacrimal system. In contrast 
to the intestinal and nasal epithelia, which consist of a single layer of cells joined by 
TJs, the corneal epithelium is made of several layers of cells, also joined by TJs (47). 
A number of peptides and proteins, including insulin, thyrotropin-releasing hormone, 
luteinizing hormone-releasing hormone, encephalin, calcitonin, and glucagon have 
been administered through the ocular route (55). Although the ocular route potentially 
provides relatively fast systemic absorption and the absorbed protein avoids first pass 
metabolism, the presence of peptidases in relatively high concentrations in tear fluid 
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can affect protein drug stability. Furthermore, the irritation caused by application of 
the drug to the eye can also trigger tear formation, leading to lower bioavailabilities 
(56).  
 
Studies investigating the potential use of the vaginal mucosa for protein delivery have 
found localized adverse reactions and low, variable absorption (39). Moreover, the 
non-applicability in both sexes limits the use of this route.  
 
1.5 Improving mucosal delivery: common investigated strategies 
Different strategies have been explored in an effort to improve the absorption and 
bioavailability of mucosally delivered protein therapeutics, as illustrated in Figure 
1.6. These include the use of delivery systems that prolong the contact time of the 
drug with the mucosal surfaces (mucoadhesive polymers) (57, 58) (Figure 1.6a), 
agents that increase membrane fluidity or disrupt cell membranes (e.g. surfactants) 
(59-61) (Figure 1.6b) and compounds that open the epithelial TJs (Figure 1.6c). 
Receptor-mediated transcytotic pathways (Figure 1.6d) have also been investigated 
for their potential in transmucosal delivery of protein therapeutics, as will be 
discussed later. Furthermore, compounds that improve mucosal drug access such as 
mucolytics (62-65), those that increase the stability of the administered protein drug, 
e.g. proteolytic enzyme inhibitors (66, 67), and agents which dissociate protein 
aggregation (e.g. cyclodextrins) (68) have also been employed for the same purpose.  
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Figure 1.6. Common strategies investigated for improvement of mucosal absorption of protein 
therapeutics. a) Mucoadhesive polymers prolonging the residence time of the complexed protein 
drug at the mucosal surface, b) Surface-active permeability enhancers compromising cell membrane 
integrity, whereby otherwise membrane-impermeable protein drug crosses the epithelial barrier, c) 
TJ opening where the paracellular space is increased, improving the paracellular access of protein 
molecules, and d) Exploiting epithelial transcytotic mechanisms by conjugating the drug (or a drug 
carrier nanoparticulate system) to a ligand (not shown) that is transported transepithelially via this 
route. 
 
1.5.1 Absorption enhancers 
 
Absorption (or permeation/permeability) enhancers are compounds that transiently 
disrupt the epithelial barrier and TJs, thereby increasing the permeability of drugs and 
potentially improving the drug's bioavailability. An ideal enhancer would be non-
toxic and biocompatible, pharmacologically inert, compatible with drugs and exhibit a 
reversible effect to limit or prevent damage to epithelia. Common absorption 
enhancers include surfactants, which enhance absorption by improving the 
transcellular transport (by disrupting the lipid bilayer), calcium chelators and 
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chitosans, which act on the paracellular transport (through disruption of the TJs) (69). 
 
1.5.1.1 Surfactants  
Various ionic and non-ionic surfactants have been investigated for their potential use 
as mucosal absorption enhancers. Their absorption-enhancing property has been 
demonstrated in many studies (70-72). However, a large number of these studies 
found that the use of surfactants as permeability enhancers is associated with cell 
toxicity, frequently observed in the form of cell membrane damage, altered cell 
morphology (70, 73-75) and mucociliary arrest (76, 77), which limits their 
application. 
 
Recently, alkylglycosides, a class of nonionic amphipathic surfactant compounds 
containing alkyl chains of variable lengths, glycosidically attached to either a 
monosaccharide or disaccharide have been investigated, both in vitro and in vivo, for 
their potential to improve the systemic bioavailability of macromolecular peptides and 
proteins delivered mucosally (59-61, 78-80). Alkylglycosides will be discussed in 
greater detail in Chapter 4. 
 
1.5.1.2 Calcium-depleting agents 
The role of extracellular calcium in regulating the epithelial TJs and therefore 
maintaining the barrier property of the epithelium has been known for a long time. 
Studies on epithelial cell lines showed that depletion of extracellular calcium prevents 
the formation of TJs (81), induces opening of (existing) TJs (21, 82) and increases TJ 
permeability (21, 83-86). As a result, different compounds possessing an ability to 
bind calcium, reducing its extracellular levels, have been investigated for their 
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potential to enhance the mucosal absorption of macromolecules through the 
paracellular route. However, the conditions under which extracellular calcium 
depletion produces pronounced opening of the TJs and whether this strategy can be 
used to improve the absorption of macromolecular therapeutics in the in vivo settings 
is somewhat unclear from the literature. Work attempting to address these points was 
conducted in this thesis and is presented in Chapter 5. 
 
1.5.1.3 Polymeric enhancers  
Chitosan, the deacetylated form of chitin, is one of the most extensively investigated 
polymeric absorption enhancer. This is probably due to its low production costs, 
biodegradability, biocompatibility and FDA approval (87). Its property to enhance the 
absorption of macromolecules across the mucosal surfaces has been demonstrated in 
many studies. For example, chitosan salts, such as hydrochloride and glutamate 
increased the transport of buserelin and insulin in vitro (88). The capacity of chitosan 
to enhance the intestinal transport of peptides was also confirmed in vivo, with 1.5% 
w/v chitosan hydrochloride increasing the absolute bioavailability of buserelin, 
following its intraduodenal application in rats, from 0.1% (in control buffer) to 5.1% 
(89). Application of a chitosan solution effectively enhanced nasal absorption of 
salmon calcitonin (sCT) in vivo in rats (90) and significantly increased the 
permeability of fluorescein isothiocyanate recombinant hirudin-2 (FITC-rHV2) across 
the excised rabbit nasal epithelium and its bioavailability following the nasal 
administration to rats (91). In addition to its ability to facilitate paracellular transport, 
chitosan can also be used to formulate microparticles or NPs. The permeability 
enhancing property of chitosan NPs in comparison to solution is investigated in this 
work and the results will be described and discussed in Chapter 6. Additionally, the 
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mechanisms thought to be involved in TJ-opening by chitosan will be discussed there. 
 
Chitosan is a weak base and an acidic environment is required to transform it into the 
positively charged, water-soluble form; at neutral or physiological pH most chitosan 
molecules will lose their charge and precipitate from solution (92). The chitosan 
derivative N-trimethyl chitosan chloride (TMC) has been synthesised in an attempt 
to improve its solubility at neutral pH. In solutions in the 1.5Ð2.5% concentration 
range, at pH 7.4, TMC was found to markedly increase the permeability of peptide 
drugs (buserelin and porcine insulin) across Caco-2 cell monolayers (88). TMC, 
applied on Caco-2 cell monolayers at pH 7.4 provided permeability enhancement that 
was similar to chitosan that was applied at pH 5.6 (93). The degree of quarterization 
(DQ) and hence charge density, is a determinant factor for the permeability-enhancing 
property of TMC in neutral environments. The use of TMC derivative with a 60% 
degree of substitution (TMC60) at pH 7.2 was associated with a higher mannitol 
transport enhancement ratios across Caco-2 cells than TMC40 (40% DQ), whereas 
TMC with the lower degree of substitution (12.3%) was ineffective at neutral pH (94). 
Similarly, TMC afforded an improvement in bioavailability of buserelin by more than 
7-fold and more than 16-fold, depending on the DQ, after intraduodenal 
administration in rats (95) and intratracheal instillation of octreotide in combination 
with TMC in rats resulted in a 2.5- and 3.9-fold increase in the AUC for TMC20 
(20% DQ) and TMC60, respectively (96). Nevertheless, there is evidence that a 
higher of DQ in TMC leads to a greater toxicity (97). 
 
Poly-L-arginine molecules of varying MWs were found to increase nasal absorption 
of the model drug, FITC-dextran of approximately 4 kDa, (FD4), in rats. The 
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observed bioavailability of FD4, shown to be dependent upon the MW of poly-L-
arginine, was higher than that produced by chitosan (98). Nasal absorption in rats of 
recombinant human granulocyte colony-stimulating factor (RhG-CSF, MW of 18.8 
kDa) was increased following its coadministration with 1% w/v poly-L-arginine, 
producing a bioavailability of about 11% (99). The absorption enhancing effect of 
poly-L-arginine was shown to be transient (100). Additionally, this molecule, was 
also demonstrated to increase the translocation of FD4 across excised rabbit nasal 
epithelium (101). The considerable correlation between the permeability and the 
electrical conductance of the membrane indicated that the enhancer exhibited its 
effect on the paracellular pathway. This pathway was also visualized by Confocal 
Laser Scanning Microscopy (CLSM), which showed that the use of poly-L-arginine 
was associated with a marked localisation of fluorescence in the paracellular space. 
 
1.5.1.4 Other TJ modulating agents  
A number of relatively novel experimental approaches (including RNA interference, 
gene cloning and high throughput tissue culture assays) have been used to identify TJ 
targets that are most suitable for pharmacological manipulation in order to enhance 
paracellular drug delivery. Dutzar et al. (102) evaluated the effects of siRNA knock 
down of claudins 1, 3, 4, 9, 12, 20, JAM-1 and occludin in functional assays for TJ 
formation and permeability. Knockdown of claudin 4 inhibited TJ formation and 
resulted in a significant decrease in transepithelial electrical resistance (TEER) and an 
increase in FD4 permeability. Combination knockdowns between claudin 4 and 
occludin or JAM-1 showed synergistic effects. Interestingly, Kondoh et al. (103) also 
confirmed the potential of claudin as a novel target for drug delivery system. The 
authors of this study found that the C-terminal fragment of Clostridium perfringens 
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enterotoxin (C-CPE) is a potent absorption enhancer with an enhancing activity of 
400-fold greater compared to sodium caprate (a clinically used enhancer) without 
showing any mucosal toxicity in rat jejunum. The enhancing activity involved an 
interaction between C-CPE and claudin-4.  
 
Johnson et al. (104) developed a novel TJ modulating peptide, PN159, the application 
of which was associated with a reduction in TEER across a tissue barrier and 
increased paracellular transport of dextran, with low cytotoxicity and no decrease in 
cell viability. In a subsequent study (105), this peptide, which is polycationic and 
amphipathic, was shown to afford a significant improvement in permeation of salmon 
calcitonin, parathyroid hormone 1-34 and peptide YY 3-36 across epithelial tissue. 
Additionally, the TJ modulating peptide, PN159, dramatically increased the 
bioavailability of peptide YY 3-36 when dosed intranasally in rabbits. 
 
1.5.2 Bioadhesive polymers 
There is some evidence that the interaction between various types of 
bio(muco)adhesive polymers and epithelial cells can affect mucosal permeability, 
with adhesion of the drug delivery system to the surface of intestinal epithelial cells 
leading to enhanced uptake by nonspecific receptor-mediated endocytosis (55). 
However, for this technology, there is a need for improvement in localization or 
retention of the drug delivery system at the desired mucosal region (106) as presently, 
mucoadhesive systems are susceptible to the sloughing of the mucosa (107) and 
displacement by mucus excretion (108). 
 
The muco- or bio-adhesive nature of some materials has been explained through 
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different theories, amongst which the adsorption theory is the most widely accepted. 
This theory states that mucoadhesion occurs due to secondary forces such as hydrogen 
bonds, van der Waals interactions and ionic bonds (109). Anionic polymers such as 
poly(acrylic acid), poly(methacrylic acid), and others bearing carboxyl and hydroxyl 
groups have been shown to exhibit better bioadhesion than cationic or neutral 
polymers (110).  
 
The mucoadhesive properties of Carbopol¨, a derivative of poly(acrylic acid), 
providing an intimate and prolonged contact between the drug and the mucosal 
surface are potentially favourable for use in transmucosal drug delivery. Carbopol¨ 
has also been reported to open the paracellular spaces of Caco-2 cell monolayers, 
thereby enhancing the epithelial permeability (111) and inhibit calcium-dependent 
proteases, thus improving the stability of peptide/protein drugs at mucosal surface 
(112). Carbopol¨ has been demonstrated to enhance the intraduodenal absorption of 
the peptide buserelin in rats, with an increase in bioavailability from 0.1% (with 
control buffer) to 2.0% (with 0.5% w/v Carbopol¨ 934P) (89). Furthermore, the use of 
Carbopol¨ 971P in Calu-3 cell layers was associated with an increase in the apparent 
permeability of hydrophilic macromolecules such as mannitol, the peptide 
desmopressin (1-cys-deamino-8-Darginine-vasopressin), FD4, and FITC-dextran of 
approximately 10 kDa (FD10) across the cell layers, accompanied by a concomitant 
decrease in TEER (113). 
 
In addition to its ability to open the intercellular TJs, chitosan possesses inherent 
mucoadhesive properties. These are attributed to its positive charges forming a strong 
electrostatic interaction with the negatively charged sialic acid residues of mucins 
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(114). 
 
Thiolated Polymers seem to bind covalently to mucus through the thioldisulfide 
exchange reactions with mucin glycoproteins. Chitosan has been modified by 
immobilizing thiol groups on the polymer chain, with the purpose of improving its 
mucoadhesive and absorption-enhancing properties. Improved mucoadhesiveness 
results from exchange reactions between the thiol groups of the thiolated chitosan and 
disulfide groups within the mucus with formation of new disulfide bonds between the 
polymer and mucus (115). Nasal administration of chitosan-4-thio-
butylamidine/reduced glutathione/insulin microparticles to rats was associated with a 
1.6- to 3.5-fold increase in the absolute bioavailability compared to that seen with 
chitosan/insulin microparticles, and 4.3- to 7-fold higher bioavailability than that 
exhibited by mannitol/insulin microparticles (116, 117). 
 
1.6 Crossing the mucosal barriers through the transcytotic route: 
cellular uptake and trafficking of protein drugs 
Mucosal absorption through the transcellular route requires that the macromolecule 
must overcome the plasma membrane barrier once it reaches the surface of epithelial 
cells. Clathrin- or caveolin-mediated endocytosis, macropinocytosis and phagocytosis 
are all endocytic mechanisms which are known to play a role in the uptake of 
macromolecules (118). In addition to these, other clathrin- and caveolin-independent 
pathways have also been suggested to play a role in cellular uptake of material (119). 
The discussed uptake pathways are presented schematically in Figure 1.7. It should be 
emphasised that in the context of systemic mucosal drug delivery, in addition to 
effective uptake into the epithelial cell, therapeutic material has to be released into the 
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luminal side.  
 
 
Figure 1.7. Cell entry pathways. Large particles can be taken up by phagocytosis, whereas fluid 
uptake occurs by macropinocytosis. In comparison to other endocytic pathways, the size of the 
vesicles formed by phagocytosis and macropinocytosis is much larger. Cargoes can also be 
endocytosed by mechanisms that are independent of the coat protein clathrin and the fission 
GTPase, dynamin. Most internalised cargoes are delivered to the early endosome through vesicular 
(clathrin- or caveolin-coated vesicles) or tubular intermediates (known as clathrin- and dynamin-
independent carriers (CLICs) that are derived from the plasma membrane. Some pathways may first 
traffic to intermediate compartments, such as the caveosome or glycosyl phosphatidylinositol-
anchored protein enriched early endosomal compartments (GEEC), before reaching the early 
endosome. Taken from (119). 
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1.6.1 Clathrin-independent endocytosis 
Clathrin-independent endocytosis includes the constitutive pinocytotic pathway and 
endocytosis mediated by caveolae and glycolipid rafts (120). Caveolae are inverted 
omega-shaped invaginations with a maximal diameter of 50-100 nm connected to the 
plasma membrane or plasmalemma by a neck-like structure, which provides spatial 
continuity with the extracellular environment (121). The principal component, which 
is also a critical functional element is a protein called caveolin (122). Cholesterol is 
also very important component of caveolae and it is required to maintain structural 
integrity; caveolae disappear in cells that are depleted of cholesterol (123). 
 
Caveolae can function as both intracellular and transcellular transport systems and 
they appear to be able to deliver their cargo either to endosomes or across the cell to 
opposite cell membrane surface (124). In contrast to classic clathrin-dependent 
endocytosis, there is evidence that caveolar internalization avoids lysosomes and 
hence the degradation of engulfed molecules (125). 
 
The sensitivity of endocytosis via caveolae to cholesterol depletion with agents such 
as filipin, nystatin, or methyl-cyclodextrin distinguishes these pathways from both the 
clathrin-dependent and constitutive pinocytotic pathways. For example, Schnitzer et 
al. (124) showed the ability of filipin to disassemble endothelial noncoated vesicles, 
which selectively inhibits caveolae-mediated intracellular and transcellular transport 
of some macromolecules such as insulin and albumin in cultured endothelial cell 
monolayers. Filipin inhibits insulin uptake by endothelium for transcytosis, a 
cavelolae-mediated process, but not endocytosis for degradation, mediated by 
clathrin-coated pathway. The transcytosis process could occur by one of these two 
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mechanisms: caveolae could either pinch off from the plasma membrane, travel the 
short distance across the cell and fuse with the opposite surface, or, they may 
transiently fuse with each other producing channels through which ligands pass (126). 
 
1.6.2 Uptake and transport of cargo in epithelial cells  
The low rate of drug absorption through the mucosal surfaces is partly due to the low 
rate of endocytotic activity operating at the apical plasma membrane of epithelial 
cells. This phenomenon can be explained by the important physiological role of 
epithelia, and specifically the apical plasma membrane, filtering and repeling foreign 
substances in order to protect cells and organs from the external milieu (127). 
Endocytosis in non-polarised cells and at the basolateral plasma membrane of 
polarised epithelial cells was found to be several-fold faster than that operating at the 
apical plasma membrane (128, 129). 
 
Polarized epithelial cells can internalize macromolecules from both apical and 
basolateral plasma membrane domains (130). In Madin-Darby canine kidney 
(MDCK) epithelial cells, used by many researches to study membrane protein 
trafficking in polarised epithelial cells (131), endocytosis occurs by both clathrin-
dependent and independent mechanisms (132). The fate of material following 
endocytosis varies. After internalisation from the apical or basolateral sides of these 
cells, fluid-phase markers have been shown to enter distinct populations of apical 
early endosomes or basolateral early endosomes (133, 134). While a proportion of 
apically internalized fluid is thought to recycle or transcytose, some is delivered to a 
shared population of late endosomes and lysosomes (130). 
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1.6.2.1 IgG/FcRn transcytotic pathway 
It has long been known that IgG is actively transferred from mother to offspring, 
conferring short-term passive immunity (135, 136). The transport of IgG is mediated 
by the neonatal Fc receptor (FcRn) (137, 138). This receptor is a potential candidate 
for mucosal delivery of therapeutic proteins as it is expressed in the lung (139) and 
the intestine (140) where it is involved in transepithelial transport of IgG. FcRn is 
known to undergo transcytosis in both apical-to-basolateral and basolateral-to-apical 
directions (141). Apical-to-basolateral transcytotic pathway of IgG/FcRn has been 
explored in various cell types, and is presented schematically in Figure 1.8. Briefly, 
IgG either binds to FcRn at the apical surface of the cells or is internalized by fluid-
phase endocytosis, encountering FcRn in the apical early endosome (AEE). In the 
AEE, IgG/FcRn is sorted from fluid-phase markers and is either delivered to the 
apical recycling endosomes (ARE) or to the common recycling endosomes (CRE). 
Within the CRE, IgG/FcRn is sorted into coated vesicles that could serve as exocytic 
carriers to the basolateral cell surface (141) . 
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Figure 1.8. IgG/FcRn transport pathway. IgG may bind to FcRn at the apical cell surface (step 1), 
or is internalized by fluid-phase endocytosis (step 2) (depending on the cell type) and encounters 
FcRn in the apical early endosome (AEE). In the AEE, FcRnÐIgG is sorted from fluid-phase 
markers, which are delivered to late endosomes (LE) (step 3a) and lysosomes (not shown), and is 
either delivered to the apical recycling endosomes (ARE, step 3b) or delivered to the common 
recycling endosomes (CRE) (step 3c). In the CRE, FcRnÐIgG is sorted into coated vesicles that 
probably serve as exocytic carriers to the basolateral cell surface (step 4). FcRn can also transport 
IgG in the basolateral-to-apical direction, although the intracellular pathway remains to be defined. 
A likely possibility is that IgG, internalized by fluid-phase endocytosis (step 5), binds to FcRn in the 
acidic pH of the basolateral early endosomes (BEE). FcRnÐIgG either recycles (step 6a), or is 
delivered to the common recycling endosomes (CRE) (step 6b), ARE (step 7) and apical plasma 
membrane (step 8) where ligand dissociation and release occurs. Taken from (141).  
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Recent studies investigating pulmonary absorption of therapeutic proteins 
(erythropoietin and follicle-stimulating hormone) through the FcRn pathway in non-
human primates proved promising (142, 143). Furthermore, Bitonti et al. (144) 
investigated the prospect of exploiting this transcytotic pathway for absorption of 
protein drugs through the lung in healthy male volunteers and in doing so, 
demonstrated a dose-dependent absorption through the lungs. The potential of the 
IgG/FcRn pathway for mucosal delivery of macromolecules and NPs has been studied 
in this work and the results will be presented/discussed in Chapter 7.  
 
1.6.2.2 Vitamin B12 transcytotic pathway 
Gastrointestinal absorption of vitamin B12 (VB12) occurs through receptor-mediated 
endocytosis. VB12 is first bound to the intrinsic factor (IF), following which the VB12-
IF complex binds to the IF receptor located on the apical membrane of the villous 
enterocytes. The complex is subsequently endocytosed and transcytosed to the 
circulation (88). It is potentially possible to utilise VB12 uptake mechanism to co-
transport peptides and proteins. Russell-Jones and his coworkers (145-148) have 
demonstrated the potential of VB12 to increase the oral uptake of various peptides 
such as luteinising hormone releasing hormone analogues, α-interferon, erythropoietin 
and granulocyte colony-stimulating factor by covalently linking the peptides to VB12. 
Their later studies have focused on modifying the surface of the nanocarriers with 
VB12, eliminating the need for conjugation and at the same time possibly increasing 
the transport capacity of the oral delivery system (145). Nevertheless, delivering 
drugs via VB12 receptor-mediated transport is not without its associated problems. The 
limited transport capacity may be insufficient for less potent drugs and sharing a 
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physiological transport pathway of limited capacity, such that of VB12 may lead to 
competition with other nutritional factors (149).  
 
1.6.3 Other strategies for transcellular delivery of protein drugs 
More recent strategies investigated for transmucosal delivery of proteins include the 
use of cell-penetrating peptides (CPPs). Recently, Khafagy et al. found that 
different forms of penetratin and octaarginine CPPs dramatically increased nasal 
absorption of insulin, with the most pronounced effect observed for L-penetratin. This 
compound exhibited a dose-dependent increase in insulin bioavailability from 1.7% 
(in control) to between 15.1% and 50.7% (depending on concentration) relative to the 
subcutaneous route. In a separate sudy by the same group, CPPs based on 
oligoarginines were investigated for their potential to improve intestinal absorption of 
insulin in rats. Insulin absorption increased dramatically after coadministration of 
oligoarginine of six residues of arginine in a dose-dependent manner, with resulting 
increase in bioavailability of up to 15.7% compared to the subcutaneous route (150). 
However, intestinal absorption of a larger molar mass interferon-β (23 kDa) was not 
affected by co-administration with oligoarginine, indicating that the MW of the protein 
therapeutic may present limitations to the usefulness of CPPs in their mucosal 
delivery. 
 
Dendrimers possess unique characteristics and are considered to be promising 
candidates for biopharmaceutical delivery. The polyamidoamines (PAMAMs) are the 
most widely studied from a pharmaceutical perspective. A study by 
Wiwattanapatapee et al. (151) has demonstrated that PAMAM dendrimers crossed 
intestinal epithelial barriers at sufficient rates to act as potential drug delivery 
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systems, whereby anionic dendrimers were more efficient in crossing the epithelial 
barrier than cationic dendrimers. The uptake pathways were dependent on the sizes 
and charges of the dendrimers. On the other hand, Jevprasesphant et al. (152) revealed 
that cationic dendrimers were associated with a significantly greater permeability 
through Caco-2 cell monolayers than anionic dendrimers, an effect that was attributed 
to the interaction of cationic dendrimers with TJs, facilitating paracellular transport. 
In addition to paracellular movement, the studies discussed above indicate that 
transmucosal dendrimer transport may also occur via endocytic/transcytotic pathways.  
 
Lectins are proteins or glycoproteins of plant, bacterial or vertebrate origin that 
recognise and bind to polysaccharide or glycoconjugate moieties (149). Plant lectins 
appear to be attractive carriers for oral drug delivery because of their ability to bind 
specifically to the sugar moieties of glycocalyx expressed on the intestinal epithelial 
cells and they are generally resistant to digestion within the gastrointestinal tract 
(149). Tomato lectin (TL) was one of the first lectins explored as a candidate in oral 
drug delivery because of its safety profile and resistance to gastrointestinal 
degradation (153). In the in vivo studies pioneered by Hussain et al. (154), although 
TL-conjugated NPs were entrapped within the mucus layer, they could efficiently 
penetrate the mucus gel and were transported across the epithelial cells. However, a 
major drawback of TL is its cross-reactivity with N-acetylglucosamine in mucus 
glycoprotein and a resultant reduction in the amount of TL conjugates available for 
interaction with epithelial cell surfaces (155).  
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1.7 Nanoparticles for mucosal delivery of protein therapeutics 
Nanocarriers have great potential to improve the mucosal delivery of peptides and 
proteins (156). Polymeric NPs have been extensively investigated for the oral delivery 
of insulin. Insulin-loaded poly(iso-butylcyanoacrylate) (PIBCA) nanocapsules 
induced a reduction of glycemia in diabetic rats for up to 20 days (157). Their 
absorption has been shown to occur through the paracellular or transcellular pathways 
by enterocytes (and Goblet cells) (158). This nanoparticulate system, however, 
induced a variable therapeutic response when tested in dogs (159), which has limited 
its development. Coating of NPs with hydrophilic polymers, such as PEG (160) and 
chitosan (161) was found to improve the in vivo transport of proteins through 
preferential interaction with the mucus (mucoadhesion), and, in some cases, through 
the opening of TJs and paracellular transport.  
 
Nanoparticulates were also used in an attempt to deliver peptide/protein drugs through 
the nasal mucosa. Nasal administration of chitosan NPs loaded with insulin resulted in 
a significant and relatively rapidly reduction of glycaemia compared to insulin mixed 
with soluble chitosan in rabbits (162). Coating of NPs with PEG and chitosan was 
found to increase their transport across the nasal mucosa, as demonstrated for 
PEGylated poly(lactide) (PLA) NPs (163) and chitosan-coated nanocapsules (164).  
 
Administration of insulin-loaded poly(lactic-co-glycolic acid) (PLGA) NPs to guinea 
pig lungs resulted in a significant reduction in blood glucose level compared to insulin 
solution, an effect that lasted up to 48 hours (165). Similarly, pulmonary 
administration of insulin-loaded NPs of a different polymer, poly(butyl cyanoacrylate) 
(PBCA), were shown to extend the duration of a hypoglycemic effect (glucose level 
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below 80% of the original levels) over 20 hours, as compared to insulin solution 
(166). PLGA NPs coated with chitosan enhanced the absorption of calcitonin when 
delivered to the lungs of guinea pigs. This was attributed to a mucoadhesive effect 
and a possible opening of the TJs (167).  
 
Recently, a rare study investigating the cellular uptake and transport of NPs (rather 
than soluble material) across MDCK polarised cells concluded that NP surface charge 
may significantly affect the mechanism of their internalization. Poly(ethylene glycol)-
D,L-polylactide (PEG-PLA) NPs of both positive and negative surface charge (of 
approximately 90 nm and 96 nm, respectively) were found to mostly target the 
clathrin endocytic machinery, with a proportion internalized through a dynamin- and 
clathrin-independent process such as the macropinocytic pathway. The positive 
charge on the surface of NPs was seen to stimulate the movement of the NPs into 
clathrin-coated pits, with a fraction of internalized NPs following an endocytic 
pathway. A significant amount of cationic NPs and a fraction of the anionic NPs 
transcytosed and accumulated at the lateral plasma membrane. Importantly, cationic 
NPs were seen to avoid the lysosomal degradative pathway, which was not the case 
for anionic NPs (127). 
 
Introducing hydrophilic PEG and hydrophobic alkyl side-chains potentially reduces 
adsorption of plasma proteins onto the NP surface (168, 169). PEG coated NPs offer 
greater stability against aggregation, minimal toxicity and diminished 
immunogenicity and thus have significant potential in controlled-release, targeted 
drug delivery. NP uptake by cells of the reticuloendothelial system can also be 
reduced by the presence of PEG on the surface, which ultimately extends the half-life 
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of NP-incorporated drugs and alters their tissue distribution (170), possibly improving 
the therapeutic profile of the drug. 
 
1.8 General considerations in formulation design for mucosal 
delivery of proteins 
In delivering protein therapeutics through the mucosal surfaces, several issues must be 
addressed. Firstly, the potential unwanted immunogenicity of protein pharmaceuticals 
in general seems very difficult to avoid (3), with evidence that the extent of this 
problem apparently depends on the route of administration. For example, the use of 
pulmonary insulin Exubera¨ was associated with a higher incidence of antibody 
formation compared to subcutaneous administration (3).  
 
The safety of absorption enhancers has been assessed by various procedures, 
including the effect on ciliary beat frequency, reversibility of TEER, exclusion of 
membrane-impermeable compounds from epithelial cells, maintenance of 
morphological integrity and release of the intracellular enzyme, LDH (47). The use of 
some absorption enhancers, as discussed previously, gives rise to possible problems 
with toxicity. While the systemic toxicity of large, polymeric absorption enhancers is 
generally regarded as low (as because of their size they are not normally absorbed into 
systemic circulation) (47), absorption enhancers generally exert their effect by 
causing modification of the epithelial surfaces. This therefore raises concerns with 
regards to the maintenance of epithelial cell viability and the preservation of the 
physiological functionality. Furthermore, studies reported in the literature 
predominantly evaluate the toxicity of absorption enhancers following a single use (in 
epithelial cell lines or animals). In a clinical setting, however, repeated and often 
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long-term applications of the therapeutic system incorporating absorption enhancer(s) 
would be required; the long-term toxicity of such repeated application remains 
unknown. 
 
Chitosans have in some cases been shown to produce dose-dependent toxicity on 
Caco-2 cells. Toxicity was directly related to the degree of deacetylation and, 
therefore, to the positive charge density of the polymer (171). Furthermore, an 
important factor affecting the extent of toxicity of chitosan towards buccal epithelial 
cells was the pH of the solution. As a more acidic pH leads to a higher charge density, 
this study confirmed that toxicity is related to positive charge density. Overall, the use 
of chitosan as an absorption enhancer is considered as substantially safe on the 
intestinal, nasal, ocular and buccal epithelia (47). 
 
With regards to the use of nanoparticulates in an attempt to improve mucosal delivery 
of protein drugs, a major barrier is the lack of our understanding on how NPs interact 
with epithelial surfaces, the mechanism by which they traverse the epithelial barriers 
and ways to maximise transepithelial transport. Furthermore, a lot remains unknown 
about the toxicity and immunogenicity associated with the long-term use of nano-
sized drug carriers.  
 
Finally, the majority of studies investigating mucosal protein delivery, including those 
in this work, use mucosal models of various complexity. One must exercise caution in 
using the data generated in these studies, and even those performed in various animals 
in vivo, to make predictions in man. 
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1.9 Conclusion  
In an era of biotechnology, the discovery of very specific and powerful protein drugs 
is proliferating, but their administration is presently limited to injections. 
Disadvantages associated with this method of drug administration make alternative 
ways of administering protein therapeutics greatly sought after. Mucosal surfaces 
offer high potential for delivery of this class of drugs, though biological barriers 
associated with this route present problems to the drug delivery scientist. Delivery of 
protein therapeutics across various mucosal surfaces, including gastrointestinal, 
respiratory, nasal and buccal is actively being researched by both the pharmaceutical 
industry and academia. Different strategies have been investigated in an attempt to 
improve the bioavailability of mucosally administered protein drugs. These include 
the use of absorption enhancers, mucoadhesive excipients and attempts to exploit 
epithelial transcytotic mechanisms, with or without the use of nanoparticulate drug 
delivery systems. While each of these approaches is not without its problems, 
significant progress has been achieved within this field. An ideal mucosal delivery 
strategy would incorporate systems that exhibit no toxicity upon repeated 
administration, preserve the biological activity of the therapeutic molecule, are 
applicable to most protein drugs, achieve acceptable bioavailability and do not 
substantially increase the cost of the formulation. Such a system would make mucosal 
administration of protein drugs widely available, which would be highly beneficial to 
both the patient and the pharmaceutical industry.  
 
1.10 Project aims 
The foregoing introduction argues that mucosal surfaces potentially provide non-
invasive routes for administration of protein therapeutics. The main aim of this thesis 
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is to explore different strategies with a view to improving the transport of 
macromolecules (proteins and models of protein drugs) across mucosal surfaces. To 
this end, polarised epithelial cell layers will be adopted to serve as an in vitro model 
of airway epithelium. Initial work will focus on establishing and characterising this in 
vitro model, which will be based on the Calu-3 cell line. Thereafter, different 
strategies based on paracellular and transcellular transport pathways will be 
investigated for their potential to improve the translocation of macromolecules across 
the cell layers. These strategies will include the use of surfactants, tight junction 
modulation through the use of calcium depletion and chitosan, and lastly, exploitation 
of the IgG/FcRn transcytotic pathway for transmucosal protein and NP delivery.  
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Chapter 2 
Materials and General Methods 
  
2.1 Materials 
2.1.1 Cells, culture media, media components and cell solutions 
Calu-3 cells were obtained from the American Type Culture Collection (ATCC) and 
used at passages 19-48. Caco-2 and HT-29 cells were obtained from the European 
Collection of Cell Cultures (ECACC) and used between passages 44-58 and 142-160, 
respectively. Essential Minimum EagleÕs Medium (EMEM) medium was obtained 
from ATCC-LGC standards. DulbecoÕs Modified Eagles Medium (DMEM), 
McCoyÕs-5A medium, Hanks Balanced Salt Solution (HBSS) with sodium 
bicarbonate and without phenol red and HBSS with sodium bicarbonate, without 
phenol red, calcium chloride and magnesium sulfate (referred to as calcium-free 
HBSS, CFHBSS) were all obtained from Sigma Aldrich. Phosphate buffered saline 
(PBS) tablets were purchased from Oxoid (Basingstoke, UK). 2.5% Trypsin/EDTA 
solution, Antibiotic/Antimycotic solution (containing penicillin, streptomycin and 
amphotericin), L-glutamine and Foetal Bovine Serum (FBS, non-USA origin) were 
all obtained from Sigma Aldrich. All cell media (EMEM, DMEM and McCoyÕs-5A) 
were supplemented with penicillin, streptomycin and amphotericin at final 
concentrations of 100 units/ml, 0.1 mg/ml and 0.25 µg/ml, respectively, and FBS at 
final concentrations of 10% v/v. DMEM was further supplemented with L-glutamine 
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and 1 mM sodium pyrovate. Note that from this point onwards, supplemented media 
are referred to as cell media, DMEM, EMEM or McCoyÕs-5A. Dimethylsulphoxide 
(DMSO), used as cryopreservant, was purchased from Sigma Aldrich. 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 2-(N-
Morpholino)ethanesulfonic acid (MES) were obtained from Sigma Aldrich.  
 
2.1.2 Plasticware and glassware 
Transwell¨ permeable supports, referred to in this thesis as 'filters', of 12 mm 
diameter, 0.4 µm pore size (with polystyrene membranes) were obtained from 
Corning Life Sciences (Holland). Cell culture flasks (75 cm2, canted neck with vented 
caps), 96-well polystyrene microplates (black or clear, non-cell culture treated) and 
sterile pipettes, used routinely for the maintenance of cells, were also purchased from 
Corning Life Sciences. Clear, tissue culture treated 96-well plates and ELISA 
(Immuno 96 MicroWellª) plates were obtained from NUNC. Sterile centrifuge tubes 
(of 15 ml and 50 ml volume capacity) were purchased from Grainer (USA). Sterile 
universals (5 ml and 30 ml volume capacity) were obtained from Sterilin (UK). Sterile 
cryovials (1 ml capacity) were supplied by NUNC. Freezing container ('Mr Frosty'), 
providing 1¡C per minute cooling rate was purchased from Nalgene¨ Labware. 
Haemocytometer (Improved Neubauer, to British Standard 748) was purchased from 
Scientific Laboratory Supplies (SLS), UK.  
 
2.1.3 Cell toxicity assay reagents 
AlamarBlue¨ reagent was obtained from AbD Serotec (UK), while 3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) reagent (commercially known as 'CellTiter 96 AQueous One Solution Cell 
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Proliferation Assay') was purchased from Promega (USA). Lactate Dehydrogenase 
(LDH) assay kit (known commercially as 'In Vitro Toxicology Assay Kit, TOX7') 
was purchased from Sigma Aldrich.  
 
2.1.4 Antibodies  
IgG from human serum (hereinafter referred to as 'IgG') and IgG from rabbit serum 
(rIgG), both as lyophilized powders, and fluorescein isothiocyanate (FITC)-labelled 
IgG (FITC-IgG) solution were purchased from Sigma Aldrich. FITC-IgG was 
dialysed extensively against PBS (to remove sodium azide from the solution) prior to 
its use in cell experiments. IgG Fc fragment and FITC-labelled IgG Fc fragment were 
obtained from Jackson Immunoresearch Europe Ltd. Anti-human IgG, horseradish 
peroxidase (HRP)-conjugated, was purchased from The Binding Site, UK. Mouse, 
anti-human Zonula Occludens-1 (ZO-1, TJ protein) was purchased from Zymed (part 
of Invitrogen). Goat, anti-mouse FITC-IgG and goat, anti-mouse Cy5-IgG were 
purchased from Sigma Aldrich and Invitrogen, respectively. Goat, anti-human FcRn 
antibody (polyclonal IgG) and donkey, anti-goat TRITC-IgG were purchased from 
Santa Cruz (USA). Mouse, anti-human mucin-1 (MUC-1) was purchased from AbD 
Serotec, UK. Anti-mouse FITC-IgG was obtained from Sigma Aldrich. 
Investigational therapeutic (anti-cancer) antibodies, hCTMO1 (whole antibody, MW 
147033), hCTMO1 (Fab, MW 95815), mA33γ1 (Fab, MW 24724.67) and mA33γ1 
Fab-diPEG (Fab conjugated to PEG, MW 64724.67), were supplied by UCB (Slough, 
UK). 
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2.1.5 Chemicals  
FITC-labelled dextrans ('FDs') of approximate average MW of 4 kDa (FD4), 10 kDa 
(FD10), 20 kDa (FD20), 40 kDa (FD40), 70 kDa (FD70) and 150 kDa (FD150), and 
FITC-labelled insulin (FITC-insulin) were supplied by Sigma Aldrich. n-Dodecyl-§-
D-maltoside (DDM), n-Tridecyl-§-D-maltoside (TriDM) and n-Tetradecyl-§-D-
maltoside (TDM) were obtained from Anatrace (USA). Ethylene diamine tetraacetic 
acid (EDTA) was obtained from Sigma Aldrich. Fluo-4 fluorescent calcium-sensing 
dye was obtained from Invitrogen (Paisley, UK). Polyacrylic acids (PAA) of varying 
average MW, namely 100 kDa, 250 kDa and 450 kDa were purchased from 
Polysciences Europe GmbH (Eppelheim, Germany). Ultrapure chitosan chloride 
(commercially known as 'Protasan UP CL 113', 75-90% deacetylated, with MW in the 
range of 50-150 kDa) was obtained from NovaMatrix (Norway). Pentasodium 
tripolyphosphate (TPP) was purchased from Sigma Aldrich. Fluorescein 
isothiocyanate (FITC, Type I) was purchased from Molecular Probes (Paisley, UK). 
Paraformaldehyde, osmium tetroxide, Triton X-100, Bovine Serum Albumin (BSA), 
Tween 20, FITC-phalloidin, glutaraldehyde and 1,4-Diazabicyclo-octane (DABCO, 
UV mountant) were all obtained from Sigma Aldrich. 3,3,5,5-tetramethylbenzidine 
(TMB) was purchased from Autogen Bioclear Ltd (UK). DAPI (4',6-diamidino-2-
phenylindole) with antifade mounting media (commercially known as Slowfade 
Gold¨) and CellTrackerTM Green were obtained from Invitrogen. Fluorescent and non-
fluorescent polystyrene nanoparticles (NPs) used in this work were purchased from 
different sources. Sulfate-modified, red NPs of 30 nm nominal diameter were 
obtained from Sigma Aldrich; sulfate-modified, yellow-green (YG) NPs 
(FluoSpheres¨) of 20 nm diameter were obtained from Invitrogen (California, USA); 
carboxy-modified, YG NPs (Fluoresbrite¨) of 50 nm diameter and non-fluorescent 
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carboxy-modified NPs of 50 nm (Polybead¨) were supplied by Polysciences Europe 
GmbH (Eppelheim, Germany). All other chemicals were obtained from Sigma 
Aldrich. 
 
2.2 Methods 
2.2.1 Maintenance of cells  
2.2.1.1 Maintenance of cells in culture flasks 
All cell lines were routinely cultured in 75 cm2 flasks at 5% CO2, 95% relative 
humidity and 37¡C until confluence (in this work confluence was considered as 
approximately 75-95% coverage of the flask surface by cells). Cell culture media was 
replaced every other day by aspirating the old culture media from the flasks, followed 
by the addition of 12-15 ml of fresh media, pre-warmed to 37¡C. Cell growth was 
monitored regularly by viewing the cells under an optical microscope. Once 
confluent, cells were passaged using the following procedure: culture medium was 
removed (aspirated) from the flask and cells washed with PBS (5 ml, pre-warmed to 
37¡C), which was added to the flask and the flask gently swirled. PBS removes any 
dead cells remaining in the flask and traces of media; it was important to perform this 
step prior to the addition of trypsin/EDTA solution to cells since FBS present in the cell 
culture media inhibits the action of trypsin. PBS was then aspirated and replaced with 
2.5-3 ml of pre-warmed (37¡C) 2.5% trypsin/EDTA solution. The flask was gently 
swirled to ensure that trypsin/EDTA solution covered the cells and then transferred to 
the incubator at 37¡C. The flask was observed at regular intervals for cell detachment 
from the tissue culture flask plastic. The period of incubation with trypsin/EDTA 
solution was dependent on the cell line and the extent of confluence. Generally, for 
HT29 and Caco-2 cells an incubation period of approximately 10 min was sufficient, 
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resulting in complete cell detachment from the flask plastic. On the other hand, Calu-
3 cells required up to 15-20 min incubation with trypsin/EDTA for complete 
detachment from the flasks. Following cell detachment, approximately 10 ml of pre-
warmed (37¡C) culture medium was added to the flasks in order to dilute the cell 
suspension and deactivate trypsin (different media were used for each cell line, as will 
be described later). The resulting cell suspension was transferred to a sterile 
centrifuge tube and the cells centrifuged (pelleted) at 250g for 5 min. Trypsin-
containing supernatant was aspirated and prewarmed culture medium (37¡C, 5-10 ml) 
added to the cell pellet to create a cell suspension. A proportion of the resulting cell 
suspension was transferred to a new flask (containing prewarmed culture medium 
appropriate for the cell line) for further culturing. Split ratios between 1:3 and 1:5 
were normally used for Calu-3 cells, while ratios between 1:4 and 1:8 were typically 
used for both HT29 and Caco-2 cells. Calu-3, Caco-2 and HT29 cells were cultured in 
EMEM, DMEM and McCoy's-5A medium, respectively. Culture media were 
supplemented with various components as described above (section 2.1.1).  
 
2.2.1.2 Frozen storage of cells 
Cells were cultured to confluence and then detached from the flask in the manner 
described previously (section 2.2.1.1). Following centrifugation of the cell suspension, 
the supernatant was aspirated, and the cell pellet was re-suspended in 1 ml of complete 
culture medium containing sterile DMSO. The concentration of DMSO used was 5% v/v 
for Calu-3 and Caco-2 cells and 7.5% v/v for HT29 cells. The cell suspension was added 
to a sterile cryovial (clearly labelled with the cell type, passage number, user name and 
date), which was placed into a freezing container ('Mr Frosty') in a -80¡C freezer for a 
gradual, controlled temperature decrease. Cells were stored at Ð80¡C for up to 4 weeks. 
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Thereafter, cells were transferred into a liquid nitrogen cell storage tank. Note that cells 
from a single confluent monolayer in one 75 cm2 tissue culture flask were transferred 
and stored frozen in one cryovial; multiple flasks of cells were routinely detached and 
transferred into the equivalent number or sterile cryovials for frozen storage. 
 
2.2.1.3 Cell revival  
Cryovials containing frozen cells were removed from the liquid nitrogen-containing 
storage tank and thawed by placing the cryovial in the incubator at 37¡C for 
approximately 5 min. DMSO-containing medium was removed by transferring the cell 
suspension into a centrifuge tube containing approximately 10 ml of warm (37¡C) 
culture medium, centrifuging the resulting suspension at 250g for 5 min and aspirating 
the supernatant. The cell pellet was thereafter suspended in approximately 5 ml of 
culture medium and transferred into a 75 cm2 flask containing approximately 10 ml of 
fresh, warmed (37¡C) culture medium. Note that cells from one cryovial were revived 
and transferred into one tissue culture flask.  
 
2.2.1.4 Culture of cells on transwells 
2.2.1.4.1 Calu-3 cells  
Calu-3 cells were cultured to confluence in 75 cm2 flasks at 5% CO2 and 37¡C. Cells 
were then detached from the flasks using the method described above (2.2.1.1). 
Transwell¨ filters were incubated with EMEM (250 µl and 1.5 ml on the apical and 
basolateral chambers, respectively) at 37¡C for approximately 15 min prior to the 
addition of cells. This was performed in order to coat the surface of the filter plastic 
with proteins present in the culture medium (serum), possibly resulting in 
improvement of cell attachment to plastic. Cells were counted using a 
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haemocytometer and the volume of the cell suspension containing the required 
number of cells was calculated. These volumes were subsequently added to the donor 
compartments of the transwells. The number of cells added ('seeding density') was 105 
per 1 cm2 of the Transwell¨ filter area. The apical chamber volume was made up to 
500 µl by adding warmed EMEM. After seeding on filters, cells were maintained at 
5% CO2, 37¡C with EMEM. 
 
Following the initial seeding on filters, Calu-3 cells were cultured in two ways: 1) 
cells were continuously exposed to culture medium on both apical and basolateral 
sides (0.5 ml and 1.5 ml, respectively), i.e. cells were grown using liquid covered 
culture (LCC); and 2) cells were cultured on transwells with medium present in the 
basolateral (acceptor) chamber only. The latter culture condition where the cells are 
exposed to the culture medium on their basal surface only is known as air-interfaced 
culture (AIC) or air-liquid interface (ALI) (note that the abbreviation AIC will be 
used in this work). Following their seeding on filters, cells were cultured using LCC 
conditions for two days. Thereafter, AIC conditions were created where cells were 
cultured with the culture medium (0.5 ml) present in the basolateral chamber only; 
cells were maintained at AIC for the remainder of the culture period.  
 
For both culture conditions (LCC and AIC), the culture medium was subsequently 
replaced with fresh medium periodically (every other day). It is worth noting at this 
stage that, in this thesis, Calu-3 cells were typically cultured using AIC conditions 
only. However, in some cases cells were also cultured using LCC conditions for the 
purpose of comparison (of barrier properties and receptor expression) with AIC cells, 
as it will be apparent from Chapter 3 and 7. In cases where Calu-3 cells were cultured 
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using LCC conditions, this will be clearly stated; where culture conditions are not 
specified, cells were cultured using AIC. Calu-3 cells were typically cultured on 
filters for a period of 9-14 days prior to their use in experiments as confluent and 
polarised cell layers; work detailed in Chapter 7 was exclusively conducted on Calu-3 
cells cultured on filters for 13-14 days. 
 
2.2.1.4.2 Caco-2 cells 
Caco-2 cells were seeded on filters in a similar way to Calu-3 cells, except that a 
density of 2x105 cells/cm2 was used. Caco-2 cells were cultured using LCC conditions 
only, with DMEM as the culture medium and were routinely grown on filters for 21-
23 days (with culture medium replaced every other day) prior to their use in 
experiments as confluent, polarised cell monolayers. 
 
2.2.2 Measurement of TEER 
Transepithelial Electrical Resistance (TEER) is a measure of resistance to ion flux 
across an epithelial layer largely reflecting the degree of confluence of the cells and 
the paracellular pathway. TEER measurement has in the last two decades become 
universally established as the most convenient, reliable and non-destructive method to 
monitor the growth of epithelial tissue cultures in vitro, evaluate cell layer integrity 
and determine the presence and the tightness of the cellular tight junctions (TJs) (1). 
Measurements of TEER were conducted using the system depicted in Figure 2.1. 
Briefly, the chopstick electrodes were firstly sterilised by immersing in absolute 
ethanol for approximately 30 min prior to their use. The electrodes were then washed 
with PBS and carefully placed in the culture medium bathing the cell layers; the 
shorter electrode was submerged in the medium bathing the cells on the apical side, 
Chapter 2  Materials and General Methods 
 60 
while the longer electrode was placed in medium present on the basolateral chamber. 
The resulting readings were recorded. TEER was measured immediately upon 
removal of the cells from the incubator in all cases, in an attempt to minimise 
variability in observed TEER arising due to differences in temperature (TEER is 
affected by changes in temperature).  
 
 
 
 
 
 
 
Figure 2.1. Schematic representation of the Epithelial Voltohmmeter system used to measure TEER 
of the cell layers. 
 
In situations where measurements were conducted for the sole purpose of monitoring 
the cell growth, TEER was measured in the culture medium. For Calu-3 cells cultured 
using AIC conditions, culture medium was removed from the basolateral side and 
replaced with fresh, warmed medium on both apical and basolateral sides (0.5 ml and 
1.5 ml, respectively). TEER was then measured following the incubation of cells with 
the culture medium on both sides (apical and basolateral) for approximately 45 min. 
This was done in order to minimise any possible effect that the physical shock 
resulting from replacement of the culture medium may have on TEER. In order to 
prevent any damage that may result from a possible leakage of ions from the 
electrodes, the culture medium was replaced following TEER measurements. 
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During the initial culture of Calu-3 cells on filters, TEER was measured every other 
day starting from day 2 to 15 of culture (daily measurements were avoided due to the 
possibility of cell damage from the measurement process and leakage of ions from 
electrodes). This step was repeated and the TEER development profile was found to 
be reproducible. TEER was subsequently only measured prior to the use of cell layers 
in experiments in order to establish cell confluence, cell layer intactness and TJ 
formation. 
 
TEER values reported in this work take into account the area of the cell layer 
(assumed to amount to the area of the Transwell¨ filter) and are expressed as Ωcm2. 
Furthermore, electrical resistance across the cell-free Transwell¨ filters (background 
resistance) was also measured on every batch of Transwell¨ filters used in the 
experiments. This value (typically 100-110 Ωcm2, depending on the batch) was 
subtracted from the measured cell layer TEER in all experiments in this work; 
background filter resistance is therefore accounted for in all the reported values in this 
thesis. 
 
2.2.3 Evaluation of TJ modulation through measurement of TEER  
The purpose of these experiments was to assess the TJ modulating (opening) capacity 
of various compounds. Considering the nature of the experiments, only filter-cultured 
cell layers exhibiting TEER of 500 Ωcm2 or above were considered adequate for the 
purpose of these studies. Note that filter-cultured cells with a TEER ≥500 Ωcm2 are 
referred to as 'confluent cell layersÕ throughout this thesis. The experiments were 
conducted in HBSS, which was buffered at pH 6.0 (with 10 mM MES) or pH 7.4 
(using 25 mM HEPES). Prior to application of the test samples to cells, the culture 
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medium was removed, cells washed with PBS and HBSS (warmed to 37¡C; pH 7.4) 
added to both sides of the cell layers. Cells were equilibrated in HBSS (i.e. incubated 
at 37¡C, 5% CO2) for approximately 45 min, following which initial TEER 
measurements were conducted; the recorded values were considered as baseline 
TEER. HBSS was then removed from the apical side of the cell layers and replaced 
with the test samples (previously warmed to 37¡C). Unless otherwise stated, cells 
were incubated with the samples for 2 hours, with TEER measurements at times 0.5, 
1, 1.5 and 2 hours following sample application in the presence of the tested samples 
in HBSS. The samples were removed from the cells 2 hours post-application and cells 
washed with PBS (3 times). Culture medium (appropriate for the cell line, see section 
2.2.1.1) was then added to the cell layers and cells incubated with the culture medium 
overnight. In order to determine whether the effect of the tested samples on TEER (if 
any) was reversible, TEER was measured (in culture medium) 4 hours and 24 hours 
(the following day) after test sample application. TEER changes are reported as 
percentage of the baseline value (i.e. TEER value before sample addition). In some 
cases confluent cell layers incubated with HBSS instead of the test samples were used 
as controls. All experiments were conducted in triplicate or quadruplicate. 
 
2.2.4 FITC-dextran (FD) permeability experiments 
In a similar way to TJ modulation experiments (in the previous section), only filter-
cultured cell layers exhibiting TEER ≥500 Ωcm2 (i.e. 'confluent cell layers') were 
considered adequate for FD permeability experiments. TEER measurements were 
conducted prior to the permeability experiments in order to ensure that the cell layers 
were confluent and intact. TEER was also recorded after the permeability experiment 
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in order to confirm intactness of the cell layers throughout the experimental period 
and hence validate the permeability data. 
 
Fluorescein isothiocyanate (FITC)Ðlabeled dextrans (FDs) of varying MWs were used 
in this work as macromolecular tracers (also referred to as 'solutes' and 'penetrants') 
modelling hydrophilic, large MW protein drugs. The availability of FDs in different 
MWs and being fluorescent (enabling a relatively simple quantification) makes these 
molecules ideal for use in experiments investigating macromolecular permeability 
across epithelial cell layers. 
 
HBSS is the most commonly used medium in drug transport experiments (2). To 
enable comparison of the data obtained in this work with those reported in the 
literature, HBSS was used in all transport experiments described in subsequent 
chapters. The availability of HBSS without fluorescent phenol red (present in the 
culture media), which would interfere with the fluorescent macromolecular tracers is 
another advantage associated with the use of HBSS. In order to maintain a desired pH, 
HBSS was supplemented with buffer systems. As described in the previous section, 
HEPES (25 mM) was added to HBSS to maintain a physiological pH 7.4, whereas 
MES (10 mM) was used to supplement HBSS in order to maintain a slightly acidic 
pH 6.0. In the subsequent chapters of this thesis, HBSS is sometimes referred to as the 
'transport medium'. HBSS buffered at pH 6.0 and 7.4 represents HBSS supplemented 
with MES and HEPES, respectively. Note that 'HBSS pH 6.0' signifies the use of 
MES-buffered HBSS in the forthcoming Chapters; where the pH is not specified, 
HBSS was buffered (pH 7.4) by supplementing with HEPES. 
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Unless otherwise stated in individual chapters, permeability experiments were 
conducted in the following way. Culture medium was removed from the cell layers 
and cells washed with warm (37¡C) PBS. HBSS was then added to the apical (0.5 ml) 
and basolateral (1.5 ml) chambers of the Transwell¨ system. Cells were incubated (at 
37¡C/5% CO2) with HBSS for approximately 45 min for the purpose of equilibration. 
TEER was then measured in order to confirm the 'confluence' and the intactness of the 
cell layers, following which HBSS was removed from the apical side. Unless 
otherwise stated, permeability experiments were started by applying 0.5 ml of the test 
solution to the apical side of the cells (donor compartment of the transwells). Test 
solutions contained a FD with or without a compound that was investigated for its 
permeability enhancing effect. The final concentration of FDs in the apical chamber 
was kept constant at 500 µg/ml in all FD permeability experiments.  
 
FD permeability was determined by sampling the basolateral solution at regular time 
intervals. More specifically, 100 µl volumes were removed from the basolateral 
chamber of the Transwell¨ system every 30 min for 3 hours. The sampled solutions 
were immediately replaced with equal volumes of the transport medium (HBSS). 
Between sampling times, cells were incubated at 37¡C/5% CO2. To ensure that the 
cell layer integrity remained intact during the permeability experiment, TEER was 
measured following the final sampling point. Sampled solutions were transferred into 
a black 96-well plate, which was then covered with aluminium foil to protect from 
light. Sample solution fluorescence (485 nm excitation, 535 nm emission) was then 
determined using an MFX microtiter plate fluorometer (Dynex Technologies, USA).  
 
FD in the basolateral solutions was quantified by converting the fluorescence readings 
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into FD concentrations and ultimately amounts, through construction of calibration 
curves. Briefly, this involved measuring the fluorescence intensity of progressively 
diluted FD solutions of known FD concentrations. At least three such calibration 
curves were established; the mean values were then calculated and used for FD 
quantitation in each experiment.  
 
FD permeability is expressed as the apparent permeability coefficient (Papp), 
calculated using the following equation: 
      
 
  
Where:  
¥ Papp is the apparent permeability in cm/s  
¥ ∆Q/∆t is the permeability rate [amount FD (µg) traversing the cell layers over 
time (s)]. This was determined by plotting the amount of transported solute 
over time and calculating the gradient of the straight-line (i.e. steady state) 
portion (typically transport over time points 30 min Ð 3 h) of the resulting 
curve 
¥ A is the diffusion area of the layer (cm2), and  
¥ Co is the initial FD concentration (500 µg/ml) 
 
2.2.5 Cell toxicity studies 
2.2.5.1 Background information on toxicity tests  
 
AlamarBlue
¨
 assay, which was first described by Fields et al. (3), involves the 
addition of a fluorogenic redox indicator to growing cells in culture. The oxidized 
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form of alamarBlue¨, which has a dark blue color, has little intrinsic fluorescence. 
However, in response to a chemical reduction of growth medium resulting from cell 
growth, the dye is reduced and turns red. The reduced form of alamarBlue¨ is highly 
fluorescent. The extent of this conversion is a reflection of cell metabolic activity and 
can be quantified by fluorescence. 
 
There are many advantages associated with the use of the alamarBlue¨ assay to 
determine cell proliferation or toxicity, including its simplicity (the indicator is added 
directly to cells in culture) and non-toxicity to the cells and the user. Furthermore, it 
has been reported that the alamarBlue¨ assay is comparable in sensitivity to the 
thymidine incorporation and tetrazolium reduction assays for the measurement of cell 
proliferation and cytotoxicity (4, 5). 
  
The MTS assay is also a colorimetric method for determining the number of viable 
cells in proliferation or cytotoxicity assays, containing a novel tetrazolium compound, 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-
tetrazolium (inner salt), and an electron coupling reagent (phenazine ethosulfate; 
PES). PES has enhanced chemical stability allowing its combination with MTS to 
form a stable solution. The MTS tetrazolium compound is bioreduced by cells into a 
colored formazan product that is soluble in tissue culture medium. This conversion is 
thought to occur by NADPH or NADH produced by dehydrogenase enzymes in 
metabolically active cells (6). 
 
Lactate dehydrogenase (LDH) assay is a simple and convenient method for 
assessing cytotoxicity or cell viability. This assay, first described as a cytotoxicity test 
by Legrand et al. (7), can be used as an indicator of relative cell viability as well as a 
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function of membrane integrity of cells. With respect to the latter, the LDH assay is 
particularly valuable for testing compounds that perturb the cell membrane. The assay 
is based on the reduction of NAD by the action of LDH. The resulting reduced NAD 
(NADH) is used in the conversion of a tetrazolium dye into a coloured compound, 
which can then be measured spectrophotometrically. The extent of membrane damage 
results in a concomitant change in the amount of substrate converted. In this work, the 
LDH assay was used to test cell membrane integrity as a function of the amount of 
cytoplasmic LDH released into the medium relative to controls (described later). 
 
2.2.5.2 AlamarBlue
¨
 Cell Metabolic Activity Assay  
 
This assay was used to test the cytotoxicity of compounds on confluent Calu-3 layers 
or cells cultured on multiwell plates. In the first scenario, cell layers were incubated 
with the tested compounds and controls, followed by washing with PBS (three times). 
HBSS and Triton X-100 (0.1% v/v in HBSS) were used as the negative and positive 
control, respectively. AlamarBlue¨ stock solution was diluted 1 in 10 in HBSS to 
produce alamarBlue¨ working solution; this solution was then applied above and 
below the cell layers (0.5 ml and 1.5 ml, respectively). Cells were incubated with the 
alamarBlue¨ reagent for 90 min following which 100 µl samples were collected (from 
the apical side) and transferred into a black 96-well plate (covered with aluminium 
foil to protect from light). Sample fluorescence (Ex 560 nm/ Em 590 nm) was then 
measured using an MFX microtiter plate fluorometer (Dynex Technologies, USA).  
 
AlamarBlue¨ assay was also conducted on cells cultured on 24-multiwell plates. Cells 
were incubated with the tested compounds and controls, followed by washing with 
PBS. 1 ml of the alamarBlue¨ working solution was then applied to the wells. Cells 
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were incubated with the alamarBlue¨ reagent for 90 min following which 100 µl 
volumes of this solution were collected and tested for fluorescence as before.  
 
The relative cell metabolic activity (%) was calculated using the following equation:  
 
 
Where:  
¥ S is the fluorescence of the tested samples 
¥ T is the fluorescence of cells incubated with Triton X-100, and 
¥ H is the fluorescence of cells incubated with HBSS 
 
2.2.5.3 MTS Cell Metabolic Activity Assay  
The MTS assay was performed on Calu-3 cells. Unless otherwise stated, the assay 
was conducted in the following way. Cells were seeded on 96-well plates (sterile, cell 
culture treated) at a density of 104 cells per well and incubated at 37¡C/5%CO2 for 24 
hours. This seeding density was chosen (optimised) as it produced an absorbance 
value within the linear range of the assay, as recommended by the manufacturer. 
Culture medium was carefully aspirated (while making sure that the sterile pasteur 
pipette used for this purpose did not touch the cells) and replaced with test sample 
solutions (at different concentrations), dissolved in HBSS (at pH 6.0 or 7.4, as 
specified in the individuals chapters). Cells incubated with HBSS (at the same pH as 
the test samples) were used as the negative control, whereas cells incubated with 
Triton X-100 (0.1% v/v in HBSS at pH identical to that of the test samples) were used 
as the positive control. Samples and controls were previously warmed and applied to 
cells at 37¡C. Following the application of the samples and controls, cells were 
=
S "T
H "T
#100Relative metabolic activity 
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incubated at 37¡C/5%CO2 for 2 hours. Sample solutions (and controls) were then 
aspirated and cells washed with PBS. 100 µl of culture medium (at 37¡C) was added 
onto each well, followed by application of 20 µl of the MTS reagent. Cells were 
incubated with the culture medium/MTS reagent for 1-4 hours (more typically 2-3 
hours), following which absorbance at 492 nm was measured using a Dynex 
absorbance microplate reader (Dynex Technologies, USA). 
 
The relative cell metabolic activity (%) was calculated using the following equation:  
 
 
Where:  
¥ S is the absorbance with the tested samples 
¥ T is the absorbance with Triton X-100 
¥ H is the absorbance with HBSS 
 
2.2.5.4 LDH assay 
The LDH assay was performed to test the membrane toxicity of different compounds 
on Calu-3 cells. Cells were seeded on 96-well plates (sterile, cell culture treated) at a 
seeding density of 104 cells per well and cultured for 24 hours before the assay. 
Culture medium was removed and cells washed with PBS. Test compounds of 
different concentrations dissolved in HBSS (pH 6.0 or 7.4, at 37
o
C) were then 
applied. Triton X-100 (0.1% v/v in HBSS) was used as the positive control to induce 
LDH release, whereas HBSS (pH 6.0 or 7.4) was used as the negative control. Cells 
were incubated with samples and controls for 2 hours, after which 50 µl of the 
solutions were removed from each well and placed onto a new 96-well plate. 100 µl 
Relative metabolic activity 
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of the LDH reagent was added to the samples and an incubation time of 20-30 min at 
room temperature was allowed. After this period, absorbance at 490 nm was measured 
using the Dynex absorbance microplate reader. LDH release was calculated as the 
percentage relative to the controls, using the following equation: 
    
    
   Relative LDH release  
Where: 
¥ S is the absorbance obtained with the tested samples 
¥ H is the absorbance with HBSS 
¥ T is the absorbance with Triton X-100 
 
2.2.6 Cell imaging and labelling  
2.2.6.1 Scanning Electron Microscopy (SEM) 
Filter-cultured confluent Calu-3 layers were fixed by replacing the culture medium 
with 1:1 mixture of culture medium and fixing solution, which comprised 2.5% v/v 
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) on both apical and 
basolateral sides of the transwells. Following an incubation interval of 5 min, this 
solution was removed and replaced with 100% of the fixing solution. The fixing 
solution was then removed and replaced with 1% w/v osmium tetroxide in water; cell 
samples were incubated with this solution at room temperature for 90 minutes. 
Osmium tetroxide is used in electron microscopy both as a fixative and a heavy metal 
stain for lipids in membranous structures and vesicles (8). Osmium tetroxide solution 
was then removed and samples dehydrated in progressively increasing concentrations 
of ethanol in water (25%, 50%, 75%, 95% and 100% v/v). Samples were dried using a 
=
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critical point dryer before filters were removed and mounted on aluminium stubs with 
adhesive double-sided carbon tape. The samples were gold coated for 3 minutes under 
an argon atmosphere in a Blazers Union SCD030 sputter coater unit (Blazers Ltd, 
UK).  Coated samples were examined with a JEOL 6060LV (JEOL, Welwyn, UK) 
variable pressure scanning electron microscope operating at an accelerating voltage of 
10 kV. Image analysis was carried out using the in-built SEM control user interface 
software (version 6.57) and digital imaging system.  
 
2.2.6.2 Transmission Electron Microscopy (TEM) 
Confluent Calu-3 layers were fixed with 4% paraformaldehyde and then washed with 
0.1 M phosphate/cacodylate buffer. Cells were post fixed with 1% aqueous osmium 
tetroxide for 30 mins, followed by extensive washing (5x1 min) with distilled water. 
Samples were then dehydrated in a graded ethanol series by washing the cells for 5 
min (twice) with 50% ethanol, followed by 70% ethanol, followed by 90% ethanol 
and then finally with 3x10 min washes with 100% ethanol. Finally, two 5 min washes 
were performed with 100% dried acetone. Cell samples were then infiltrated with 
resin for a duration of 30 minutes in 1:3 resin:acetone mix, 1 hour in 1:1 resin:acetone 
mix and 3x1 hour incubations in pure resin. Samples were embedded in the resin and 
left in the embedding oven for 48 hours at 60¡C. Once the resin block polymerised, 
the substrate was removed from the cells by immersing the block in liquid nitrogen 
and snapping the substrate from the block. The block was then embedded in a 
microcentrifuge tube containing fresh resin and was polymerised as before, enclosing 
the cell layer in a resin block. The layer was cut out of the block by sawing either 
slide of it to give a disc of resin with the layer running through the middle. The disc 
was cut in half to form 2 semi-circles, which were stuck onto the top of a blank resin 
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block (using Araldite¨ epoxy resin). The Araldite¨ was left to set for a period of 1 
hour. Ultrathin sections were cut using a cryoultramicrotome (Leica EM, UC6/FC6, 
Milton Keynes, UK) and viewed by TEM (Jeol JEM 1010 Electron Microscope, 
Japan). Note that some aspects of sample preparation for TEM were performed by the 
Advanced Microscopy Unit group, School of Biomedical Sciences, University of 
Nottingham.  
 
2.2.6.3 CellTrackerª staining 
CellTrackerª reagents pass through the cell membranes and once inside the cells 
they are converted into cell membrane-impermeant products. These dyes contain a 
chloromethyl or bromomethyl group that reacts with thiols, which is thought to occur 
in a glutathione S-transferaseÐmediated reaction since this has been shown to occur in 
vitro (9). Since glutathione levels are high (up to 10 mM) in most cells and 
glutathione transferase is ubiquitous, the reagent is transformed into a cell-
impermeant fluorescent dyeÐthioether product.  
 
50 µg of CellTrackerª Green stock solution was dissolved in high quality DMSO to 
produce a 10 mM solution. This solution was subsequently diluted to 10 µM with 
serum-free culture media and warmed to 37¡C. Filter-cultured, confluent Calu-3 
layers were washed with PBS, following which 500 µl of the labelling solution was 
added to the apical side of the cells; cells were incubated with CellTrackerª green 
solution for 45 min. The labelling solution was then removed and replaced with 
culture medium (EMEM). Cells were incubated with EMEM for 30 min. EMEM was 
then aspirated and cells fixed by incubating with 4% paraformaldehyde in PBS for 
approximately 10 min. Transwell¨ filters (containing cells) were then excised and 
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mounted (using DABCO mounting medium) on glass slides for confocal imaging. 
Cells were imaged using a Leica TCS SP2 system mounted on a Leica DMIRE2 
inverted microscope. 
 
2.2.6.4 Actin staining 
Calu-3 cells were cultured on filters until confluent cell layers were formed, as 
described previously. Culture medium was removed and cells washed with BSA 1% 
w/v in PBS (BSA/PBS). Cells were then fixed in 4% paraformaldehyde (in PBS) for 
approximately 10 min at room temperature. The fixative was then removed and cells 
washed (3 times) with 1% BSA/PBS. Cells were permeabilised by applying cold 
permeabilising solution (consisting of 20 mM HEPES, 300 mM sucrose, 50 mM 
NaCl, 3 mM MgCl2 and 0.5% v/v Triton X-100; in PBS at pH 7.4); cells were 
incubated with the permeabilising solution for 5 min in the freezer (-20¡C), ensuring 
that the solution did not freeze. The permeabilising solution was then removed and 
cells washed three times with 1% BSA/PBS. Cells were incubated with 10 µg/ml 
FITC-phalloidin for 20 min at room temperature. FITC-phalloidin solution was then 
removed and cells washed with 1% BSA/PBS (3 times). Cell layer-containing filters 
were then excised carefully with a scalpel and placed on glass slides. Samples were 
mounted on glass slides with DABCO and covered with glass cover slips. Cells were 
imaged using the Leica confocal system, described in the previous section.  
 
2.2.6.5 MUC-1, mucus protein staining 
Calu-3 cells were cultured on filters as before. Confluent cell layers were fixed in 
paraformaldehyde (by incubating for approximately 10 min) at room temperature. 
Cells were then washed with PBS and permeabilised by incubating with Triton X-100 
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(0.1% v/v in PBS) for approximately 10 min. Cells were then washed and incubated 
with 1% w/v BSA in PBS for approximately 1 hour; this step was performed to 
block/minimise any non-specific antibody binding. BSA/PBS was then removed and 
cells incubated with mouse, anti-human MUC-1 (primary) antibody for approximately 
1 hour. Following the incubation with the primary antibody, cells were washed 
extensively (5 times) with PBS, following which goat, anti-mouse FITC-IgG 
(secondary antibody) was added and cells incubated with the secondary antibody for 
approximately 1 hour. Cells were then washed extensively and Transwell¨ filters 
excised and mounted on glass slides (using DAPI-containing, ProLong¨ Gold 
antifade/mounting medium) for confocal imaging. Confocal imaging was performed 
using the Leica TCS SP2 confocal system. 
 
2.2.6.6 Zonula Occludens (ZO-1) TJ staining 
Confluent, filter-cultured cell layers were fixed in paraformaldehyde for 
approximately 10 min at room temperature. Cells were then washed with PBS and 
permeabilised by incubating with Triton X-100 (0.1% v/v in PBS) for approximately 
10 min. Cells were then washed with PBS, followed by the application of 1% 
BSA/PBS for approximately 1 hour. Thereafter, BSA/PBS solution was aspirated and 
replaced with mouse, anti-human ZO-1 (primary) antibody, diluted in 1% BSA/PBS 
to a final concentration of 10 µg/ml. Cell samples were incubated with the primary 
antibody for 1 hour. The primary antibody solution was then removed and cells 
washed with PBS (5 times). FITC- or Cy5-labelled goat, anti-mouse (secondary) 
antibody, diluted according to manufacturerÕs instructions in 1% BSA/PBS was then 
applied to the cells for 1 hour. The secondary antibody solution was then aspirated 
and cells washed with PBS extensively. The Transwell¨ filter membrane was excised 
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and mounted on glass slides (using the ProLong¨ Gold mounting medium) for 
confocal imaging, which was performed using the confocal system described in 
section 2.2.6.3. 
 
2.2.7 Antibody quantitation  
2.2.7.1 Quantitation of IgG by ELISA following transport experiments 
Basolateral solutions (100 µl volumes), sampled following IgG transport experiments 
(see Chapter 7) were placed on 96-well polystyrene ELISA plates and incubated 
overnight at 4¡C; this was performed so that any IgG present in the basolateral 
solutions coated the surfaces of the multiwell plate. The following day, sample 
solutions were removed and the plate washed three times with the wash buffer 
consisting of Tween 20, 0.05% v/v in PBS. The wells were then blocked by applying 
200 µl of 1% BSA w/v in PBS (blocking buffer) for 1 hour at room temperature. 
Blocking buffer was then removed and the wells washed (with the wash buffer) as 
before. 100 µl of anti-human IgG conjugated to horseradish peroxidase (HRP), diluted 
1:1000 in blocking buffer was added to individual wells; the plate was incubated for 2 
hours at room temperature. Anti-human IgG-HRP solution was then removed and the 
plate wells washed with the wash buffer (3 times). TMB substrate (100 µl) was added 
into each well for approximately 10 min. The reaction was stopped by adding 20 µl of 
2.5 M sulphuric acid, following which the plates were transferred into the Dynex 
microplate reader for determination of absorbance (measured at 450 nm).  
 
IgG was quantified by converting the absorbance readings into concentrations (and 
eventually amounts) through preconstructed calibration curves. In a similar way to FD 
calibrations curves, ELISA was performed on series of progressively diluted solutions 
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of known IgG concentrations. The resulting absorbance readings were plotted against 
concentrations. Calibration curves were constructed in triplicate and the calculated 
mean value was used for quantitation. The straight-line segment of the resulting curve 
was used to convert the absorbance readings of samples (i.e. basolateral solutions 
containing unknown IgG levels) into IgG concentrations. Note that calibration curves 
were created for each IgG transport experiment and that ELISA was performed in the 
same manner for both calibration curves and samples containing unknown IgG 
concentrations.  
 
2.2.7.2 Quantitation of investigational therapeutic antibodies by HPLC  
hCTMO1 antibody, hCTMO1 Fab, murine mA33γ1 Fab and murine mA33γ1 Fab-
diPEG) were quantified by high-pressure liquid chromatography (HPLC) using a 
Gilson Model 600 pump equipped with a Gilson photodiode array detector, a 20 µl 
loop injection autosampler and Empower software. For analysis, a Zorbax GF250 size 
exclusion column was eluted with 0.2 M sodium phosphate buffer (prefiltered using 
0.2 µm filters and degassed) at pH 7.0 in isocratic mode. The flow rate of 1 ml/min 
was maintained and the column eluent was monitored continuously at 277 nm. 
Quantitation of the compounds was carried out by measuring the peak areas in 
relation to those of the calibration curves (i.e. series of progressively diluted antibody 
solutions of known concentrations) chromatographed under the same conditions. 
 
2.2.8 Statistical analysis 
Statistical comparisons were performed by Student's t-test. Values of p<0.05 were 
considered statistically significant. 
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Chapter 3 
Calu-3 Layer Model: Morphological and 
Barrier Characteristics  
 
3.1 Introduction  
An essential prerequisite for investigation of mucosal drug absorption in vitro for the 
purpose of predicting in vivo absorption is a mucosal tissue model. An ideal model is 
simple, economical and represents the in vivo conditions as closely as possible. 
Different mucosal tissue models are available. These include excised mucosal tissues, 
three dimensional models based on multiple cell types and epithelial cell layers of 
primary cells and those based on cancerous cell lines. There are advantages and 
disadvantages associated with the use of each of these models. For example, although 
the in vivo conditions are most closely represented by an excised tissue of interest 
(usually from animals with similar tissue characteristics to humansÕ), this model 
usually requires animal sacrifice and suffers from limited viability of the tissue ex 
vivo.  
 
In vitro models based on epithelial cell lines are popular in studies of drug transport 
processes. This is because, compared to an in vivo approach, these models offer the 
simplicity, reduced operational costs, robustness and better control in experiments. 
Furthermore, they minimize animal usage and eliminate variation among animals (1). 
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In vitro cell systems can be manipulated in ways not possible in vivo, allowing 
researchers to study the effects of different variables (such as temperature, 
pharmacological agents, etc.), which is particularly useful in investigating the 
mechanisms of drug transport processes. 
 
A considerable amount of knowledge about active and passive drug transport 
mechanisms has been obtained from studies in various epithelial cell cultures. In fact, 
both cell culture and drug transport experiments across epithelial cultures have been 
automated, with these models being used as a screening tool in the pharmaceutical 
industry for the prediction of intestinal drug absorption (2). This is due to an observed 
good correlation between passive drug transport through various epithelial cell 
monolayers and that observed across the human intestine in vivo (3-5). The 
importance and credibility of the data obtained from drug transport experiments on 
epithelial cell monolayers is highlighted by the fact that both the FDA and the 
European Medicines Agency (6) recommend the use of monolayers of suitable 
epithelial cells for classifying the permeability of drug compounds. However, it is of 
utmost importance to highlight the fact that homogenous epithelial cell cultures lack 
the structural complexity and variability found in vivo and for this reason it is 
important to be cautious in extrapolating in vitro results to the in vivo situation and to 
compare results obtained in the two systems. 
 
The Calu-3 cell line has been extensively researched in the past, partly due to the 
expression of the cystic fibrosis transmembrane conductance regulator (CFTR) 
protein (7, 8), which is important in studies related to cystic fibrosis. Calu-3 cells are 
derived from submucosal gland acini (9) and have been shown to express secretory 
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component, secretory leukocyte protease inhibitor, lysozyme and lactoferrin in 
addition to CFTR (7, 10, 11), which are all markers of serous submucosal gland cells 
(12). On the other hand, Calu-3 cell do not express the epithelial surface marker 15-
lipoxygenase (11). Expression of the mucin gene, muc-2, found in surface goblet cells 
and gland mucous cells of native epithelium, has also been reported (11). Microscopic 
examinations of Calu-3 cells have shown that they contain granules typical of mucus-
secreting cells (9). In culture, the Calu-3 cell line produces features of differentiated, 
functional human airway epithelial cells (7) including the formation of tight junctions 
(TJs), making it one of the few available respiratory cell lines exhibiting this property 
(13-23). It is the combination of all these characteristics and the fact that the Calu-3 
cell line has demonstrated excellent in vitroÐin vivo correlation (24) that enables 
utilization of the Calu-3 cell line as a model of the airway epithelium in mucosal drug 
delivery research.  
 
There is reported evidence to suggest that the characteristics of the Calu-3 layers are 
determined upon the culture conditions employed for their growth (25, 26). Some 
researchers argue that, when grown under air-interfaced culture (AIC) conditions, the 
resulting cell layer resembles the native epithelium (27-29) to a greater extent than 
cells grown using liquid-covered culture (LCC). A study by Grainger et al. has 
reported increased mucus secretion, and more physiological TEER values in cell 
layers cultured using AIC compared to LCC-grown cells (9).  
 
However, marked inconsistencies exist in the literature with regards to the 
morphology and permeability of the Calu-3 layers cultured using AIC and LCC. 
While Fiegel et al. reported a greater abundance of mucus-related acidic glycoproteins 
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in Calu-3 layers cultured using AIC compared to LCC (19) and Florea et al. found a 
reduced differentiated morphology for Calu-3 cultured using LCC (30), other studies 
have indicated no difference between AIC and LCC conditions (18). Furthermore, 
Pezron et al. and Patel et al. reported the appearance of abundant cilia and visible 
mucus production in Calu-3 cells grown using LCC (17, 18). Likewise, while some 
groups reported similar expression of the TJ protein, ZO-1, in AIC and LCC cells 
(19), others have shown a higher expression of this protein in LCC compared to AIC 
cells (9). Inconsistencies in the literature also exist with regards to the presence of 
cilia in Calu-3 cells, with some studies reporting their presence (17, 18) and other 
work reporting no such findings (7, 19, 21, 31). It is because of these inconsistencies 
that, to date, there is no generally accepted consensus on the culture conditions that 
should be followed in growing Calu-3 cells on filters. As a consequence of inter-
laboratory variation in culture conditions, it has been argued that it is important to 
characterise the filter-cultured Calu-3 layers before using them as a model of the 
airways (9). This, therefore, is the rationale for the work detailed in this chapter. 
 
In this part of the project, Calu-3 cells grown using AIC and LCC conditions were 
compared with respect to their TEER profiles (development of TEER with culturing 
time) and the barrier they present to the permeability of hydrophilic macromolecules 
and nanoparticles (NPs). To obtain morphological information, filter-cultured (using 
AIC conditions) Calu-3 layers were characterised by imaging the cells by different 
microscopic techniques. Furthermore, the effect of a mucolytic compound on the 
permeability of a hydrophilic solute across Calu-3 layers was also tested with the aim 
to assess whether the presence of mucus provides a barrier to translocation of 
macromolecules. The barrier properties of Calu-3 layers were also compared with 
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those of Caco-2 cells. As noted previously (section 2.2.1), AIC conditions were 
normally employed for growth of Calu-3 cells in filters; in cases where cells were 
cultured using LCC, this will be clearly stated. 
 
3.2 Methods 
3.2.1 TEER profiles of filter-cultured Calu-3 cells: AIC and LCC conditions 
Calu-3 cells were cultured on flasks until confluence. Thereafter cells were detached 
from the flasks, seeded and cultured on filters using AIC and LCC conditions 
following the methods detailed previously (section 2.2.1). TEER measurements were 
conducted (in the manner described in section 2.2.2) every 2 or 3 days, starting from 
day 2 to day 15 of culture. 
 
3.2.2 Morphological characterisation of filter-cultured Calu-3 cells  
Calu-3 cells were grown using AIC conditions as per usual protocol (section 2.2.1). 
Cells were imaged once they formed confluent and polarised layers (as judged by 
TEER measurements). SEM, TEM, CellTrackerTM Green labelling, F-actin staining, 
MUC-1 (mucus protein) staining and Zonula Occludens-1 (ZO-1) staining were 
performed according to methods described in section 2.2.6. 
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3.2.3 Permeability studies  
3.2.3.1 FD4 permeability across AIC and LCC Calu-3 layers 
Calu-3 cells (of the same passage number) were cultured on filters using AIC and 
LCC conditions. Both AIC- and LCC-grown cell layers were in this instance used for 
FD4 permeability experiment at day 10 of culture. Culture medium was initially 
replaced with warmed (37¡C) HBSS (transport medium). Cells were allowed to 
equilibrate in HBSS for approximately 30 min, following which TEER measurements 
were conducted in order to confirm cell layer intactness and select those with the 
desired values (see sections 2.2.3 and 2.2.4 for further information on TEER values 
that were considered appropriate for TEER and permeability studies). HBSS was then 
removed from the apical side of the cells and replaced with a solution of FD4 
dissolved in the HBSS (500 µg/ml). The rest of the experiment was conducted in the 
manner described previously (section 2.2.4). 
 
3.2.3.2 Effect of N-acetyl cysteine on FD4 permeability 
Calu-3 cells were cultured on filters using AIC conditions and were used in this 
experiment as confluent layers. Culture medium was removed and replaced with a 
solution containing N-acetyl cysteine (NAC), dissolved in HBSS at 0.3% w/v, on the 
apical side and HBSS only on the basolateral compartment of the transwells. Cells 
were incubated with NAC for 30 min after which NAC-containing apical solution was 
removed. Fresh solution of NAC in HBSS was re-applied to the apical side and cells 
incubated with NAC for a further 30 min. Preservation of the intactness of the cell 
layers following the incubation with NAC was assessed by TEER measurements, 
which were conducted before the application of NAC (baseline value) and at the end 
of the incubation period with NAC. NAC-containing solution was then removed from 
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the apical side of the cells and replaced with solutions of FD4 in HBSS (500 µg/ml). 
FD4 permeability was measured by sampling the basolateral solution in the way 
described previously (section 2.2.4). TEER was measured again immediately after the 
last sampling point. 
 
A control experiment was performed by measuring FD4 permeability across the cell 
layers incubated with HBSS for 1 hour, with its replacement at 30 min, to replicate 
the conditions followed for NAC (above). For the purpose of comparison, TEER 
measurements were also performed on control cell layers at the same intervals as on 
the cells exposed to NAC. 
 
3.2.3.3 Permeability of varying MW FDs across Calu-3 layers 
Confluent Calu-3 layers cultured using AIC conditions were evaluated for their 
permeability characteristics with respect to the molar mass of the macromolecular 
solutes (penetrants). FDs with a different molar mass were used as tracer solutes to 
test the effect of MW on permeability. Prior to the application of the tracers, culture 
medium was removed and replaced with HBSS; cells were equilibrated in HBSS for 
approximately 45 min. HBSS was then removed from the apical side and replaced 
with FD solutions, comprising of FD20, FD40, FD70 and FD150 dissolved in HBSS 
(37¡C) at 500 µg/ml. The permeability of different FDs was determined by regular 
sampling of the basolateral solution and quantitation by measurement of fluorescence 
in the same way as for FD4, which was described previously (section 2.2.4).  
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3.2.3.4 Insulin translocation across Calu-3 layers 
Calu-3 cells were cultured on filters as before and used as confluent layers. 
Permeability experiments were commenced after replacement of the culture medium 
with HBSS and equilibration in HBSS (for approximately 45 min). Stock solutions of 
FITC-insulin dissolved in HBSS at pH 6.0 at a concentration of 160 µg/ml were 
prepared on the day of the permeability experiment. FITC-insulin solution was 
applied to the apical side of the cells at a final concentration of 80 µg/ml (in HBSS; 
pH 6.0) and its transport across the cell layers was determined by sampling (100 µl 
volumes) the basolateral solution at regular time intervals. The sampled volumes from 
the basolateral chamber were replaced with fresh HBSS. Insulin was quantified by 
fluorescence measurements (485 nm excitation, 535 nm emission) in a similar way to 
quantitation of FDs (described in section 2.2.4). The results were expressed as 
apparent permeability coefficient (Papp), calculated according to the equation in 
section 2.2.4. 
 
3.2.3.5 Comparison of FD permeability across Calu-3 and Caco-2 layers  
FD20 and FD40 were used as large molar mass tracer solutes for the purpose of this 
experiment. Calu-3 cells were cultured using AIC conditions in a way described 
previously, while Caco-2 cells were cultured on filters in the manner described in 
section 2.2.1.4.2 prior to their use. The experiment was conducted in an identical way 
for the cell layers of both cell lines: HBSS was used as the transport medium for both 
Calu-3 and Caco-2 cells and both cell lines were equilibrated in the transport medium 
for the same period of time (approximately 45 min) prior to the start of the 
experiment. Additionally, FDs were used at an equal concentration (500 µg/ml) and 
the permeability was assessed over the same time period (3 hours), with sampling at 
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the same time intervals (every 30 min). FDs were quantified by fluorescence using the 
method described previously (section 2.2.4).  
 
3.2.4 Nanoparticle translocation across Calu-3 and Caco-2 layers  
Calu-3 and Caco-2 cells were cultured on filters in the manner described previously 
(section 2.2.1). Calu-3 cells were cultured using both AIC and LCC conditions. Cell 
layers were equilibrated in HBSS for approximately 45 min. TEER was measured just 
before the addition of NPs; Calu-3 layers with a TEER ≥500 and Caco-2 monolayers 
with a TEER ≥1000 Ωcm2, were included in the experiment. Carboxy-modified, 
fluorescent (yellow-green) polystyrene NPs (Fluoresbrite¨) of 50 nm nominal 
diameter, were diluted in HBSS (1 in 100) and applied to the apical side of the cell 
layers. Apical-to-basolateral translocation was measured by sampling the basolateral 
solution (i.e. removing 100 µl volumes) at 30 min intervals for 2 hours. The extent of 
NP translocation across the cell layers was determined by measuring the fluorescence 
(485 nm excitation, 535 nm emission) of the basolateral solutions and converting the 
obtained values into concentrations and percent amount relative to that applied 
apically through pre-constructed calibration curves (based on the same principle as for 
FD quantitation). NP transport across the cell layers is expressed as % of the applied 
amount.  
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3.3 Results 
3.3.1 TEER profiles of filter-cultured Calu-3 cells: AIC and LCC conditions 
Figure 3.1 compares changes in TEER over time observed for Calu-3 layers cultured 
using AIC and LLC conditions. No meaningful increase in TEER was observed until 
day 6 of culture for cell layers cultured using either AIC or LCC conditions. 
Thereafter, TEER increased sharply, but subsequently plateaued after day 10 in 
culture, for both AIC and LCC cells. Of notable difference are the maximal TEER 
values reached in different culture conditions; these equated to 817 Ωcm2 and 1525 
Ωcm2 in AIC and LLC cells, respectively.  
  
Figure 3.1. TEER profiles of Calu-3 cells cultured on filters using AIC and LCC conditions. TEER 
is expressed as the measured resistance per area (cm
2
) of the cell layer. Background TEER due to 
the filter was subtracted from the reported TEER values. Data presented as the mean ± SD (n=5).  
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3.3.2 Morphological characterisation of filter-cultured Calu-3 cells 
3.3.2.1 SEM  
SEM revealed that Calu-3 cells form a tightly packed layer of cells when cultured on 
filters using AIC conditions (Figure 3.2). Furthermore the presence of microvilli can 
be observed from the figure. Apical projections on the surface of the cells and cilia 
were, however, not observed. 
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a)             b)          c) 
 
 
 
 
 
 
 
Figure 3.2. Characterisation of the Calu-3 layer model by SEM.  a) Imaging of a larger area showing closely packed cells, b) Magnified image, and c) A further 
magnified image showing the presence of microvilli on the surface of the cells. The observed cracks are artifacts resulting from sample processing for imaging. Cell-
cell boundaries can be seen in all images. While lines represent scale bars of 50 µm (a) and 5 µm (b and c). 
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3.3.2.2 TEM  
TEM micrographs (Figure 3.3) indicated that filter-cultured Calu-3 cells express 
round granules of approximately 1 µm diameter, which were located apically (3.3a 
and 3.3c). These granules were electron-translucent, with some exhibiting an electron 
dense core (3.3c). Furthermore, cellular tight junctions ('TJ') and desmosomes ('DES') 
interconnecting adjacent cells can clearly be seen (3.3b). The presence of microvilli 
('MV') on the apical membrane is also apparent (3.3 a and c), as are the cell 
boundaries ('CB') (3.3 a and b). The Transwell
¨
 filter ('filter') can also be seen on the 
micrographs.   
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  a)       b)              c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. TEM micrographs of confluent, filter-cultured Calu-3 cells. a) A cell expressing microvilli (MV) 
on the apical membrane, secretory granules (SG) and a TJ structure at the point of contact with the adjacent 
cell; cell bounday (CB) can also be seen. b) Adjacent cells inter-connected by a TJ; desomosomes (DES) can 
also be observed. c) Apical surface of a single cell showing the presence of secretory granules (SG) and 
microvilli (MV). White lines represent scale bars of 2 µm.  
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3.3.2.3 Whole cell labelling and staining for F-actin and MUC-1, mucus protein 
Figure 3.4 shows confocal micrographs of Calu-3 layers. More specifically, Figure 
3.4a depicts cells labelled with CellTracker
TM
 Green, a non-specific whole cell label. 
Closely packed cells covering the whole imaged area can be seen from the figure.  
 
Confocal imaging of the cells, following their staining for cytoskeletal F-actin 
revealed the presence of perijunctional rings of F-actin, seen as continuous rings of 
fluorescence at cell-cell contacts (Figure 3.4b).  
 
Figure 3.4c, on the other hand, shows a confocal micrograph of Calu-3 cells stained 
for MUC-1, mucus protein. Green fluorescence, apparent on the micrograph, shows 
distribution of the MUC-1 protein (more specifically it shows the distribution of 
FITC-IgG, targeted towards anti-MUC-1 antibody), while blue fluorescence is that 
resulting from cell nuclei label, DAPI. It is apparent from the image that green 
fluorescence is predominantly distributed on the apical side of the cells (labelled A).  
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     a)                         b)              c) 
 
 
 
 
 
 
 
Figure 3.4. Confocal micrographs of confluent, filter-cultured Calu-3 layers: a) Cells following staining with CellTracker
TM
 Green, b) Cells following their 
staining with FITC-phalloidin, and c) Staining for the mucus protein, MUC-1, where green fluorescence is that resulting from goat, anti-mouse IgG FITC, 
which is a secondary antibody to mouse, anti-human MUC-1 and blue fluorescence is due to DAPI used to label the cell nuclei (A = apical side, B = basolateral 
side). White lines represent scale bars of 20 µm. 
B A 
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3.3.3.4 Zonula Occludens-1 (ZO-1) staining 
Immunostaining of confluent, filter-cultured Calu-3 cells with an antibody to ZO-1 
protein, a structural and functional component of TJs, revealed the distribution of this 
protein as continuous 'rings' at cell-cell contacts. This is shown in Figure 3.5. 
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 a)      b)      c) 
 
 
 
 
 
 
 
 
Figure 3.5. Staining of a confluent, filter cultured Calu-3 layer for Zonula Occludens-1 (ZO-1) TJ protein. i) Blue channel showing DAPI-labelled cell nuclei, ii) Far red 
channel showing ZO-1 distribution (specifically the fluorescence pattern is that of Cy5-labelled goat, anti-mouse IgG, an antibody to mouse, anti-human ZO-1), and iii) 
Overlay image (Blue cell nuclei and Red ZO-1) 
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3.3.3 Permeability studies  
3.3.3.1 FD4 permeability across AIC and LCC Calu-3 layers 
Permeability of FD4 across filter-grown Calu-3 cells cultured using AIC and LCC 
conditions is shown in Figure 3.6. Confluent cell layers grown at AIC presented a 
greater barrier to FD4 translocation compared to cells cultured using LCC. The 
obtained fluorescence readings resulting from gradual accumulation of FD4 in the 
periodically sampled basolateral solution were converted into apparent permeability 
coefficients (Papp). These values were calculated to be approximately 1.7x10
-7
 cm/s 
and approximately 5.7x10
-7
 cm/s for AIC and LCC layers, respectively, revealing an 
approximately 3-fold higher rate of FD4 permeability across the cell layers cultured 
using LCC compared to those cultured using AIC.  
 
 
 
 
 
 
 
 
 
Figure 3.6. Effect of culture conditions on FD4 permeability across Calu-3 layers. Black bar 
(labelled AIC) represents permeability across cells cultured under AIC conditions and empty bar 
(labelled LCC) represents permeability across cells cultured using LCC conditions. FD4 
permeability expressed as Papp, calculated using the equation in section 2.2.4. Results presented as 
the mean ± SD (n=3).  
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3.3.3.2 Effect of N-acetyl cysteine on FD4 permeability 
FD4 permeability across Calu-3 layers that were previously incubated with NAC is 
shown in Figure 3.7. This is compared with FD4 permeability in cell layers not 
subjected to NAC treatment (control). FD4 traversed the cell layers pre-incubated 
with NAC more readily compared to cells not subjected to NAC treatment. The 
apparent permeability coefficient (Papp) values obtained were 6.1x10
-8
 cm/s and 
1.7x10
-8
 cm/s and, respectively, revealing a 3.6-fold higher permeability in cells 
exposed to NAC. 
 
 
 
 
 
 
 
 
 
Figure 3.7. Effect of NAC on FD4 permeability across Calu-3 layers. Black bar represents cells 
treated with NAC, whereas empty bar (control) represents untreated cells. Calu-3 cells were cultured 
using AIC conditions. FD4 permeability is expressed as Papp, calculated according to the equation in 
section 2.2.4. Data presented as the mean ± SD (n=4). 
 
Treatment of cells with NAC, however, resulted in a decrease in TEER (shown in 
Figure 3.8). A drop in TEER by approximately 44% compared to the baseline value 
and by approximately 29% compared to the control (i.e. decrease in TEER resulting 
from the application of HBSS) was observed at the end of incubation with NAC. 
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However, measurements at the end of the permeability experiment revealed a 
recovery in TEER within the permeability study period (3 hours), with the TEER 
values of the cell layers pre-incubated with NAC reaching 103% of the baseline value, 
while the TEER of control cell layers reverted to approximately 99% of the baseline 
value. 
 
 
 
 
 
 
 
 
 
Figure 3.8. Effect of NAC on TEER of Calu-3 layers. TEER was measured after incubation of the 
cells with NAC and again at the end of the permeability experiment. TEER was also monitored in 
control cells (incubated with HBSS). Changes in TEER are reported as % change compared to the 
TEER measured before the application of NAC (baseline value). Results are presented as the mean 
± SD (n=4).   
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3.3.3.3 Permeability of varying MW FDs across Calu-3 layers 
Permeability of FDs with a different molar mass across the Calu-3 layers is shown in 
Figure 3.9. It is apparent from the figure that the permeability of FDs decreased with 
an increasing MW, with FD20 (MW 20 kDa) permeating the cell layers most readily 
(Papp approximately 6.5x10
-9
 cm/s), and the largest dextran, FD150 (MW 150 kDa), 
exhibiting the lowest permeability (Papp 1.4x10
-9
 cm/s).  
 
 
 
 
 
 
 
 
 
Figure 3.9. Permeability of varying MW FDs (FD20, FD40, FD70 and FD150) across Calu-3 layers. 
Permeability expressed as apparent permeability coefficient (Papp), calculated according to the 
equation in section 2.2.4.  Data presented as the mean ± SD (n = 3). * denotes statistically different 
(p=0.011) from the preceding bars. 
 
3.3.3.4 Insulin translocation across Calu-3 layers  
The calculated Papp for translocation of FITC-insulin across the Calu-3 layers was 
found to equate 1.01x10
-8
 cm/s ± 2.89x10
-9
 (n=3). 
 
3.3.3.5 Comparison of FD permeability across Calu-3 and Caco-2 layers  
Figure 3.10 compares the rate of permeability of two FDs (FD20 and FD40) across 
confluent Calu-3 and Caco-2 layers. Again there was a MW effect on permeability, 
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with FD20 observed to permeate the cell layers more readily than FD40 in both cell 
lines. There was a marked difference in the extent of permeability for both solutes 
between Calu-3 and Caco-2 layers, with a 15-fold and 13-fold higher permeability 
observed across Caco-2 monolayers compared to Calu-3 for FD20 and FD40, 
respectively.  
 
 
 
 
 
 
 
 
 
Figure 3.10. Permeability of FD20 and FD40 across Calu-3 and Caco-2 layers. Permeability is 
expressed as apparent permeability coefficient (Papp), calculated according to the equation in section 
2.2.4. Data presented as the mean ± SD (n = 3). 
 
3.3.3.6 Nanoparticle transport across Calu-3 and Caco-2 layers  
Transport of polystyrene NPs (nominal diameter of 50 nm) across Calu-3 cells 
cultured on filters using AIC or LCC-conditions and Caco-2 cells is depicted in 
Figure 3.11. Data shows a low level of NP transport across the cell layers of both cell 
lines. Two important observations can be made from the figure: 1) Calu-3 layers 
cultured using AIC presented a greater barrier to NP translocation compared to those 
grown using LCC, and 2) Calu-3 layers cultured using either AIC or LCC conditions, 
presented a greater barrier to NP movement than Caco-2 monolayers. 
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Figure 3.11. Apical-to-basolateral transport of polystyrene NPs (carboxy-modified; 50 nm nominal 
diameter) across Calu-3 (grown using AIC and LCC conditions) and Caco-2 layers. NP transport 
expressed as % relative to the NP amount applied apically. Data presented as the mean ± SD (n=3). 
 
 
3.4 Discussion 
The Calu-3 cell line is generally considered as one of the few respiratory cell lines to 
express features of the airway epithelium, including expression of TJs and mucus 
production, when appropriately cultured in vitro. Although this cell line has been 
relatively well characterised, large inconsistencies exist in the literature regarding its 
barrier and morphological properties, as discussed in section 3.1. Initial work 
therefore focused on determining the morphological and barrier characteristics of the 
cell culture model used in this project, whereby the suitability of the model system 
was investigated.  
 
When Calu-3 cells were cultured on permeable supports using either AIC or LCC 
conditions, cell layer TEER was found to increase with time in culture. The observed 
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increase in TEER, which was eventually seen to plateau, suggests formation of 
polarised, confluent and restrictive cell layers. Since functional structures providing 
this restrictiveness in epithelial cells are the intercellular TJs (the expression of which 
was shown, as will be discussed below), high TEER values are therefore suggestive of 
cells that express and are interconnected by functional TJs. Continuous monitoring of 
the TEER while culturing cells on filters provided information regarding the time 
course needed for Calu-3 cells to form confluent cell layers. This time, which was 
found to be at least 9 days, proved to be consistent throughout the project. 
Establishing this information at an early stage of the project was therefore important 
with regards to planning experiments. (In practice, in subsequent experiments, cells 
were cultured on filters for 9-14 days without regular TEER measurements; to 
minimise culture handling and possible damage to the cells by the measurement 
process, TEER was only recorded prior to the experiments in order to confirm 
confluence and therefore the suitability of the cell layers for inclusion in 
experiments.)  
 
It is interesting to note that the maximal TEER values obtained for Calu-3 cells 
cultured using AIC (approximately 800 Ωcm
2
) and LCC (approximately 1500 Ωcm
2
) 
differ significantly, with these values being nearly two-fold higher for cells cultured 
using LCC compared to AIC. The reasons behind this difference are not clear, but 
other groups have reported similar results (9). TEER values obtained in this work are 
higher than those found in some studies (7, 14, 16, 20, 32), but fall within the range of 
values (between 700 and 2500 Ωcm
2
) reported by Loman et al. (32). TEER variability 
in the literature was observed by Foster et al. (31), depending on the technique 
employed for measurements. Furthermore, other effects such as cell passage number, 
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filter type and filter coating are likely to affect the TEER, creating difficulties in 
comparing reported TEER values across labs.  
 
The gradual decrease in TEER following attainment of a peak value is consistent with 
previous studies (14). This observation has been explained to possibly result from an 
increase in number of cells packed within the layer, increasing the total length of cell 
perimeter per area of the layer (TEER developed by an epithelial cell layer is 
determined to a large extent by the nature of its cell boundaries), as growth arrested 
cells have been shown not to exhibit such a reduction in TEER as cells age (33).  
 
Cell imaging by different techniques revealed valuable morphological information. 
SEM and confocal microscopy showed that, when cultured on filters (under AIC 
conditions), Calu-3 cells predominantly grow as single layers (multilayer formation 
was evident in limited areas) whereby cells are closely packed. SEM further revealed 
the presence of microvilli on the apical surface of the cells, while ciliated structures 
were not observed. Electron-translucent granules, with some exhibiting an electron 
dense core (Figure 3.9c) were clearly seen by TEM. These granules, which resemble 
mucin granules of airway mucous goblet cells in organization and size (34), were also 
reported by other groups (7, 9, 35). Imaging of the cell layer by confocal microscopy 
following immunostaining for the ZO-1 protein, which is a structural component 
associated with functional epithelial TJs, clearly showed its expression and presence 
as continuous 'belts' at cell-cell contacts. In combination with the measured TEER, 
this confirms that the restrictiveness of the cell layers is mediated by the presence of 
the functional intercellular TJs. Immunostaining for MUC-1, a mucin protein, on the 
other hand revealed heavy presence of this mucus protein, which is in agreement with 
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a study by Kreda et al. (35). Additionally, its predominant distribution on the apical 
side of the cells confirmed cell polarity. 
 
Although TEER is an easily measurable parameter that is an indicator of cell layer 
intactness and presence of functional TJs, it may not always correlate with the 
paracellular permeability of large hydrophilic molecules (36), which is another 
parameter used to characterise the formation of the cell layer barrier. Therefore, in 
addition to monitoring the ion permeability of TJs (i.e. TEER), the paracellular 
permeability of hydrophilic tracers was also established in this work to complement 
the TEER and provide more complete information on TJ functionality. One such 
hydrophilic tracer is dextran, which is commercially available in different MWs and 
fluorescent forms allowing an easy quantitation through measurement of fluorescence.  
 
The low permeability rate of a modestly sized macromolecule, FD4, across the Calu-3 
layers confirms the barrier properties of the cell layer. The calculated apparent 
permeability coefficients (Papp) of 1.7x10
-7
 cm/s for AIC and 5.7x10
-7
 cm/s for LCC 
cells, are somewhat larger than those reported in the literature. Papp values of 6x10
-9
 
(AIC), 1.3x10
-8
 (AIC), 5.1x10
− 8
 (culture conditions not specified) and 9.9x10
−8 
cm/s 
(culture conditions not specified) have been reported by Florea et al. (30), Li et al. 
(37), Chono et al. (38) and Seki et al. (39), respectively. Similarly to data variability 
with regards to TEER, large discrepancies in reported permeability values exist due to 
inter-laboratory differences in culture conditions, including the type of the filter and 
its coating to promote cell adherence, cell passage number, media, experimental 
procedures used to determine the permeability, etc. Therefore, caution must be 
exercised in comparing these values. Furthermore, it must be noted that, as it will be 
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apparent from the future chapters of this thesis, calculated Papp values for FD4 in other 
experiments in this thesis are variable and range from approximately 1.7x10
-7
 to about 
1x10
-8
 cm/s (in cells cultured using AIC conditions). This variability in data is likely 
to be a result of different factors, with cell culture age (i.e. time in culture) at the time 
when permeability experiments were conducted likely to play an important role.  
  
Of particular interest is the finding that FD4 permeability was about 4-fold lower in 
Calu-3 cell layers cultured using AIC compared to cells cultured at LCC. This is 
rather surprising, considering that significantly higher TEER values were observed in 
LCC cells, suggesting a more restrictive barrier. There are conflicting reports in the 
literature regarding the permeability characteristics of Calu-3 cell layers cultured 
using AIC and LCC. While notable differences in permeability to sodium fluorescein 
between Calu-3 cell layers grown using AIC and LCC have been found (16), with 
Grainger et al. (9) reporting higher permeabilities of sodium fluorescein and FDs of 
varying MWs in AIC cells compared to LCC, others found similar permeabilities (19, 
20), attributing the finding to the existence of a threshold TEER barrier above which 
the rates of transport are similar. For example, Foster et al. (31) reported an inverse 
relationship between TEER and Lucifer yellow flux up to TEER of approximately 
300 Ωcm
2
, but once the cell layers achieved a higher TEER, there was very little 
change in Lucifer yellow flux.  
 
Lower FD4 permeability in AIC cells may possibly result from a greater presence of 
mucus in cell layers cultured using these conditions. Numerous groups have found 
that AIC growth conditions are favourable for mucus production. Grainger et al. (9) 
observed heavier glycoprotein staining in Calu-3 layers grown using AIC compared to 
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those cultured using LCC, arguing that, any secreted mucus under LCC conditions, is 
likely to disperse into the culture medium and is removed by medium exchange. 
Furthermore, Fiegel et al. (19) examined the impact of direct deposition of 
aerosolized poly(lactic-co-glycolic)acid (PLGA) microparticles on Calu-3 cell layers 
grown under AIC or LCC conditions. Determined Papp for disodium fluorescein (FNa, 
376 Da) across the layers following the particle deposition suggested that cells grown 
under AIC conditions remained unaltered following microparticle deposition, while a 
significant increase in Papp was observed in the cells cultured under LCC condition. 
The authors attributed this finding to existence of a dense mucus coating developed 
during the AIC which may have protected the cell surface from the deposition insult.  
 
To test whether the presence of mucus presents a barrier to the translocation of 
macromolecules across the cell layers, in this work FD4 permeability was measured 
following the incubation of cell layers grown at AIC with N-acetyl cysteine (NAC). 
NAC is a mucolytic agent that reduces mucus viscosity by splitting disulfide bonds 
linking proteins present in the mucus (mucoproteins) (40). A relatively low 
concentration of NAC (0.3% w/v) was used for this purpose to ensure that its addition 
caused minimal damage or disruption of the cell layer integrity, which would affect 
FD4 permeability; this was determined by measuring changes in TEER following the 
addition of NAC. A considerably higher rate (4-fold) of FD4 permeability was 
observed in cell layers pre-incubated with NAC. It is possible that reduction of mucus 
viscosity by the action of NAC, and its resulting removal from the cell layers (with 
replacement of NAC solution prior to the permeability experiment) may have played a 
role in the observed higher rate of FD4 permeability in NAC-incubated cells 
compared to control. It could be argued that higher penetrant permeability associated 
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with the application of NAC may have resulted from TJ opening and/or compromised 
cell layer integrity as application of NAC resulted in a decrease in cell layer TEER. 
Nevertheless, the decrease in TEER was relatively modest and recovered within the 
time frame of the permeability experiment.  
 
Measurement of the permeabilities of varying MW FITC-dextrans (20 kDa-150 kDa) 
revealed an inverse relationship between the MW of the solute and its extent of 
permeability (Papp value). Similar results are reported in the literature. For example, 
the permeability Papp of differently sized FDs across the Calu-3 cell layers was shown 
to decrease from 2x10
-9
 cm/s to 1x10
-9
 cm/s and to 0.2x10
-9
 cm/s as the MW of the 
solutes increased from 10 kDa to 20 kDa and to 70 kDa, respectively (30). With 
respect to our data, it is interesting to note that with the largest two FDs, namely 
FD70 and FD150, the decrease in permeability with MW is not as marked as that 
observed between FD20 and FD40, and the difference between FD40 and FD70. This 
finding is in agreement with a previously reported study investigating dextran 
transport across rat alveolar epithelial cell monolayers (41). The authors of this study 
describe that FD Papp decreased gradually from 1.35x10
-8 
cm/s for FD4 to 0.32 x10
-8 
cm/s for FD40. In contrast, the calculated Papp values for FD70 and FD150 were 
almost identical at 0.13x10
-8 
cm/s. Furthermore, when FD transport was tested at 4¡C, 
Papp decreased in a size-dependent manner, with observed decreases of approximately 
40% for FD4 to FD40 and >80% for FD70 and FD150, compared to transport at 37¡C 
(41). Observation of these phenomena was explained by the authors through the 
possibility that smaller macromolecules (radius <5 nm) translocated across the cell 
monolayers through the paracellular pathway, whereas larger macromolecules were 
likely to traverse the cells via other pathways such as pinocytosis. 
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Permeability of FITC-insulin, as an example of a therapeutic macromolecular protein, 
was tested in order to assess whether the Calu-3 layers present a similar barrier to its 
movement compared to FDs, which were used as model drugs throughout this thesis. 
The calculated Papp value for FITC-insulin movement across the Calu-3 layers 
(cultured using AIC) amounted to 1.01x10
-8
 cm/s ± 2.89x10
-9
. This is lower than the 
Papp for FD4 observed in the experiment in this chapter (1.7x10
-7
 cm/s), but falls 
within the range of FD4 Papp values obtained throughout the project (approximately 
2.5x10
-7
 to 1x10
-8
 cm/s). However, it must be noted that a direct comparison in 
permeability between insulin and FD4 and is not possible considering the different 
molecular structure of the two compounds. More specifically, insulin is a globular 
molecule existing in aqueous environment as dimers, tetramers, and hexamers in 
equilibrium (42), with the hexameric conformation having a hydrodynamic radius of 
2.8 nm (43), while FD4 has a linear geometry with a hydrodynamic radius estimated 
to be 1.8 nm (44). Furthermore, FITC-insulin and FD4 permeability experiments were 
conducted on cells of different passage number. Observed FITC-insulin Papp value is 
higher than Papp of 0.41x10
-8
 ± 0.02x10
-8
 cm/s reported by Pezron et al. (18) when 
determining insulin permeability across the Calu-3 cell layers and  Papp of 1.28 × 10
−9
 
cm/s, reported by Seki and co-workers (39).  
 
In comparing the barrier properties of the Calu-3 layers with those of the intestinal 
Caco-2 cell line, which is a well-established cell line and widely-used in drug 
transport studies, FD was found to traverse the Caco-2 monolayers considerably more 
readily than the Calu-3 layers. This was the case for two tested FDs, FD20 and FD40, 
with calculated Papp values approximately 12-fold higher in Caco-2 cell monolayers 
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compared to Calu-3 cells, for both dextrans. This finding is particularly interesting 
considering the substantially higher measured TEER in Caco-2 monolayers 
(approximately 2000 Ωcm
2
). Although the Caco-2 cell line has been reported to form 
looser TJs than Calu-3 cells (45), it is unclear why, in this work, this was not reflected 
in the TEER profile of the two cell lines. It has been shown that paracellular 
permeation of hydrophilic molecules is directly related to the number of tight 
junctional strands between epithelial cells and their density (46). Epithelial cells with 
a high number of tight junctional strands, such as gall bladder epithelia, have a low 
paracellular permeability (47), whereas those having a low number of tight junctional 
strands, such as the intestinal epithelia, have a high permeability (48). It is possible 
that the Calu-3 cell layers present a greater barrier to the movement of FDs due to 
morphological differences, including the number of tight junctional strands, between 
the two cell lines. Furthermore, other differences in cellular morphology, structural 
organisation and physiological functions (including the production of mucus by Calu-
3 cells) may account for the observed differences in permeability.  
 
Transport of NPs (polystyrene, 50 nm diameter) across the cell layers was 
investigated in order to test the extent of the barrier presented by Calu-3 and Caco-2 
epithelial cells to the movement of small NPs. Mucosal transport of nanoparticulate 
materials, as potential drug carriers, has been researched previously (49-54) and in 
fact it is also the focus of this thesis (Chapters 6 and 7). Comparison of NP transport 
across Calu-3 cells cultured at AIC and LCC conditions and Caco-2 monolayers 
revealed a very low rate of NP translocation in all cases, highlighting the fact that cell 
layers severely restrict NP movement. However, it is interesting to note that the 
proportion of applied NPs traversing the cell layers was found to be moderately 
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higher across Caco-2 cell monolayers compared to Calu-3 cells cultured under LCC 
conditions and significantly higher compared to the NP translocation seen in AIC 
Calu-3 cells. It should be stressed that a similar trend was described above for FD4 
permeability across the Calu-3 layers, with a notably lower permeability across AIC 
cells. Although transport of NPs is likely to occur through a different route to FD4, 
with NPs likely to traverse the cell layers through the transcellular route (across the 
cell) and FD4 predominantly via the paracellular pathway, the possible presence of a 
denser layer of mucus in AIC cells may impede transport of both FD4 and NPs.  
 
As mentioned earlier, previous reports found that AIC Calu-3 layers exhibit a more 
physiological TEER and ultrastructure (9). Notably, a detailed study by Grainger et 
al. (9) comparing the effect of AIC and LCC conditions on the properties of the Calu-
3 cell layers, found that AIC conditions produced cells with characteristics more 
similar to the tracheobronchial epithelium compared to cells grown using LCC. The 
authors consequently concluded that AIC conditions produced Calu-3 cell layers that 
are more suitable as a model of the tracheobronchial epithelium than LCC. Although 
AIC and LCC conditions were not directly compared in terms of the resulting cellular 
morphology, present work confirmed previous reports of a more physiologically 
relevant TEER observed in AIC compared to LCC grown cells. Combined with the 
finding that AIC cells presented a greater barrier to the movement of macromolecules 
and desirable morphological features, AIC conditions were therefore considered more 
appropriate for producing cell layers modeling the airway epithelium, which is in 
agreement with the aforementioned study. AIC conditions were therefore normally 
employed in culturing Calu-3 cells on filters in the subsequent experiments in this 
thesis.  
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3.5 Conclusion 
Work presented in this chapter focused on characterising filter-cultured Calu-3 layers, 
which were adopted in this thesis to serve as a mucosal model. This was deemed 
necessary as, although the Calu-3 epithelial cell line has been (and continues to be) 
used extensively as a mucosal model, there is a large body of evidence suggesting that 
culture conditions (which vary between labs) influence their morphological 
characteristics and the barrier property of the model. Our work showed that filter-
cultured Calu-3 cells exhibited TEER, which increased with time in culture and that 
cells cultured using AIC conditions exhibited a lower TEER, than those grown under 
LCC. Microscopic examination showed that cells cultured under AIC conditions 
formed polarized layers of tightly packed cells that express features found in the 
native airway epithelium, including cell microvilli, secretory granules, TJs and mucus 
protein. AIC conditions produced cell layers that presented a greater barrier to the 
translocation of macromolecules and NPs compared to LCC conditions. Calu-3 layers 
in general (cultured under AIC or LCC conditions) presented a greater barrier to the 
movement of dextrans and NPs compared to intestinal Caco-2 cells. Owing to 
observations of a more physiological TEER and a greater barrier to macromolecular 
transport and observation of relevant cell ultrastructure, Calu-3 cells grown using AIC 
conditions were regarded as a suitable mucosal model for the purpose of the 
investigations performed in this thesis. 
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Chapter 4 
Evaluation of the Toxicity of Alkylglycoside 
Surfactants  
 
4.1 Introduction 
Alkylglycosides (AGs) are water-soluble, nonionic and amphipathic surfactant 
compounds containing alkyl chains of variable lengths, glycosidically attached to 
either a monosaccharide or disaccharide. They can be economically synthesised and 
purified, and are metabolised to non-toxic alcohols and sugars (1). AGs have been 
investigated, both in vitro and in vivo, for their potential to improve the systemic 
bioavailability of macromolecular peptides and proteins delivered mucosally (2-7). 
When included in nasal or ocular formulations, AGs were reported to significantly 
increase the systemic bioavailability of peptides such as insulin and calcitonin (4, 6). 
The potential of AGs for use as agents facilitating mucosal absorption of protein 
therapeutics was in fact considered high enough as to result in their commercial 
exploitation; the drug delivery platform of Aegis Therapeutics is based on these 
compounds (8).  
 
The precise molecular mechanism by which AGs exert their absorption-enhancing 
effects in vivo is, however, unclear. It is believed that AGs increase drug absorption 
via a direct effect on the epithelium rather than through a specific interaction with the 
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drug itself because AGs have been shown to improve absorption of several different 
types of macromolecules (6, 9). AGs were found to increase the paracellular 
movement of mannitol by opening the tight junctions (TJs) between cultured 
bronchial epithelial cells, suggesting that the paracellular route may be predominantly 
involved in the movement of macromolecules in cells treated with AGs (2, 9). 
Nevertheless, other studies have demonstrated that AGs intercalate into the lipid 
bilayers and fluidise the membrane leading to induction of endocytosis, hence 
increasing transcellular drug movement (2). The ability of AGs to fluidise and/or 
subsequently solubilise artificial phospholipid bilayers in vitro has been established 
(2). Arnold et al. (10) suggest that the absorption-enhancing mechanism of 
alkylglycosides in the nose appears to involve a different types of interactions of the 
surfactant with the nasal surface, which includes mucus dilution, inhibition of ciliary 
clearance and improved paracellular and transcellular movement. 
 
Although the absorption-enhancing properties of AGs have been relatively well 
documented, the data on their toxicity is somewhat limited. Most published studies 
investigating AGs in vivo measured the reversibility of increased mucosal absorption 
(absorption of macromolecules measured at a certain period after the application of 
the surfactants) as an indication of toxicity (7, 11, 12). In vitro studies with epithelial 
cell models on the other hand determined reversibility in TEER, as a demonstration of 
toxicity (13), while to the best of our knowledge, cell toxicity assays measuring the 
effect of AGs on cell viability were not included in any of the published in vitro 
studies of AGs. 
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Present work attempts to establish mechanism(s) by which AGs exhibit mucosal 
absorption enhancing effects. Furthermore, the toxicity of AG surfactants in vitro is 
evaluated in detail by commonly used cell toxicity assays. Three representative AGs, 
with relatively long alkyl chains, namely dodecylmaltoside (DDM, 12 carbons), 
tridecylmaltoside (TriDM, 13 carbons) and tetradecylmaltoside (TDM, 14 carbons) 
were selected in this work as these compound are the most extensively studied and 
also because longer chain AGs, such as those used in this work have been shown to 
produce a more potent absorption enhancing effect compared to those with shorter 
alkyl chains. The molecular structures of these compounds are depicted in Figure 4.1. 
 
a)  
 
 
b)  
 
 
c)  
 
 
Figure 4.1. Chemical structures of AGs. a) Dodecylmaltoside (DDM), b) Tridecylmaltoside (TriDM) 
and c) Tetradecylmaltoside (TDM), containing a 12, 13 and 14 carbon alkyl chain, respectively, 
linked to maltose. 
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4.2 Methods 
4.2.1 Effect of AGs on Calu-3 layer TEER  
Calu-3 cells were cultured on filters (using AIC conditions) to produce confluent cell 
layers in the manner described previously (Chapter 2, section 2.2.1). Culture medium 
(EMEM) was aspirated from the cells and replaced with HBSS (0.5 ml and 1.5 ml in 
the apical and basolateral chambers of the TranswellTM system, respectively). Cells 
were equilibrated (incubated at 37¡C) in HBSS for approximately 45 min. TEER was 
measured before the application of AGs and the recorded values were treated as the 
baseline TEER. Stock solutions of AGs were prepared fresh on the day of the 
experiment by dissolving each AG in HBSS at 0.25% w/v. AG sample solutions, 
which consisted of three AGs, DDM, TriDM and TDM, were applied to the apical 
side of the cells at a concentration of 0.125% w/v in HBSS. Triton X-100 (0.1% v/v, 
dissolved in HBSS) was used as a positive control causing cell death and therefore 
irreversible decrease in TEER, whereas HBSS per se was used as a negative control. 
TEER measurements were conducted 5 min, 15 min, 30 min and 45 min following the 
application of the samples (and controls). After the TEER measurement at time 45 
min, AG solutions were removed from the apical side of the cell layers, while HBSS 
was removed from the basolateral chamber. Cell layers were washed with PBS and 
then culture medium was applied on both apical and basolateral sides of the cell 
layers; cells were incubated further in the culture medium. In order to determine 
whether any changes in TEER observed following the application of AGs were 
reversible, further measurements of electrical resistance were conducted at times 150 
min, 180 min, 210 min and 24 hours.  
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4.2.2 Effect of AGs on Calu-3 metabolic activity: alamarBlue
¨
 assay 
AlamarBlue
¨
 assay was conducted on filter-cultured Calu-3 cells once they formed 
confluent layers. Culture medium was aspirated from the cells and HBSS added to the 
basolateral side. Stock solutions of AGs were prepared fresh on the day of the 
experiment by dissolving each AG in HBSS at 0.25% w/v. AG solutions consisting of 
DDM, TriDM and TDM were applied to the apical side of the cells at a concentration 
of 0.125% w/v in HBSS for 45 min. Triton X-100 (0.1% v/v in HBSS) and HBSS 
were used as the positive and negative control, respectively. Following the incubation 
with AG solutions, cells were extensively washed with PBS. AlamarBlue
¨
 assay was 
then conducted following the method described in section 2.2.5.2.  
 
4.2.3 Effect of AGs on HT29 metabolic activity: alamarBlue
¨
 assay 
HT29 cells were seeded on a 24-well plate at a density of 5x10
4
 cells per well and 
cultured for 2 days in McCoyÕs 5A medium. Stock solutions of the AG surfactants 
were prepared by dissolving each AG in HBSS at 0.25% w/v and were used on the 
same day. Culture medium was replaced with pre-warmed (37¡C) solutions of AGs 
(DDM, TriDM and TDM), used at 0.0625%, 0.125% and 0.25% w/v (in HBSS). 
HBSS and Triton X-100 (0.1% v/v in HBSS) served as negative and positive controls, 
respectively. HT29 cells were incubated (at 37¡C/5%CO2) with the test sample 
solutions for 45 min. AG solutions were then removed and cells washed with PBS. 
Thereafter, alamarBlue
¨
 assay was conducted in the manner described previously 
(section 2.2.5.2).  
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4.2.4 Effect of AGs on Calu-3 metabolic activity: MTS Assay  
Calu-3 cells were seeded on a 96-well plate at a density of 10
4
 cells per well and the 
cells were incubated in the culture medium for 24 hours. AG sample solutions were 
prepared on the day of the experiment by dissolving each AG in HBSS. Culture 
medium was removed from each well and replaced with AG sample solutions, 
consisting of DDM, TriDM or TDM at concentrations of 0.0156%, 0.03125%, 
0.0625% and 0.125% w/v (in HBSS). Triton X-100 and HBSS were used as the 
positive and negative control, respectively, as described in the preceding section. 
Cells were incubated with AG samples (and controls) for 2 hours. MTS assay was 
thereafter performed in the way detailed previously (section 2.2.5.3). 
 
4.2.5 Effect of AGs on membrane toxicity: LDH assay 
Calu-3 cells were seeded on a 96-well plate at a density of 10
4
 cells per well and 
incubated in the culture medium for 24 hours before the assay. AG stock solutions 
were prepared fresh on the day of the experiment by dissolving each AG (DDM, 
TriDM and TDM) in HBSS. Culture medium was removed and replaced with AG 
sample solutions at the following concentrations: 0.05%, 0.025%, 0.0125%, 
0.00625% and 0.003125% w/v. Triton X-100 and HBSS were used as the positive and 
negative control, respectively, as described in section 4.2.3. Cells were incubated with 
AG solutions (and controls) for 2 hours, after which LDH assay was conducted 
according to the methods in section 2.2.5.4.  
 
4.2.6 Effect of AGs on cell penetration of FD4  
Calu-3 cells were cultured on filters and used in this experiment as confluent layers 
(i.e. exhibiting a TEER ≥ 500 Ωcm
2
). AG and FD4 stock solutions were prepared 
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fresh on the day of the experiment by dissolving DDM or TDM in HBSS at a 
concentration of 0.002% w/v and FD4 at a concentration of 1 mg/ml. Culture medium 
(EMEM) was firstly removed and cells washed with PBS. HBSS was then added to 
the basolateral compartment, whereas samples consisting of of DDM or TDM in 
combination with FD4 were added to the apical compartment of the Transwell
¨
. The 
final concentrations of DDM or TDM and FD4 on the apical side of the cells were 
0.001% w/v for AGs and 500 µg/ml for FD4. Cells were incubated with each AG in 
conjunction with FD4 for 1 hour. A control experiment was performed by applying 
FD4 at the same concentration (500 µg/ml in HBSS) without the presence of AGs and 
incubating the cells for the same duration (1 hour). AG/FD4 samples (and FD4 only, 
for the control experiment) were then removed from the apical side of the cell layers, 
followed by extensive washing of the cells with PBS. Cells were then fixed with 4% 
w/v paraformaldehyde (in PBS) for approximately 10 min. The filters were then 
excised and prepared for confocal imaging in the manner described previously 
(section 2.2.6.5). 
 
4.3 Results  
4.3.1 Effect of AGs on Calu-3 layer TEER 
Addition of AG solutions to confluent Calu-3 layers resulted in an immediate and 
dramatic decrease of TEER (Figure 4.2). The observed effect on TEER was very 
similar for all three tested AGs, with a sharp decrease of TEER to approximately 3-
4% of the baseline value within 5 min of their application. Furthermore, the TEER 
pattern resulting from application of the AGs paralleled that seen with Triton X-100. 
TEER values remained low even after removal of AG solutions and the replacement 
with culture medium (at time point of 45 min, indicated in Figure 4.2 by the arrow), 
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an effect also observed in cells incubated with Triton X-100, but not in control cell 
layers incubated with HBSS. TEER of control cell layers decreased by approximately 
17% (in relation to the baseline value) initially, 5 min after application of HBSS, but 
recovered to levels near the baseline value within 30 min, following which it 
remained relatively constant throughout the experiment. Measurements conducted 24 
hours following sample application (and 23.15 hours after their removal) revealed no 
recovery of TEER in cell layers incubated with AG samples, as well as Triton X-100. 
These values amounted to approximately 2-3% of the baseline TEER for all three 
AGs, which were comparable with the value recorded for Triton X-100 (2.6% of the 
baseline TEER). In contrast, control cell layers incubated with HBSS exhibited TEER 
similar to the baseline value (approximately 105% of the baseline figure). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Effect of AGs on Calu-3 layer TEER. Dodecylmaltoside (DDM), tridecylmaltoside 
(TriDM) and tetradecylmaltoside (DDM) were applied to confluent cell layers at 0.125% w/v. HBSS 
and Triton X-100 (0.1% v/v in HBSS), were used as the positive and negative control, respectively. 
Arrow indicates when AG sample solutions were removed and culture medium added. Data 
expressed as % of the baseline TEER and presented as the mean ± SD (n=3).  
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4.3.2 Effect of AGs on Calu-3 metabolic activity: alamarBlue
¨ 
assay 
Figure 4.3 shows the effect of tested AG molecules on the metabolic activity of Calu-
3 cells, as confluent, filter-cultured layers, as measured by the alamarBlue
¨
 assay. All 
three AGs were associated with a remarkable reduction of relative metabolic activity, 
amounting to more than 95% with DDM, TriDM and the two highest doses of TDM. 
The two lowest doses of TDM still produced a metabolic activity reduction of >85%. 
These values appeared to show a concentration-dependent effect. The diminution in 
cell metabolic activity caused by the highest concentration (0.125% w/v) of all AG 
compounds was greater than that seen with Triton X-100, resulting in negative 
metabolic activity values (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Effect of AGs on Calu-3 metabolic activity, as determined by the alamarBlue
¨ 
assay. 
Dodecylmaltoside (DDM), tridecylmaltoside (TriDM) and tetradecylmaltoside (TDM) were applied to 
cell layers at concentrations of 0.0625%, 0.125% and 0.25% w/v (in HBSS). Data expressed as % 
relative metabolic activity calculated in the manner described previously (section 2.2.5.2). Data 
presented as the mean ± SD (n=4). 
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4.3.3 Effect of AGs on HT29 metabolic activity: alamarBlue
¨ 
assay 
Metabolic activity of intestinal HT29 cells following their incubation with AGs is 
shown in Figure 4.4. The dramatic metabolic activity-decreasing effect of the 
surfactants exhibited on Calu-3 cells was replicated on the HT29 cell line. Apart from 
the lowest concentrations of TriDM, calculated metabolic activity values were 
negative due to lower alamarBlue¨ fluorescence values obtained with AG samples 
compared to those seen with Triton X-100.  
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Effect of AGs on HT29 metabolic activity. Dodecylmaltoside (DDM), tridecylmaltoside 
(TriDM) and tetradecylmaltoside (TDM) were used at concentrations of 0.0156%, 0.03125%, 
0.0625% and 0.125% w/v. Data expressed as relative metabolic activity and presented as the mean ± 
SD (n=4). 
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Figure 4.5 demostrates that the tested AGs showed a significant reduction in Calu-3 
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agreement with the previous assay (alamarBlue
¨
) conducted on Calu-3 and HT29 
cells.  
 
Figure 4.5. Effect of AGs on Calu-3 metabolic activity, as determined by the MTS assay. 
Dodecylmaltoside (DDM), tridecylmaltoside (TriDM) and tetradecylmaltoside (TDM) were applied to 
cells at concentrations of 0.0156%, 0.03125%, 0.0625%, and 0.125% w/v. Data expressed as relative 
cell metabolic activity and presented as the mean ± SD (n=4). 
 
4.3.5 Effect of AGs on membrane integrity: LDH assay 
Application of AGs to Calu-3 cells was associated with a dramatically significant 
release of the cytoplasmic enzyme, LDH (Figure 4.6). The extent of this release with 
two highest concentrations (0.05% and 0.025% w/v) of all three surfactants was 
greater than that observed with Triton X-100 (used as a positive control), resulting in 
relative LDH release values of greater than 100%. The degree of LDH release was 
concentration-dependent for TriDM and, to some extent, TDM. Even at the lowest 
concentrations of 0.003125% w/v, relative LDH release following the application of 
AGs amounted to approximately 100%, 71% and 84%, for DDM, TriDM and TDM, 
respectively. 
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Figure 4.6. Effect of AGs on LDH release from Calu-3 cells. DDM, Tri-DM and TDM were applied 
to cells at concentrations of 0.003125%, 0.00625%, 0.0125%, 0.025% and 0.05% w/v (in HBSS). 
Data expressed as relative LDH release, calculated using the equation described in section 2.2.5.4 
and presented as the mean ± SD (n=4). 
 
4.3.6 Effect of AGs on cell penetration of FD4 
Figure 4.7 shows the fluorescence distribution of the cell membrane impermeable 
compound, FD4, following its application to Calu-3 layers, on its own (4.6a) or in 
conjunction with AG compounds, DDM or TDM (4.6b and 4.6c, respectively). In the 
cell layer incubated with FD4 only, observed FD4 fluorescence (imaged in the red 
channel in this case) was limited. In contrast, large areas of FD4 fluorescence can be 
observed in cell layers subjected to concurrent FD4 and AG incubation.  
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Figure 4.7. Association of FD4 with Calu-3 layer following its application on its own or with AGs. a) 
FD4 in the absence of AGs (control), b) FD4 in conjunction with DDM, and c) FD4 in combination 
with TDM. AGs were applied to cells at 0.001% w/v and FD4 at 500 µg/ml. i) Blue channel: nuclei 
labelled with DAPI, ii) Red channel: FD4, and iii) Overlay image.  
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4.4 Discussion 
AG surfactants have recently been shown to improve transmucosal delivery of 
protein, peptide and non-peptide macromolecular therapeutics (7, 14) leading to their 
commercial exploitation. For example, Ahsan et al. (8) investigated the effect of 
TDM on translocation of insulin across the human bronchial epithelial cell line 
16HBE14o
-
. Application of TDM to the apical surface of cells decreased the TEER to 
approximately 60% of the baseline value and resulted in increased mannitol 
permeability (by approximately 3.2-fold). Furthermore, the authors reported a higher 
basolateral insulin recovery with application of TDM compared to control; this effect 
was attributed to loosening of the TJs. 
 
While Aegis Therapeutics claim that their drug delivery technology, namely 
Intravail
¨
 absorption enhancing excipients based on AGs, effectively delivers protein 
and peptide drugs of up to 30 kDa through the nasal route without causing irritation of 
the nasal tissue (8), literature information on their toxicity is sparse. Furthermore, the 
mechanism of absorption-enhancing action of these molecules is not completely 
understood. Our work therefore aimed to fully evaluate these compounds for their 
toxicity towards epithelial cells in vitro and also attain information with regards to the 
mechanisms involved in their mucosal absorption enhancement.   
 
Application of tested AGs to confluent Calu-3 layers, used as a model of the airway 
epithelium, resulted in an irreversible decrease in TEER, an early indication of 
toxicity of these compounds. The use of TEER as a sensitive measure of cell toxicity 
has been applied before. The application of membrane-perturbing toxicants, 
benzalkonium chloride and saponin was shown to rapidly decrease the TEER of the 
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intestinal Caco-2 cell monolayers. TEER values and released LDH (another 
cytotoxicity test also used in our work and will be discussed later) measured under 
various conditions were found to correlate negatively. However, the decrease in 
TEER was detectable at a lower concentration of a toxicant than that for LDH release 
(15). Similarly, Clostridum difficile toxin A was found to decrease the TEER values 
of human intestinal T84 cell monolayers, while the LDH release test was not always 
showing the toxic effect at the same concentration (16). A correlation between the 
TEER decrease and LDH release was also found when investigating the cytotoxic 
effect of heavy metals such as cadmium (Cd) (17). Prozialeck et al. (18) have 
demonstrated that the loss of the integrity of cell monolayers of the porcine renal 
epithelial cell line, LLC-PK1, caused by Cd occurred faster than cell disruption. 
While the LDH cytotoxicity assay requires increased membrane permeability and cell 
disruption as an indication of cell toxicity, measurement of TEER can detect early 
stages of the cytotoxic processes such as loss of cell layer integrity, making this a 
highly sensitive measure of cytotoxicity, particularly that caused by membrane-
perturbing toxicants. 
 
However, it may be possible that a decrease in TEER may arise from factors other 
than cell death. For example it could arise from an irreversible effect on TJ proteins 
(and opening of TJs) or cell detachment from the surface of the filter, leading to the 
loss of the barrier to the movement of ions across the filter/cell layer and therefore 
lower observed TEER. Further tests investigating the cell toxicity of AGs were 
therefore conducted, including the use of three different cytotoxicity assays in two 
epithelial cell lines (Calu-3 and HT29).  
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AlamarBlue
¨ 
cell metabolic activity test was firstly performed on Calu-3 cells to test 
the toxicity of AGs exhibited towards cells cultured as polarised layers. The tested 
compounds showed a remarkable reduction in Calu-3 metabolic activity. In fact, the 
suppression of cell metabolic activity was in some cases (with the highest tested 
concentration) more potent than that of 0.1% Triton X-100. A similar effect was 
observed when testing the effect of AGs on the metabolic activity of intestinal HT29 
cells (cultured in multiwell plates) through the same assay (AlamarBlue
¨
). AGs were 
found to inhibit the metabolic activity of HT29 cells, used for corroboration, to an 
extent greater than Triton X-100, resulting in negative relative cell metabolic activity 
values. Determination of the effect of AGs on Calu-3 metabolic activity was repeated 
by applying the MTS assay, which works on the same principle (measures metabolic 
activity through an oxidation/reduction reaction) as AlamarBlue
¨
. This test, used for 
corroboration, confirmed the previous observation of the dramatic negative effect of 
AGs on the metabolic activity of Calu-3 cells.  
 
In addition to cell toxicity assays based on measurement of (products of) metabolic 
activity (MTS and AlamarBlue
¨
), the LDH assay was further conducted to test any 
adverse effects that AGs may have on the membrane integrity of Calu-3 cells. LDH is 
a cytoplasmic enzyme (MW 140 kDa), which is released into the extracellular milieu 
when apical membrane of cells is damaged (19). The amount of enzyme detected in 
supernatant correlates to the proportion of lysed cells (20). This assay, first described 
by Legrand et al. (21), is therefore particularly useful for testing membrane perturbing 
effects of compounds. Application of AGs to Calu-3 cells was associated with 
remarkably high detection of cytoplasmic LDH, suggesting its release into the 
extracellular medium, which in turn indicates plasma membrane damage. Similarly to 
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findings obtained with the previous assays, higher concentrations of AGs caused a 
greater release of LDH than the positive control, indicating the severity of the effect 
of these molecules on Calu-3 cell membranes. 
 
In investigating the effect of TDM on translocation of insulin across the human 
bronchial epithelial cell line 16HBE14o
-
, Ahsan et al. (9) applied 0.125% w/v TDM 
to the apical surface of the cell layers. In our work, application of TDM to Calu-3 
cells at this concentration was associated with a striking decrease in cell metabolic 
activity. In fact, much lower concentrations of TDM, namely 0.0156% and 0.03125%, 
also affected cell metabolic activity dramatically. The reasons behind such a marked 
difference in sensitivity towards TDM between the 16HBE14o
-
 cell line in the above 
study and the Calu-3 cell line (also a bronchial cell line) in our work are not entirely 
clear. However, it must be noted that in the discussed work by Ahsan et al., TDM was 
not fully evaluated for its toxicity towards cells, although it was shown that TEER 
recovered to >95% of initial values, though this recovery took place following a long 
interval (36-40 hours) post TDM application.  
 
A study evaluating a series of AGs (13 compounds) for their ability to open the 
cellular TJs on intestinal epithelial cell lines, T-84 and HT29Cl19A (a subclone of 
HT29 cells) showed that the concentrations of AGs required to open the TJs with 
minimal disruption of cellular membranes were between 0.01% and 0.1% w/v (13). 
Of the 13 AGs tested, 4 caused permanent decrease in TEER, which the authors 
attributed to irreversible solubilisation of cell membranes, 5 resulted in a partial 
recovery of the cell monolayer TEER and 4 induced a decrease in TEER with a more 
complete recovery. The 4 AGs associated with an irreversible decrease in TEER 
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included TDM, applied at concentration of 0.01% w/v. The authors, however, found 
that TriDM, applied at 0.01% w/v, had no effect on TEER. Used at a higher 
concentration of 0.1% w/v, TriDM was associated with a decrease in TEER by 90%, 
but the recovery (measured 18 hours after its removal) was only partial (to 29% and 
32% of the initial value in T-84 and HT29 cells, respectively). DDM, on the other 
hand, applied at 0.1% w/v, lowered the TEER by 95% and 88%, on T-84 cells and 
HT29Cl19A cells, respectively, with a recovery to 90% of the baseline value on both 
cell lines.  
 
In a separate study, Tirumalasetty et al. (22) investigated the effect of octylglucoside 
(OG) on permeation of insulin across monolayers of two intestinal epithelial cell 
lines, T-84 and Caco-2. Application of OG at concentrations of 0.2% - 0.5% w/v was 
associated with a concentration-dependent reduction of TEER in both monolayers, 
with a full recovery of TEER observed only with 0.2% and 0.3% w/v OG. The 
authors speculated that the lack of TEER recovery is possibly a result of solubilisation 
of TJ-associated proteins (TJAPs) or ATP depletion, altering the phosphorylation 
state of TJAPs resulting in inactivation of kinases. With regards to permeability 
studies, the highest OG concentration associated with a reversible reduction of TEER 
(0.3% w/v) did not result in a significant enhancement in the permeability of insulin 
across the cell monolayers of both cell lines compared to controls. Although a 
noticeable increase in insulin permeability was observed with higher concentrations of 
OG (0.4% and 0.5% w/v), the authors note that basolateral accumulation of insulin 
after 4 hours was irregular (not steady state), indicating cell damage and disruption of 
the cell monolayers, revealing that the study was not able to find a compromise 
between a permeability-enhancing effect and an acceptable cellular toxicity. 
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A study by Hussain et al. (23) used 16HBE14o- and Calu-3 cells to assess the impact 
of octylmaltoside on insulin permeability across cell layers of these cell lines. It is 
interesting to note that octylmaltoside was applied to the cells at concentrations 
between 0.125% and 0.5% w/v. Although the addition of octylmaltoside was 
associated with a decrease in TEER and a significant increase in insulin permeability 
across both 16HBE14o- and Calu-3 layers, with both effects shown to be 
concentration-dependent, toxicity studies were not performed. A different study by 
Pillion et al. (4) investigated the effect of AGs on systemic absorption of insulin when 
administered via nosedrops in rats. The absorption-enhancing effect of AGs was 
found to be dose-dependent and varied with the alkyl chain length. DDM, TriDM and 
TDM were used in nosedrops at concentrations between 0.03% and 0.125% w/v and 
all three AGs at all concentrations were associated with a significant hypoglycemic 
response. Again, this study does not include any toxicity/irritancy tests performed on 
rats following the administration of AGs.  
 
A study by Arnold et al. (2) evaluated the toxicity of TDM by determining the 
alterations in nasal morphology of rats, following treatment with this AG. Nasal 
formulations consisting of saline or TDM were administered, followed by animal 
sacrifice and removal of nasal septa, 15 min later. Light microscopy revealed that 
tissue samples from rats treated with 0.125% w/v TDM had less uniform cilia and 
increased endocytotic activity. In samples from rats exposed to 0.5% w/v TDM, cilia 
could not be observed at the apical surface of the septal tissue and an altered cellular 
morphology was apparent with both epithelial and goblet cells. Examination of the 
tissues by TEM showed that treatment with 0.125% TDM resulted in mild-to-
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moderate morphological changes, with thinned cilia and appearance of numerous 
vesicles, which the authors attributed to stimulation of endocytosis by TDM.  
 
Another study on AGs that addressed the assessment of their toxicity is that by 
Mustafa et al. (12). In this study, the authors assessed the effect of intranasally 
administered octylmaltoside (OM), decylmaltoside (DM), dodecylmaltoside (DDM) 
and tetradecylmaltoside (TDM) at concentrations 0.25%, 0.5% and 1% w/v in an 
attempt to improve the nasal absorption of enoxaparin in rats. The acute toxicity of 
the surfactants in this work was determined by 'reversibility studies', whereby 
absorption enhancers and drugs are administered separately at different time intervals. 
In this case, AGs were administered at 0.5% w/v, followed by the administration of 
enoxaparin at time zero (immediately afterwards), at 60 min or at 120 min. The 
authors reported a decrease in systemic absorption of enoxaparin when administered 
120 min after the application of the surfactants compared to enoxaparin absorption 
immediately after application of the surfactant. However, the extent of this decrease 
was modest, with values of less than 2-fold with DDM and approximately 2-fold with 
TDM. Furthermore, absorption of enoxaparin following its administration 120 min 
after the application of AG remained significantly higher compared to control (where 
saline was administered instead of AG). In fact, the effects of DDM and TDM were 
sustained for >240 min, which could indicate toxicity effects towards the nasal 
epithelium. 
 
One can assess membrane-disruptive effects of a compound by applying this 
compound to confluent, polarised cell layers in combination with a cell membrane-
impermeable fluorescent probe, followed by measurement/observation of the 
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distribution of fluorescence in the cell layer. The distribution of the cell membrane-
impermeable probes in living cells with intact plasma membrane is not expected to 
occur in significant levels within the interior of the cells due to the exclusion of the 
dye by the plasma membrane. On the other hand, any disruption of the plasma 
membrane will result in penetration of this marker into the interior of the cells, which 
can then be visualized by fluorescence microscopy. The use of this simple method, in 
conjunction with fluorescence microscopy, therefore provides visual information on 
cell membrane-disruptive effects of the tested compound. Due to their molecular size 
and hydrophilicity, FDs can be used as cell membrane-impermeable fluorescent 
markers (24). Application of a solution containing a combination of FD4 with either 
DDM or TDM (which were used at a low concentration of 0.001% w/v) to a confluent 
Calu-3 layer resulted in a widespread detection of FD4 fluorescence even after 
extensive washing of the cells following their incubation with FD4/AGs. This 
observation strongly indicated that AGs caused a cell membrane-disrupting effect, 
which resulted in penetration of FD4 into the interior of the cells. Conversely, in the 
cell layer incubated with FD4 only, lower levels of FD4 fluorescence were observed. 
This can be explained by the exclusion of FD4 from viable cells with intact plasma 
membranes in the control layer enabling its subsequent washing off following the 
incubation interval. 
 
Although the present work set out to investigate the absorption enhancing mechanism 
of AGs, evaluation of their toxicity towards the epithelial cells (used as a mucosal 
model) highlighted severe adverse effects on cell metabolic activity and integrity of 
cell membranes. Considering this outcome, the mechanisms involved in permeability 
enhancement could not be fully elucidated. However, based on the toxicity data 
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obtained in this work, it could be speculated that the absorption-facilitating effect of 
AGs (found in the studies discussed above) results from their effect on cell 
membranes, leading to compromised integrity of epithelial cell barriers.  
 
4.5 Conclusion 
This work evaluated the toxicity of AG surfactants, as compounds that have recently 
been demonstrated to promote the mucosal absorption of peptide and protein drugs, 
towards the Calu-3 epithelial cells. A combination of different assays and methods 
indicating cellular toxicity were adopted. Permanent reduction in TEER, dramatic 
reduction in cell metabolic activity (as measured by two different assays), remarkable 
cell membrane disruption (indicated via the LDH assay) and penetration of otherwise 
cell membrane-impermeable FD4 into the cells were the experimental outcomes 
associated with the application of tested AG compounds. These phenomena were 
observed at AG concentrations lower than those typically used in the literature. This 
work therefore revealed that these compounds exhibited extremely high toxicity 
towards the Calu-3 cells (and also HT29 cells, used for corroboration), indicating the 
necessity for further evaluation of their chronic toxicity prior to the potential use of 
AGs as mucosal absorption enhancers in man. In the scope of the project described in 
this thesis, AGs were considered too toxic and therefore not investigated any further.  
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Chapter 5 
 Tight Junction Modulation by Calcium 
Depletion  
 
5.1 Introduction  
The presence of calcium in the extracellular environment of epithelial cells is essential 
for the maintenance of barrier function of the epithelium (1), with extracellular 
calcium depletion inducing opening of the cellular tight junctions (TJs) (2). The 
crucial role of extracellular calcium in regulating the TJ barrier function has been 
demonstrated in studies using different cell lines. Incubation of MDCK (Madin-Darby 
Canine Kidney) epithelial cells with a calcium-free medium containing a calcium-
chelating agent prevented the formation of TJs (3) and incubation of confluent MDCK 
layers in a calcium-free solution resulted in increased TJ permeability (4, 5).  
 
In vitro studies investigating the effects of extracellular calcium on TJs have often 
employed calcium-chelating compounds such as ethylenediaminetetra-acetic acid 
(EDTA) and ethylene glycol tetra-acetic acid (EGTA). The use of these agents has 
been demonstrated to result in opening of the TJs (6, 7) and an increased paracellular 
permeability of drug molecules (8, 9). For example, Tomita et al. (16) demonstrated 
that application of EDTA (0.25% w/v) to Caco-2 cell monolayers was associated with 
an increase in FD4 permeability, which was suppressed, concentration-dependently, 
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by addition of CaCl2. Raiman et al. (17) assessed the effect of EGTA on the 
translocation of clodronate across Caco-2 monolayers. The transport experiments 
were performed in a medium containing normal calcium concentration (1.3 mM) and 
minimal calcium levels (calcium-free apically and 100 µM basolaterally). In the 
medium with normal calcium concentration, a strong improvement in permeability 
(190-fold and 130-fold for 1 mM and 10 mM clodronate, respectively) was observed 
with EGTA (2.5 mM). When the transport experiment was performed in medium 
containing a minimal calcium concentration, EGTA did not show such a potent effect 
on the permeability of clodronate, with observed permeability enhancement factors 
between 2 and 20.  
 
The intracellular processes involved in extracellular calcium modulation of the TJ 
barrier have been examined by Ma et al. (10). In their study, incubation of filter-
cultured Caco-2 monolayers in a calcium-free solution (modified Krebs-buffer 
solution containing no calcium and 1 mM EGTA), added on both apical and 
basolateral chambers resulted in a rapid drop in TEER (to <25% of the baseline value 
within 10 min) and an increase in the permeability of paracellular markers mannitol 
and inulin, indicating TJ opening. The increase in permeability was rapidly reversible 
with reintroduction of calcium (1.8 mM) into the incubation medium. Extracellular 
calcium removal produced a rapid centripetal retraction of the TJ proteins, as 
visualized by immunofluorescence/confocal microscopy, with formation of large 
paracellular openings between the adjoining cells, which was rapidly reversed by re-
introduction of extracellular calcium.  
 
As a result of a well-demonstrated effect of extracellular calcium depletion on TJ 
Chapter 5                            Tight Junction Modulation by Calcium Depletion 
 
 142 
modulation, different compounds with a capacity to bind calcium, reducing its 
extracellular levels, have been investigated for their potential to improve the mucosal 
absorption of macromolecules through the paracellular route. The use of older 
generation 'classical' absorption enhancers such as EDTA and EGTA is generally 
limited to in vitro experimental situations. This is as a result of their local 
intolerability, possibly related to a membrane damaging effect, and the possibility that 
they may penetrate into the cells where they interact with the intracellular calcium, 
causing cellular damage or even cell death (18). However, more recently, the 
absorption-enhancing mode of action of various compounds based on polymeric 
molecules has been attributed to extracellular calcium depletion. These compounds 
include carboxylic acid-containing polymers (11) such as poly(Acrylic acid) (PAA) 
and its derivatives (12). 
 
Although the importance of extracellular calcium in maintaining the barrier property 
of the epithelium has been established long ago and the mechanisms involved in TJ 
modulation by extracellular depletion have been relatively well characterized (as 
discussed above), the conditions under which extracellular calcium depletion 
produces pronounced opening of the TJs are unclear from the literature. For example, 
it is not apparent whether lowering/exhausting calcium on the luminal side of the 
mucosal surfaces only, produces meaningful effects on TJs, whereby mucosal 
absorption of therapeutic macromolecules would be improved. Furthermore, with a 
newer generation of absorption enhancers based on calcium-binding polymers, there 
is insufficient evidence to clearly suggest that their absorption-promoting effect is 
wholly due to calcium depletion. Present work therefore attempts to address these 
points by investigating the settings in which depletion of extracellular calcium leads 
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to obvious effects on TJs and assessing the permeability-enhancing potential of a 
calcium-binding polymeric compound, PAA. 
 
Present work investigated the effect of calcium depletion on the apical or basolateral, 
or both sides of confluent Calu-3 cell layers, on TEER and permeability of 
macromolecules (FITC-dextrans, FDs). Furthermore, changes in calcium levels 
following an initial depletion (achieved by different means) were also investigated 
using a fluorescent calcium-sensing probe. Calcium depletion was produced through 
the use of a calcium-free HBSS (CFHBSS) and EDTA. The effects of PAAs as a 
model polymeric compound shown to bind calcium, resulting in its depletion, were 
also investigated. For the purpose of corroboration, some experiments were 
additionally conducted on Caco-2 monolayers.  
 
5.2 Methods 
5.2.1 Cell culture 
Calu-3 and Caco-2 cells were cultured (on flasks and filters) according to the 
protocols detailed in Chapter 2 (section 2.2.1). 
 
5.2.2 Effect of calcium-free medium on TJ modulation 
5.2.2.1 Effect of CFHBSS on TEER  
Baseline TEER was measured after culture medium (EMEM and DMEM for Calu-3 
and Caco-2 cells, respectively) was replaced with HBSS and an equilibration period 
of approximately 45 min was allowed. Following this, the experiments were 
conducted in three different ways:   
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1) HBSS was removed from both apical and basolateral sides of Calu-3 layers and 
replaced with CFHBSS. Cells were incubated with CFHBSS for 30 min, 60 min or 90 
min, following which CFHBSS was removed and replaced with HBSS. TEER was 
measured at regular time intervals while cells were exposed to both, CFHBSS and 
HBSS. 
 
2) HBSS solution was removed from the apical side of Calu-3 and Caco-2 layers and 
replaced with CFHBSS (i.e. cells were exposed to CFHBSS on their apical surface 
only). TEER was subsequently measured at regular intervals (every 30 minutes) for 3 
hours. 
 
3) In Caco-2 monolayers, HBSS was replaced with CFHBSS on both apical and 
basolateral sides and TEER was measured every 30 min for 3 hours. 
  
It must be noted that CFHBSS used in this work was also Mg
2+
-free. To establish 
whether the deficiency in Mg
2+
 affected the TEER, control experiments were 
performed by incubating the cell layers with CFHBSS (Calcium/Mg
2+
-free HBSS), 
supplemented with calcium (more specifically, CFHBSS was supplemented with 140 
mg/L CaCl2, which is found in HBSS) and measuring the effect of this solution on 
cell layer TEER.  
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5.2.2.2 Effect of CFHBSS on permeability of FDs  
Permeability experiments were conducted in confluent cell layers (previously 
equilibrated in HBSS) in the following ways:  
 
1) The effect of apical calcium depletion on FD4 permeability was measured by 
application of FD4 in CFHBSS (500 µg/ml) to the apical side of the cell layers, 
following which basolateral solution (HBSS) was sampled regularly (every 30 min) 
for 3 hours. The sampled volumes were immediately replaced with fresh HBSS. 
 
2) Solution of FD4 in CFHBSS (500 µg/ml) was applied to the apical side of 
confluent Calu-3 layers as previously. However, this solution was replaced with fresh 
FD4/CFHBSS every 30 minutes. FD4 permeability was measured by sampling the 
basolateral solution (HBSS) at regular intervals as previously. The control experiment 
was in this instance conducted by replacing the apical solution, which consisted of 
FD4 in HBSS (500 µg/ml) every 30 min. Note that in this scenario the permeability 
coefficient (Papp) values could not be calculated as FD4 was removed and re-applied 
to the cells throughout the experiment. Therefore, for the purpose of this experiment, 
permeability is expressed as the cumulative FD4 amount traversing the layers. 
 
5.2.3 Effect of EDTA on TJ modulation 
5.2.3.1 Effect of EDTA on TEER 
EDTA stock solution (0.5% w/v) was prepared by dissolving EDTA in HBSS (pH 
8.0). EDTA (0.125% w/v in HBSS) was applied to the apical side of confluent Calu-3 
and Caco-2 monolayers, which were previously equilibrated in HBSS (for 
approximately 45 min). Application of EDTA was followed by periodic 
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measurements of TEER (every 30 min for 3 hours), following which EDTA solution 
was removed and cells washed. Culture medium appropriate for the cell line was 
added to the cells and TEER measurements were also conducted 24 hours after the 
application of EDTA in order to measure cell recovery. 
 
In a separate experiment, EDTA (0.125% w/v in HBSS) was applied to either the 
apical side or the basolateral side of confluent Caco-2 monolayers (previously 
equilibrated in HBSS). TEER was subsequently recorded periodically (every 30 min) 
for 3 hours. 
 
5.2.3.2 Effect of EDTA on permeability of FD4 
Effect of apical or basolateral addition of EDTA to confluent Calu-3 or Caco-2 layers 
on apical-to-basolatereal permeability of FDs was measured in the following ways: 
 
1) EDTA was applied to the apical side of the cell layers in conjunction with FD4; 
final apical concentrations were 0.125% w/v and 500 µg/ml for EDTA and FD4, 
respectively (both in HBSS). Basolateral, solution was then sampled periodically for 3 
hours.  
 
2) EDTA solution (0.125% w/v in HBSS) was applied on the basolateral side of Calu-
3 cell layers, whereas FD4 (in HBSS, at 500 µg/ml) was added on the apical surface 
of the cells. Apical-to-basolateral FD4 permeability was measured by regular 
sampling of the basolateral solution. The sampled solutions were immediately 
replaced with solutions containing EDTA 0.125% w/v in HBSS in order to maintain 
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sink conditions and basolateral concentration of EDTA constant throughout the 
experiment. 
 
5.2.4 Effect of EDTA on cell metabolic activity: MTS assay 
Calu-3 cells were seeded and cultured on 96-well plates according to the protocol 
described in Chapter 2 (section 2.2.5.3). Culture medium was removed and replaced 
with solutions of varying concentrations of EDTA (0.5%, 0.25%, 0.125% and 
0.0625% w/v) in HBSS. Triton X-100 (0.1% v/v in HBSS) and HBSS were used as 
the positive and negative controls, respectively. Cells were incubated with EDTA 
solutions and the controls for 2 hours, following which the MTS assay was conducted 
following the protocol detailed on (section 2.2.5.3). 
 
5.2.5 Changes in calcium levels following application of CFHSS and EDTA 
5.2.5.1 Changes in apical calcium levels with apical CFHBSS 
Confluent cell layers were equilibrated in HBSS for approximately 45 min prior to the 
addition of CFHBSS or EDTA in all cases. Changes in calcium levels in the apical 
medium were measured in the following way: CFHBSS or EDTA (0.125% w/v in 
HBSS or in CFHBSS) was added to the apical surface of the cell layers (with HBSS 
present on the basolateral side). The apical solution was subsequently withdrawn (50 
µl volumes) regularly for a period of three hours and transferred onto a black 96-well 
plate. The calcium-sensing fluorescent probe, Fluo-4, was then applied (10 µM) to the 
sampled apical solutions and fluorescence was measured (485 nm excitation, 535 nm 
emission) using an MFX microtiter plate fluorometer (Dynex Technologies, USA). 
Cell layers incubated with HBSS (on apical and basolateral sides) served as a control, 
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with the apical solution removed at the beginning and at the end of the experiment 
and incubated with Fluo-4 for fluorescence determination.  
 
5.2.5.2 Changes in basolateral calcium with apical EDTA 
The change in basolateral calcium level following application of EDTA to the apical 
side of the cell layers was measured by applying EDTA (0.125% w/v) in HBSS to the 
apical side surface and sampling the basolateral medium (HBSS) at regular intervals. 
Fluo-4 was then added to the sampled solutions and fluorescence determined in the 
same way as in the preceding section. Control experiments were performed by 
measuring Fluo-4 fluorescence of basolateral solutions consisting of HBSS and 
EDTA in HBSS (0.125% w/v) (with apical HBSS in both cases).  
 
5.2.6 Effect of polyacrylic acids of varying MWs on TJ modulation 
5.2.6.1 Changes in TEER  
Stock solutions of polyacrylic acids (PAAs) of 125 kDa and 250 kDa were diluted in 
HBSS to a concentration of 0.25% w/v (pH 5.8) and applied to the apical side of 
confluent Calu-3 layers previously equilibrated in HBSS. This was followed by 
regular TEER measurements over 80 min. PAA solutions were removed from the cell 
layers after 80 min and cells washed with PBS. Culture medium was then added to the 
apical and basolateral sides of the cells and TEER was measured at 110 min, 140 min 
and 170 min in culture medium in order to determine TEER recovery. Control 
experiment was conducted by following similar experimental conditions as above, 
with the exception that HBSS (pH 5.8) was applied to the cells instead of PAA. 
Changes in TEER are reported as % relative to the baseline value, measured prior to 
sample addition. 
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5.2.6.2 Effect of PAAs on FD4 permeability  
FD4 was added to the apical side of confluent Calu-3 layers in conjunction with 
solutions containing PAAs of 125 kDa, 250 kDa and 450 kDa. Both FD4 and PAAs 
of varying MWs were dissolved in HBSS and applied to cells at concentrations of 500 
µg/ml and 0.25% w/v, respectively (at a final solution pH of 5.8). FD4 permeability 
was determined over 3 hours, with regular sampling of the basolateral solution, as 
described previously.  
 
5.3 Results  
5.3.1 Effect of calcium-free medium on TJ modulation 
5.3.1.1 Effect of CFHBSS on TEER 
Figure 5.1 shows changes in TEER resulting from the application of CFHBSS to the 
apical and basolateral sides of Calu-3 layers. A sharp decrease in TEER following 
the incubation of cells with CFHBSS was apparent. A small decrease in TEER was 
also observed 5 min after the application of CFHBSS even for control cell layers 
(incubated with CFHBSS, supplemented with CaCl2). However, in cells incubated 
with CFHBSS, TEER continued to decrease with time, reaching the lowest points 
(54%, 26% and 20% of the baseline value with cell layers incubated with CFHBSS 
for 30 min, 60 min and 90 min, respectively) at the measurement points prior to 
replacement of CFHBSS with HBSS. The TEER of control cells (those incubated 
with CFHBSS, supplemented with CaCl2) on the other hand started to increase after 
the first measurement, reaching levels similar to the baseline value within 1 hour. The 
magnitude of TEER decrease was dependent on the time during which Calu-3 layers 
were incubated with CFHBSS, with more prominent decrease in TEER with longer 
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incubation with CFHBSS. Following the replacement of CFHBSS with HBSS, TEER 
started to increase in all cases. Measurement at 180 min, showed that TEER of cell 
layers previously incubated with CFHBSS reached levels similar or close to those of 
control.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Effect of CFHBSS, applied on the apical and basolateral sides of Calu-3 layers, on 
TEER. Arrows indicate replacement of CFHBSS with HBSS. Control represents cell layers 
incubated with CFHBSS supplemented with CaCl2. TEER expressed as % relative to the baseline 
value. Results presented as the mean ± SD (n=3).  
 
Application of CFHBSS to the apical side of Calu-3 layers, while (calcium-
containing) HBSS was present on the basolateral surface also produced measurable 
changes in TEER. The TEER pattern, illustrated in Figure 5.2 shows that apical 
addition of CFHBSS resulted in a drop of TEER to 42% of the baseline value, 30 min 
following its application. However, succeeding measurements revealed that this initial 
drop in TEER was followed by an increase, with measurements at 180 min reaching 
97% of the baseline value. With regards to control cell layers, there was an initial 
⇑  
⇑  ⇑  
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decrease in TEER amounting to 19% (i.e. TEER decreased to 81% of the baseline 
value), but subsequently this recovered to levels >100% of the baseline value.  
 
Figure 5.2. TEER changes resulting from addition of CFHBSS to the apical side of Calu-3 layers. 
Control represents cell layers incubated with CaCl2-supplemented CFHBSS. TEER expressed as % 
relative to the baseline value. Results presented as the mean ± SD  (n=3).  
 
Using confluent Caco-2 monolayers, effects of CFHBSS application to the apical, or 
both apical and basolateral sides of the cells on TEER were further measured. The 
results, shown in Figure 5.3, show that both conditions produced an initial reduction 
of TEER, with application of CFHBSS to both apical and basolateral sides producing 
a somewhat larger effect. Addition of CFHBSS to the apical monolayer side only 
(with HBSS present on the basolateral chamber) resulted in a decrease of TEER to 
approximately 33% of the baseline value, while application of CFHBSS on both sides 
(apical and basolateral) produced a drop in TEER to levels approximating 25% of the 
baseline value, as measured 30 min following its application. However, subsequent 
measurements revealed an increase in TEER with time in cell monolayers exposed to 
CFHBSS apically only, with the measurement conducted at 180 min reaching 63% of 
the baseline TEER. On the other hand, in Caco-2 monolayers exposed to CFHBSS on 
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both apical and basolateral surfaces, TEER continued to drop to low levels of 
approximately 5% of the baseline value at 90 min, after which no further decrease 
was observed. In control cell monolayers incubated with HBSS, there was a 10% 
decrease in TEER at 30 min, but subsequent measurements revealed that the 
resistance remained stable (within 5% of the baseline value) throughout the 
experiment. 
 
Figure 5.3. Changes in TEER of Caco-2 monolayers following application of CFHBSS to the apical 
side only or both apical and basolateral sides. Control cell monolayers were incubated with HBSS. 
TEER expressed as % relative to the baseline value. Results presented as the mean ± SD (n=3).  
 
5.3.1.2 Effect of CFHBSS on permeability of FDs  
The impact of calcium exhaustion by addition of CFHBSS apically on the 
permeability of FD4 across Calu-3 and Caco-2 layers (measured over a period of 3 
hours) is depicted in Figure 5.4. There was a small (approximately 1.8-fold), but 
significant (p=0.001) increase in FD4 permeability across Calu-3 cell layers with 
apical CFHBSS compared to control (5.4a). A similar effect was observed in Caco-2 
monolayers (5.4b), with apical CFHBSS giving rise to the same extent of increase in 
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FD4 permeability (approximately 1.8-fold, which was statistically significant, 
p=0.007) as in Calu-3 layers.  
 
 a) 
 
  
 b) 
 
Figure 5.4. Effect of apical CFHBSS on permeability of FD4 across cell layers. a) Calu-3 layers, 
and b) Caco-2 cell monolayers. Control represents FD4 permeability in HBSS. FD4 permeability 
expressed as apparent permeability (Papp), calculated in the manner described in section 2.2.4. 
Results presented as the mean ± SD (n=3). 
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Regular replacement of the penetrant solution consisting of FD4 in CFHBSS on the 
apical surface of Calu-3 layers resulted in an increase of FD4 permeability compared 
to control (regularly replaced FD4/HBSS), as shown in Figure 5.5. Periodic 
measurement of FD4 in the basolateral solution demonstrated an increase in its 
amount with time when applied apically in both, CFHBSS and HBSS (control). 
However, accumulation of FD4 in the basolateral solution was observed to occur at a 
greater rate (0.52 µg/hour) following its apical addition in CFHBSS, which was 
replaced with fresh FD4/CFHBSS every 30 min compared to its application in 
(calcium-containing) HBSS (0.16 µg/min) (also replaced regularly to allow 
comparison), amounting to a 3.3-fold difference.  
 
 
Figure 5.5. FD4 permeability across Calu-3 layers subjected to regular replacement of apical 
penetrant solution consisting of FD4 dissolved in CFHBSS or HBSS (control). Results shown as 
amount of FDs (µg) accumulated in the basolateral chamber with time. Results presented as the 
mean ± SD (n=3).  
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5.3.3 Effect of EDTA on TJ modulation 
5.3.3.1 Effect of EDTA on TEER 
A marked reduction of TEER with time was observed in the cell layers of both Calu-3 
and Caco-2 cell lines following the application of EDTA to the apical side of the cells 
(Figure 5.6). The largest drop in TEER occurred at the measurement point of 30 min 
and was somewhat larger in Calu-3 layers (to 22% of the baseline value) compared to 
Caco-2 cells (to 28% of the baseline TEER). Thereafter, TEER decreased at a lower 
rate (from 22% to 17% and from 28% to 15% of the baseline value in Calu-3 and 
Caco-2 monolayers, respectively). Measurements at 24 hours following the 
application of EDTA to cells revealed that TEER reverted back to values similar to 
the baseline figure (±10%) in both Calu-3 and Caco-2 layers. 
 
Figure 5.6. Effect of apical addition of EDTA (0.125% w/v in HBSS) on TEER of Calu-3 and Caco-
2 layers. TEER shown as % of the baseline value (prior to EDTA application). Results presented as 
the mean ± SD (n=3).  
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Figure 5.7 compares the effects of apical and basolateral addition of EDTA (0.125% 
w/v in HBSS, pH 7.4, in both cases) on TEER of Caco-2 cell layers. Both apical and 
basolateral application of EDTA resulted in a decrease in TEER, with a steeper initial 
drop (observed in the first 15 min) obtained following the addition of EDTA on the 
apical surface of the cells. At measurement intervals of 60 min and 90 min following 
EDTA application, TEER reached similar values at 60 min, which amounted to 
approximately 35% and 40% of the baseline value with apical and basolateral EDTA, 
respectively. However, reductions in TEER at later measurement points were more 
prominent with basolateral EDTA, with a lower minimum TEER level (at 180 min) 
seen with basolateral EDTA (11% of the baseline value) compared to apical EDTA 
(23% of baseline TEER). Recordings of TEER 24 hours following the exposure of 
cells to EDTA revealed its reversibility to 93% and 132% of the baseline TEER for 
Caco-2 monolayers incubated with EDTA on the apical and basolateral surface, 
respectively. 
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Figure 5.7. Changes in TEER following the application of EDTA (0.125% w/v in HBSS) to the 
apical or basolateral side of Caco-2 monolayers. TEER shown as % of the baseline value. Results 
presented as the mean ± SD (n=3). 
 
5.3.3.2 Effect of EDTA on the permeability of FD4 
Application of EDTA to the apical side of Calu-3 and Caco-2 layers resulted in a 
significant increase in FD4 permeability across the cell layers (Figure 5.8). In Calu-3 
cells, this increase amounted to approximately 7-fold compared to control (5.8a), 
whereas the enhancement in FD4 permeability across the Caco-2 cell monolayers 
with EDTA was approximately 8-fold in comparison to control (5.8b). 
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 a) 
 
 b) 
 
Figure 5.8. FD4 permeability enhancement with EDTA. Permeability measured across Calu-3 layers 
(a) and Caco-2 monolayers (b). EDTA was added apically at 0.125% w/v in HBSS (pH 7.4). Control 
represents FD4 permeability when applied in HBSS (pH 7.4) in the absence of EDTA. FD4 
permeability is expressed as apparent permeability coefficient (Papp), calculated using the equation 
shown in section 2.2.4. Results are presented as the mean ± SE; (n=4 and 3 for Calu-3 and Caco-2 
layers, respectively). 
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Figure 5.9 compares apical-to-basolateral FD4 permeability observed with application 
of EDTA to the apical, or basolateral sides of Calu-3 layers (0.125% w/v in both 
cases). Both apical or basolateral addition of EDTA produced an increase in FD4 
permeability as compared to control (FD4 permeability in the absence of EDTA). 
However, addition of EDTA to the basolateral side induced a markedly greater 
permeability enhancing effect (45-fold compared to control) than apical EDTA (15-
times higher than the control in the current experiment).  
 
Figure 5.9. Effect of apical or basolateral EDTA on FD4 permeability across Calu-3 layers. Cells 
were incubated with 0.125% w/v EDTA (in HBSS, pH 7.4) on the apical or basolateral sides. FD4 
added on the apical side only. Control represents FD4 permeability in HBSS (pH 7.4) in the absence 
of EDTA. FD4 permeability is expressed as apparent permeability coefficient (Papp), calculated using 
the equation shown in section 2.2.4. Results are presented as the mean ± SE (n=3). 
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5.3.4 Effect of EDTA on cell metabolic activity: MTS assay 
EDTA exhibited a dose-dependent reduction in relative metabolic activity of Calu-3 
cells, ranging from 22% with 0.0625% w/v to 92% with 0.5% w/v (applied in HBSS, 
pH 7.4), as determined by the MTS assay after 2-hour exposure. The concentration of 
EDTA used in TEER and permeability experiments (0.125% w/v) caused a 39% 
decrease in relative metabolic activity. The results are presented in Figure 5.10. 
 
Figure 5.10. Effect of varying concentrations of EDTA on Calu-3 metabolic activity as determined 
by the MTS assay. EDTA was applied to the cells at 0.0625, 0.125%, 0.25% and 0.5% w/v (in HBSS, 
pH 7.4) Results are expressed as relative metabolic activity, calculated in the manner described in 
section 2.2.5.3. Data presented as the mean ± SD (n=4). 
 
5.3.5 Changes in calcium levels following application of CFHBSS and EDTA 
5.3.5.1 Changes in apical calcium levels with apical CFHBSS 
Changes in fluorescence intensity of the calcium-sensing probe, Fluo-4, following its 
incubation with different solutions present on the apical side of Calu-3 layers, which 
were sampled at different time intervals, are shown in Figure 5.11. The apical 
solutions consisted of CFHBSS, 0.125% w/v EDTA in CFHBSS, 0.125% w/v EDTA 
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cell layers, the fluorescence intensity of Fluo-4 was 3-fold lower in cells incubated 
with CFHBSS compared to the cells exposed to HBSS. However, Fluo-4 fluorescence 
intensity increased gradually with time eventually reaching a plateau at time 90 min, 
with no further significant increases beyond this time point. In sharp contrast, the 
fluorescence intensity of Fluo-4 incubated with apical samples containing EDTA (in 
HBSS, or CFHBSS) was significantly lower (up to approximately 30 and 50 times 
lower, respectively). In these scenarios, Fluo-4 fluorescence intensity remained at 
these low levels at all time points. 
 
Figure 5.11. Changes in fluorescence intensity of the calcium-sensing probe, Fluo-4, following its 
addition to apical solutions. These consisted of CFHBSS, CFHBSS/EDTA, HBSS/EDTA and 
HBSS, and were present on the apical side of Calu-3 layers for 3 hours, with sampling every 30 min. 
Results presented as the mean ± SD (n=3). 
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5.3.5.2 Changes in basolateral calcium with apical EDTA 
The effect of EDTA addition to the apical surface of Calu-3 cell layers on 
fluorescence intensity of Fluo-4 incubated with solutions sampled from the 
basolateral compartment (indicating basolateral calcium
 
levels) is shown in Figure 
5.12. There was no change in the fluorescence intensity of Fluo-4 incubated with 
basolateral solutions sampled in the first hour following the application of EDTA to 
the apical side of the cell layers. However, measurements at subsequent time intervals 
revealed a decrease in Fluo-4 fluorescence intensity, with levels measured at 180 min 
amounting to 75% of the initial value (measured at 5 min) or 69% of control cell 
layers (incubated with HBSS), measured at the same interval. In cell layers incubated 
with HBSS (control) the fluorescence intensity of basolateral solutions sampled at 
different intervals (and incubated with Fluo-4) remained high (approximately 2100-
2200) and relatively constant. On the other hand, basolateral solutions consisting of 
HBSS/EDTA had low fluorescence intensity, ranging between 122-285.  
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Figure 5.12. Changes in fluorescence intensity of the calcium-sensing probe, Fluo-4, following its 
incubation with basolateral solutions. These were sampled at different intervals and consisted of 
HBSS while EDTA (in HBSS, 0.125% w/v) or HBSS (control) was present on the apical side of cell 
layers, or EDTA (in HBSS, 0.125% w/v) with HBSS on the apical side. Results presented as the 
mean ± SD (n=3).  
 
5.3.6 Effect of polyacrylic acids (PAAs) of varying MWs on TJ modulation 
5.3.6.1 Changes in TEER   
Changes in TEER measured across the Calu-3 layers following the addition of PAA 
100 kDa and PAA 250 kDa on the apical side of the cells is illustrated Figure 5.13. 
Application of both PAAs resulted in a reduction of TEER to approximately 71-77% 
and 59-77% of the baseline value for PAA 100 kDa and 250 kDa, respectively. The 
reduction in TEER was sustainable for the duration of cell incubation with PAA 
samples and started to revert back to baseline values following the replacement of 
PAA solutions with HBSS at 80 min. Subsequent TEER measurements (after the 
replacement of samples with the culture medium) revealed its recovery to 79% and 
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100% of the baseline value for PAA 100 kDa and 250 kDa, respectively, within 3 
hours of their application.  
  
Figure 5.13. Effect of PAAs on Calu-3 layer TEER. PAAs were applied to cells at pH 5.8 (0.25% w/v 
in HBSS). Arrow indicates removal of PAA samples, cell washing and application of the culture 
medium. Results expressed as % relative to the baseline value (before sample application). Data 
presented as the mean ± SD (n=3).  
 
5.3.6.2 Effect of PAAs on FD4 permeability 
FD4 permeability following its application to the apical surface of Calu-3 layers in 
conjunction with one of the three tested PAAs is shown in Figure 5.14. It is apparent 
from the figure that PAAs produced an insignificant increase in FD4 permeability 
compared to control. 
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Figure 5.14. Effect of PAAs on FD4 permeability across Calu-3 layers. PAAs of varying MWs (100 
kDa, 250 kDa and 450 kDa) were applied to cells at 0.25% w/v (in HBSS at pH 5.8). Control 
represents FD4 permeability in HBSS (pH 5.8). FD4 permeability expressed as apparent 
permeability coefficient (Papp), calculated using the equation shown in section 2.2.4. Results 
presented as the mean ± SD (n=3). 
 
5.4 Discussion  
The property of the epithelium to function as a barrier to the movement of 
macromolecules is heavily dependent upon the presence of calcium in the 
extracellular environment of epithelial cells (1). As discussed above (section 5.1) 
different studies have demonstrated that exhaustion of extracellular calcium induces 
opening of the cellular TJs and increases the paracellular permeability. Observations 
of these phenomena have therefore led to investigation of different compounds 
possessing an ability to bind calcium, reducing or depleting its extracellular levels, in 
an attempt to induce TJ opening, potentially resulting in increased paracellular 
absorption of macromolecules. 
 
Exhaustion of extracellular calcium has been shown to induce global changes in 
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epithelial cells, including disruption of actin filaments and adherent junctions, 
reduction of cell adhesion and activation of protein kinases (2). Citi et al. (13) 
proposed that the calcium-depleting EGTA affects the calcium-dependent adhesion 
molecules concentrated at adherens junctions and induces the contraction of the 
junction associated microfilament cytoskeleton (14, 15), whereby inducing TJ 
opening. Protein kinase C (PKC) is also thought to mediate TJ-opening caused by 
extracellular calcium depletion, as demonstrated in a study on MDCK cell monolayers 
where the removal of extracellular calcium was shown to stimulate PKC which then 
dissociates adhesion molecules from cell-cell sealing and loosens junctional strands 
(2). To add to the complexity of possible mechanisms involved in TJ opening by 
extracellular calcium depletion Ma et al. (10) demonstrated that the observed increase 
in epithelial permeability induced by calcium free medium was mediated by the 
activation of myosin light chain kinase and a resulting contraction of the peri-
junctional actin-myosin filaments.  
 
The use of polymeric compounds with a capacity to bind calcium, has recently been 
proposed as a strategy to improve mucosal absorption of macromolecules by the 
paracellular route (19, 20). Numerous studies involving the use of certain polymers as 
permeability enhancers attributed the permeability-improving mechanism of these 
compounds to calcium depletion. For example, the high capacity of poly(acrylic acid) 
(PAA) to bind calcium, depleting this ion from the extracellular cell medium, has 
been provided as an explanation for the increase in the paracellular permeability 
across epithelial cell layers observed with this polymer and its derivatives (21, 22). 
 
The ability of polymeric powder formulations (microcrystalline cellulose, 
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semicrystalline cellulose, hydroxyethyl starch, cross-linked dextran, microcrystalline 
chitosan, pectin and alginic acid) to bind calcium
 
ions was, in a study by Oechslein et 
al. (18), reported to be of major importance for their potential to enhance nasal 
absorption of the somatostatin analogue peptide, octreotide, when administered 
nasally to rats. The absorption-promoting effect of the powders in this study 
correlated directly with their calcium binding capacity, which led the authors to 
suggest that the absorption-enhancing effect was due to TJ opening through a local 
decrease in calcium concentration. In another study, Kriwet et al. (20) reported that 
the weakly crosslinked poly(acrylic acid), Polycarbophil (PC), chelated up to 80% of 
the total calcium concentration in a physiological buffer, leading the authors to 
attribute the observed increase in bioavailability of drugs with PC to complexation of 
calcium ions and its removal from the physiological solution by this polymer.  
 
The access of a drug formulation incorporating an absorption enhancer is normally 
predominantly limited to the mucosal (apical) surface of the epithelium in vivo. This 
is especially true if the absorption enhancer is a large MW polymeric molecule such as 
those investigated in the studies discussed above. Therefore, in an in vivo situation, 
local reduction in extracellular calcium resulting from the mucosally administered 
polymeric (calcium depleting) absorption enhancer is likely to occur exclusively on 
the luminal side of the mucosal surfaces. But, importantly, there is some evidence 
from the literature, as will be discussed later, that meaningful improvements in 
paracellular transport induced by calcium chelators require calcium depletion on the 
serosal (basolateral) side of epithelial cells. The conditions under which removal of 
calcium gives rise to TJ-opening effects that are sufficiently pronounced as to produce 
meaningful improvements in mucosal permeability of macromolecules are therefore 
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not obvious. Additionally, and related to the previous point, it is unclear whether 
depletion of calcium exclusively on the apical side of epithelial cells (likely to be 
achieved by polymeric calcium binding molecules), produces opening of epithelial 
TJs resulting in enhanced macromolecular permeability. 
 
Present work confirmed the importance of extracellular calcium in maintaining the 
barrier properties of epithelial cells, as tested in Calu-3 and Caco-2 cell layers. 
Calcium exhaustion by application of a calcium-free medium (CFHBSS) on both 
apical and basolateral surfaces of Calu-3 layers produced a rapid decrease in TEER, 
which was reversible upon reintroduction of a calcium-containing medium (HBSS) 
(Figure 5.1), suggesting TJ opening with calcium
 
depletion. However, in Calu-3 
layers, exhaustion of calcium on the apical side only, as achieved by the addition of 
CFHBSS apically, produced a short-lived and reversible reduction in TEER. 
Importantly, TEER reverted back to near-baseline value (97% of the baseline TEER) 
during the presence of CFHBSS on the apical side of the cell layers. This effect was 
also apparent in Caco-2 monolayers, although in this case a lower extent of TEER 
reversibility was observed (63% of the baseline value, Figure 5.3) compared to Calu-3 
cells. Incubation of Caco-2 monolayers with CFHBSS on both apical and basolateral 
sides, on the other hand produced a marked reduction in TEER (reaching low levels 
amounting to approximately 5% of the baseline value) with no reversibility observed 
within the time frame of the experiment (Figure 5.3). The results therefore suggest 
that the TJs of epithelial cells recover from an initial effect caused by exhaustion of 
extracellular calcium on the apical side only.  
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The transient effect of apical calcium depletion on opening of the TJs, as observed 
through TEER measurements (discussed above), was reflected in permeability 
experiments. The data showed that apical calcium exhaustion (by application of 
CFHBSS on the apical side of cell layers) produced a modest increase (1.8-fold) in 
the permeability of FD4 across both Calu-3 and Caco-2 layers (Figure 5.4).  
 
A possible reason for the relatively mild effect that apical calcium depletion with 
CFHBSS was seen to produce on TJ modulation may be that apical calcium is 
relatively unimportant for the maintenance of TJ integrity in epithelial cells. Indeed, 
there is evidence in the literature to support our findings. It was observed that in 
Caco-2 monolayers, enhancement of paracellular transport induced by calcium-
depleting agents required their addition (i.e. calcium depletion) on the serosal side 
(25, 26). Using the same epithelial cell monolayer model, Tomita et al. (27) also 
found that basolateral calcium plays a more important role than apical calcium in 
maintenance of the barrier properties of the epithelium. In another study, Kamath et 
al. (28) incubated Caco-2 monolayers with CFHBSS supplemented with 2.5 mM 
EGTA (CFHBSS/EGTA) on the apical side and HBSS or CFHBSS on the basolateral 
side for 1 hour. Measurement of TEER 4 hours after the removal of these solutions 
and their replacement with HBSS revealed a TEER decrease of varying extents, 
depending on the condition. In cell monolayers incubated with CFHBSS/EGTA on 
the apical side and HBSS on the basolateral side, TEER amounted to 64% of the 
initial value (before application of the samples). However, cell monolayers exposed to 
CFHBSS/EGTA on the apical side and CFHBSS on the basolateral surface exhibited 
a TEER level amounting to 15% of the initial value.  
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Another factor that may possibly contribute to the unexceptional effect of apical 
calcium depletion with CFHBSS on TJ-opening in vitro is a recovery in apical 
calcium that may possibly occur following an initial depletion. This was investigated 
through the use of a calcium-sensing fluorescent marker, Fluo-4, and indeed proved to 
be the case. Measurement of Fluo-4 fluorescence following its incubation with apical 
CFHBSS present on Calu-3 layers, which was sampled at different intervals, was 
found to increase with time (Figure 5.12). This indicated rising apical calcium levels, 
following an initial depletion, to levels approaching those present in control cell 
layers (incubated with HBSS). In sharp contrast, apical EDTA led to permanently low 
Fluo-4 fluorescence, indicating low calcium levels throughout the experiment. The 
manner in which this reversibility in apical calcium levels arises is, at the present 
moment, unclear. However, it may be possible that calcium is transported in the 
basolateral-to-apical direction via the paracellular route, which has previously been 
demonstrated to occur (29). 
 
To test whether prolonged apical calcium depletion produced more pronounced 
effects on TJs, the calcium-chelating compound, EDTA, was applied to the apical side 
of confluent Calu-3 and Caco-2 layers and the effect on TJs monitored through 
measurements of TEER and FD4 permeability. Apical EDTA produced a significantly 
larger reduction in TEER, compared to apical CFHBSS, in the layers of both cell 
lines. Furthermore, the decrease in TEER was sustainable for the duration that EDTA 
was present apically. Addition of EDTA to the apical side of cell layers (Calu-3 and 
Caco-2) also produced notable effects in FD4 permeability, with a significantly higher 
permeability enhancement (approximately 7-fold and 8-fold in Calu-3 and Caco-2 
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layers, respectively) than that resulting from apical CFHBSS (1.8-fold in layers of 
both cell lines).  
 
It is possible that the larger effect produced by EDTA on TEER and FD4 
permeability, compared to apical CFHBSS, may be a result of EDTA exhibiting a 
toxic/irritant effect on the cells, in addition to calcium depletion. In this scenario, the 
barrier property of the cell layer would be compromised resulting in a lower TEER 
and increased macromolecular permeability. In fact, EDTA was tested for its toxicity 
towards Calu-3 cells and found that, at the concentration used to test TJ modulation 
(0.125% w/v), it caused a decrease in relative cell metabolic activity by 39%. Reports 
in the literature also suggest toxicity associated with higher concentrations of EDTA, 
with Zakelj et al. (31) finding that concentrations above 3 mM had an unacceptable 
effect on the viability of rat jejunum. Despite the decrease in cell metabolic activity, 
application of EDTA to cell layers at the tested concentration was associated with a 
reversible decrease in TEER (measured 24 hours following its removal from the 
cells), suggesting cell recovery. Another possibility that potentially explains the 
difference in TEER and permeability effects between CFHBSS and EDTA is the 
prolonged apical calcium depletion associated with application of EDTA (as 
suggested by the fluorescence intensity of the calcium-sensing Fluo-4, Figure 5.11), 
which may produce a greater effect on TJs compared to a reversible decrease in 
calcium levels seen with CFHBSS. Prolonged depletion/marked decrease in apical 
calcium observed with EDTA is not surprising. This is because at the concentration 
used in this work (0.125% w/v, corresponding to 4.3 mM), EDTA is expected to have 
produced total apical calcium depletion as it exceeded the concentration of calcium 
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present in the system (1.26 mM), with EDTA chelating an equivalent molar amount 
of calcium.  
 
In an attempt to deconvolute the impact that EDTA-induced prolonged apical calcium 
depletion produces on TJ modulation from other possible effects of EDTA (such as 
toxicity), which potentially influence the cell layer barrier and therefore 
macromolecular permeability, studies were conducted by applying the penetrant 
(FD4) in CFHBSS with regular replenishment on the apical side of cell layers. Any 
calcium reappearing in the apical solution with time, following an initial depletion 
achieved by applying CFHBSS, would therefore be removed regularly. The adoption 
of this experimental approach therefore permitted prolonged maintenance of minimal 
apical calcium levels. The extent of FD4 permeability enhancement achieved in this 
scenario was relatively higher (3.3-fold in Calu-3 cell layers, Figure 5.5) compared to 
that produced by a one-off application of CFHBSS (1.8-fold), suggesting that 
prolonged apical calcium removal produces a somewhat larger effect on opening of 
the epithelial TJs. However, it must be noted that the increase in FD4 permeability 
across the Calu-3 layers seen in this scenario was still lower than that achieved with 
apical addition of EDTA, suggesting that effects other than apical calcium depletion 
are likely to contribute towards the permeability-enhancing property of EDTA. 
 
In addition to assessing the impact of apical calcium depletion on TJ modulation, the 
effect of basolateral calcium removal by EDTA on FD4 permeability was also 
investigated. The observation of a 3-fold larger permeability enhancement (of FD4) 
ensuing following the application of EDTA on the basolateral side of Calu-3 layers 
compared to its addition to the apical side (used at an identical concentration of 
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0.125% w/v in both scenarios) strongly suggested that depletion of extracellular 
calcium on the basolateral side induces greater TJ-opening effects compared to 
exhaustion of apical extracellular calcium. However, achieving depletion of 
extracellular calcium on the luminal side of mucosal surfaces in vivo is likely to be 
problematic. As discussed earlier, the calcium-depleting effect of the mucosally 
administered absorption enhancer is probably almost exclusively limited to the apical 
side of the mucosal surfaces. This is because, in the case of large MW absorption 
enhancers, their translocation from the apical side into the basolateral side is limited 
due to the presence of mucosal barriers including the mucus layer, the mucociliary 
mechanism and the TJs (as discussed in Chapter 1). Even for lower MW calcium-
depleting agents, which can potentially traverse the epithelial layers through the 
paracellular route, exhaustion of extracellular calcium on the basolateral side is not 
viable due to the likely possibility of their passage into the bloodstream following 
translocation across the mucosal surface. 
 
Our finding that application of EDTA to the basolateral side (producing serosal 
calcium depletion) leads to a more enhanced effect on TJs compared to apical EDTA 
is in agreement with previous studies. Tomita et al. (32) reported that application of 
EDTA to the apical side of Caco-2 monolayers increased FD4 permeability to a lower 
extent than its addition to the basolateral side. The authors attributed the permeability-
enhancing mechanism of EDTA through its effect on the calcium susceptible 
adhesion molecule, uvomorulin, which is located in the basolateral membrane, 
maintaining TJ integrity (26, 33), with EDTA affecting this molecule more easily 
from the basolateral side of the cell monolayers. 
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Going back to the comparison of TEER and permeability effects between apical 
EDTA and CFHBSS, another possibility explaining the more pronounced action of 
EDTA is its apical to basolateral translocation following the addition on the apical 
side of cell layers. This possibility was tested experimentally through the use of 
calcium-sensing fluorescent probe, Fluo-4. Apical addition of EDTA produced a 
decrease (albeit modestly) in basolateral calcium levels (i.e. decreased the 
fluorescence intensity of Fluo-4) (Figure 5.12). The finding, firm evidence for apical-
to-basolateral movement of EDTA, is not surprising given that EDTA is a relatively 
small molecule (MW 292 Da) and therefore may traverse the cell layers through the 
paracellular route. A reduction in basolateral calcium, even if not dramatic, may have 
a prominent effect on TJ opening and permeability enhancement.  
  
This work finally assessed the potential of PAA, as an example of calcium binding 
polymeric compound investigated previously as a mucosal absorption enhancer, to 
open the cellular TJs and increase paracellular permeability. Several studies have 
demonstrated the ability of PAA to facilitate the absorption of drugs across the 
mucosal surfaces. For example, PAA has been reported to increase rectal absorption 
of calcitonin (34) and nasal absorption of insulin and calcitonin (35, 36). Furthermore 
PAA-based polymer, Carbopol
¨
, prolonged the oro-caecal transit time (by 
approximately 25%) in rats, an effect suggested by the authors to result from a 
bioadhesive interaction (37). Kriwet et al. (20) however, postulated that the depletion 
of extracellular calcium and other metal ions by PAA could explain its biological 
effects, including the improvement of drug absorption. Similarly, in investigating the 
effect of the PAA derivative, carbomer (Carbopol
¨
 934P), on the intactness of 
epithelial TJs on Caco-2 cell monolayers, Borchard et al. (19) reported a significantly 
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decreased TEER and markedly increased fluxes of [
14
C]mannitol and FD4 associated 
with application of carbomer to the apical side of the cells, which the authors 
attributed to depletion of extracellular calcium. 
 
Present work, however, showed that PAAs having a nominal MW of 100 kDa and 250 
kDa had a moderate effect on cell layer TEER following their application to the apical 
surface of Calu-3 layers (Figure 5.13), suggesting a limited effect on TJs. This was 
indeed reflected in their impact on FD4 permeability, with PAAs of three MWs (100 
kDa, 250 kDa and 450 kDa) exhibiting a negligible effect on FD4 permeability 
(Figure 5.14). The lack of effect on TJs by PAA, as assessed through the 
measurements of TEER and FD4 permeability, is an interesting observation. Factors 
accounting for the difference in the extent of TJ modulation between apical calcium 
removal and PAA are, at the present moment, unclear. However, it is possible that at 
the conditions used (concentration and pH) PAAs did not produce a sufficient 
decrease in apical calcium levels to elicit a strong effect on TJs.  
 
5.5 Conclusion  
Using Calu-3 and Caco-2 epithelial layers, this work investigated different situations 
under which extracellular calcium depletion produces the largest effect on TJs. The 
data presented here suggested that an initial removal of apical calcium (by CFHBSS) 
produced limited effects on TJs, with observed reversible decrease in TEER and 
modest improvement of macromolecular permeability. However, sustainable apical 
calcium depletion produced an effect on TJs that was somewhat more pronounced 
though still moderate. Exhaustion of calcium on the basolateral side of the cell layers 
(by application of EDTA) produced a notably larger effect on TJs as compared to 
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apical calcium depletion. However, removal of extracellular calcium on the 
basolateral surface of the epithelium is difficult to achieve in vivo, especially in the 
case of large polymeric absorption enhancers. Calcium-depleting mucosal absorption 
enhancers are likely to reduce/exhaust calcium ions on the apical side and only for the 
duration that they are present at the mucosal surfaces. Considering the inadequate 
effect of apical calcium removal on TJ opening, the calcium depletion strategy can 
therefore be regarded as relatively inefficacious for mucosal delivery of therapeutic 
macromolecules. 
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Chapter 6 
Permeability Enhancement with Chitosan 
Solution and Nanoparticles  
 
6.1 Introduction  
Chitosan has been shown to considerably enhance the mucosal (especially nasal) 
absorption of peptides and proteins, which are otherwise poorly absorbed. Chitosan is 
a cationic polymer (polysaccharide) produced by partial deacetylation of chitin and 
has been reported to be biocompatible, biodegradable and exhibiting a low toxicity (1-
3). Its absorption-promoting effect is thought to result from a combination of 
mucoadhesion and the ability to open the intercellular tight junctions (TJs) (4-6). The 
mucoadhesive properties of chitosan have been attributed mainly to an interaction 
between its positively charged amino groups with negatively charged sialic acid 
groups on the mucus membrane (7). Application of therapeutic agents in combination 
with chitosan has been reported to prolong the contact time between the agent and the 
absorptive surface for up to 84 min in man for a chitosan powder formulation (8). The 
capacity of chitosan to transiently open the TJs has been associated with an 
interaction of chitosan with the Protein Kinase C pathway (9).  
 
Different chitosan formulations, such as solutions, freeze dried or spray dried powders 
and nanoparticles (NPs) have been investigated for the potential improvement of nasal 
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absorption of various macromolecular drugs (6, 10). While chitosan solution and 
powder formulations improve mucosal absorption through mucoadhesion and TJ 
modulation, chitosan NP formulations have been developed in an attempt to deliver 
macromolecules across the mucosal surfaces by exploiting endocytic/transcytotic 
pathways (11-13). Potential advantages associated with the use of chitosan NPs 
encompass entrapment of the drug within the particle matrix, consequently ensuring 
protection against enzymatic degradation that may occur at the mucosal surface and 
the possibility of controlled drug release. However, despite these potential 
advantages, so far only one published study has shown superior mucosal drug 
absorption using chitosan NPs compared to chitosan solution (13). 
 
Dyer et al. (6) showed that in the rat and sheep models, the pharmacological 
responses to an insulin-chitosan solution or insulin-chitosan powder formulation 
applied nasally were significantly higher compared to those resulting from an 
equivalent chitosan NP formulation. Similarly, Ma and Lim (14) showed that chitosan 
NPs did not mediate translocation of insulin across intestinal Caco-2 monolayers. 
Recently Sadeghi et al. (15) found that chitosan (and its derivatives) in a 
nanoparticulate form were less efficient in opening the TJs than their soluble form 
equivalents. The authors suggested that drug movement across the cell layers would 
be more likely to occur through the transcellular pathway rather than as a result of TJ 
opening. 
 
The present work sets out to investigate the potential of chitosan NPs, formulated by 
the ionic gelation method, to improve the permeability of macromolecular compounds 
across biological membranes through TJ modulation, in comparison to the soluble 
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equivalent. Initial work assessed the effects of increasing concentrations of chitosan 
NPs and solutions on cell toxicity. The concentrations exhibiting minimal and 
reversible toxicity were then used to investigate TJ modulation and FITC-dextran 
(FD) permeability. Furthermore, the effect on structural changes in TJs is compared 
between chitosan solution and NPs. Finally, studies investigating the mucoadhesive 
property of chitosan are also included in this chapter. 
  
6.2 Methods  
6.2.1 Formulation and Characterisation of Chitosan NPs 
6.2.1.1 Formulation of chitosan NPs 
Chitosan NPs were prepared by the ionic gelation of tripolyphosphate pentasodium 
(TPP) and chitosan hydrochloride (CS), as described by Fernandez-Urrusuno et al. 
(13) and Dyer et al. (6). Preliminary experiments were performed with the objective 
of identifying the appropriate concentrations of chitosan and TPP producing NPs. 
Chitosan hydrochoride solutions of varying concentrations (2 mg/ml, 1.5 mg/ml, 1 
mg/ml, 0.75 mg/ml and 0.5 mg/ml) and TPP, at 0.84 mg/ml, were prepared in 
ultrapure water. TPP solution was added dropwise to chitosan solution while stirring. 
The resultant mixtures were broadly characterized as either clear solutions, opalescent 
mixtures or phase-separated aggregates. The formation of NPs was confirmed through 
particle size analysis (by Dynamic Light Scattering, Viscotek, UK). Excess chitosan 
(not associated with NPs) was removed by centrifugation (at 13,000 rpm, for 30 
minutes) of NP suspension until no chitosan was present in the supernatant. The 
concentration of chitosan in the supernatant was determined by a colorimetric method 
(based on the derivatization reaction of its primary amino groups with o-
phthalaldehyde and N-acetyl-L-cysteine), as described by Muzzarelli (16). Chitosan 
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concentration in the NPs was calculated by subtracting the amount lost in the 
supernatant from the starting amount used to formulate the NPs. Note that chitosan 
NP formulation and characterisation (section 6.2.1.2, below) were performed by Ruth 
Harris, Institute for Biofunctional Studies, Physical Chemistry Department, Faculty of 
Pharmacy, Complutense University of Madrid, Madrid, Spain. 
 
6.2.1.2 Chitosan NP characterisation 
The mean diameter and size distribution of chitosan NPs were measured by DLS in 
HBSS at pH 6.0. The reported results represent the mean of ten measurements, 
performed at 25¡C. Zeta potential of the NPs was measured in HBSS (pH 6.0) using a 
Zetasizer 2000 (Malvern Instruments, UK). Values reported are the mean of four 
measurements ±SD.  
 
6.2.2 Synthesis of FITC-chitosan   
100 mg of chitosan was dissolved in 10 ml of deionised water. 20 ml of DMSO was 
then added to this solution, followed by the slow addition of 5 mg of FITC, previously 
dissolved in DMSO, under continuous stirring. The reaction was carried out overnight 
at room temperature in the dark. The resulting solution was poured in an excess of 
acetone and then centrifuged for 10 min at 3000 rpm. The pellet was washed several 
times with fresh acetone until FITC fluorescence signal was no longer observed in the 
washing solution. The FITC-labelled polymer was then dissolved in water and 
dialysed against deionised water using a 1000 Da MW cut off (MWCO) membrane for 
three days while protecting from light. The labelled product was then freeze-dried for 
a further three days (17). FITC-chitosan was synthesised and FITC-chitosan NPs 
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(next section) were formulated by Luca Casettari, Pharmaceutical Chemistry Institute, 
University of Urbino ÔCarlo BoÕ, Urbino, 61029, Italy. 
 
6.2.3 Formulation of FITC-chitosan NPs 
FITC-chitosan NPs were produced using the ionic gelation technique in a similar way 
to unlabeled chitosan NPs. Preliminary experiments were performed in order to 
identify the optimal concentrations of FITC-chitosan and TPP resulting in formation 
of nano-sized complexes as confirmed by DLS. The optimal polymer:TPP ratio was 
found to be between 6:1 and  4:1. Chitosan was dissolved in HBSS (pH adjusted to 
5.0) at a concentration between 0.33 to 1.0 mg/ml. TPP solution of 0.5 mg/ml was 
added dropwise to 3 ml of the chitosan solution under mild magnetic stirring.  
 
6.2.4 Cell culture 
Calu-3 cells were cultured according to the method described previously (Chapter 2, 
section 2.2.1). 
 
6.2.5 Cell toxicity studies  
6.2.5.1 MTS assay 
The MTS assay was performed to evaluate the effect of chitosan NPs on cell 
metabolic activity and compare this effect with that resulting from chitosan solution. 
Furthermore, this test was undertaken in order to identify the highest concentration of 
chitosan NPs and solution that exhibits insignificant toxicity towards Calu-3 cells. 
The MTS assay was performed according to the manner described previously (section 
2.2.5.3). Sample solutions, the toxicities of which were tested, comprised of chitosan 
NPs or chitosan solution in HBSS (pH 6.0) of the following concentrations: 0.025%, 
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0.0125%, 0.006125%, 0.003% and 0.0015% w/v. Additionally, the effect of Triton X-
100 (0.1% w/v in HBSS, pH 6.0) and the HBSS (pH 6.0) on cell metabolic activity 
was tested and used as the positive and negative control, respectively.  
 
In order to assess whether cells recover following the application of chitosan, a further 
MTS assay was performed 15 hours after cells were exposed to the chitosan samples 
(incubated for 2 hours, as in the previous test). In the period between removal of the 
chitosan samples (NPs and solution) and the assay, cells were incubated with the 
culture medium (EMEM, at 37¡C/5% CO2).  
 
6.2.5.2 LDH assay 
The lactate dehydrogenase (LDH) release assay was conducted to assess membrane 
disruptive effects of chitosan NPs and chitosan solution. The LDH assay was 
performed in the manner described previously (section 2.2.5.4). Chitosan NPs and 
solutions tested using the LDH assay were used at the same concentrations (in HBSS, 
pH 6.0) as for the MTS assay (preceding section). Furthermore, the controls used for 
the LDH assay were the same (and at identical concentration) as those used in the 
MTS assay.  
 
6.2.6 Effect of chitosan NPs and solution on TEER 
6.2.6.1 Calu-3 layers 
Confluent filter-cultured cell layers were used in these experiments. Prior to sample 
application, culture medium was removed and replaced with HBSS (pH 6.0 and 7.4 
on the apical and basolateral side, respectively). Cells were equilibrated (incubated at 
37¡C, 5% CO2) in HBSS for approximately 45 min, following which the first TEER 
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measurement was recoded; this was treated as the baseline TEER. HBSS was then 
removed from the apical side of the cells and replaced with chitosan NPs or chitosan 
solutions (visually transparent in HBSS, pH 6.0) of 0.003% w/v and 0.006% w/v. The 
rest of the experiment was conducted according to the method described in section 
2.2.3. The reported changes in TEER are presented as percentage relative to baseline 
TEER. All experiments were performed in triplicates. 
 
6.2.6.2 Caco-2 monolayers 
The effect of chitosan NPs on TEER of Caco-2 cell monolayers was tested following 
similar procedures as those used for Calu-3 cells, with the following difference: only 
chitosan NPs were tested for their TEER-modulating effect and suspensions 
containing equivalent chitosan concentrations of 0.1%, 0.05%, 0.025% and 0.0125% 
w/v (i.e. higher concentrations than those used in Calu-3 cells) were used. 
 
6.2.7 Permeability experiments 
6.2.7.1 Effect of chitosan NPs and solution on FD permeability: Calu-3 cells 
Permeability experiments were performed on confluent, filter-cultured Calu-3 layers. 
Prior to sample application, culture medium was removed and cells washed with PBS. 
HBSS was then applied (at pH 6.0 and 7.4 on the apical and basolateral sides, 
respectively) and cells equilibrated for a period of approximately 45 minutes. 
Chitosan NPs or chitosan solution in combination with FDs (FD4 or FD10), in HBSS 
at pH 6.0 were then applied to the apical side of the cells. The final concentration of 
chitosan (as NPs or solution) was 0.003% w/v while FDs were used at a final 
concentration of 500 µl/ml. FD permeability was determined by sampling the 
basolateral solution in the manner described earlier (section 2.2.4).  
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6.2.7.2 FD4 permeability with chitosan NPs: Caco-2 cells 
Effect of chitosan NPs on FD4 permeability across Caco-2 cell layers was conducted 
in a similar manner as in the previous section, with the following exception: the tested 
concentration of NPs was that containing 0.0125% w/v chitosan.  
 
6.2.8 Effect of FITC-chitosan on TJ modulation 
Experiments evaluating the effects of FITC-chitosan on TEER and FD4 permeability 
were conducted (separately) in the same way as those for chitosan NPs and solution. 
FITC-chitosan was used at a concentration of 0.003% w/v in both cases.  
 
6.2.9 Association of FITC-chitosan NPs with Calu-3 layers 
FITC-chitosan NPs were diluted in HBSS (pH 6.0) to a concentration of 0.003% w/v 
chitosan and then applied to the apical side of confluent Calu-3 layers previously 
equilibrated in HBSS (for approximately 30 min). HBSS was present on the 
basolateral side. Cells were incubated with FITC-chitosan NPs at 37¡C for 2 hours. 
NPs were then removed and cells washed extensively with PBS. Cell layers were then 
fixed with paraformaldehyde, processed for confocal imaging and imaged by confocal 
microscopy using the confocal system in the manner described previously (section 
2.2.6.5).  
 
6.2.10 Effect of chitosan NPs and solution on ZO-1 distribution 
Chitosan in NP or solution form, of 0.003% w/v chitosan (in HBSS, pH 6.0), was 
applied to the apical side of confluent Calu-3 layers, following an equilibration step 
with HBSS. Cells were incubated with chitosan NPs or solution for a period of 1 hour 
followed by cell washing with PBS. Cells were then fixed with paraformaldehyde, 
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prior to staining for zonula occludens-1 (ZO-1) TJ protein. ZO-1 immunostaining, 
preparation of the samples for confocal imaging were conducted in the manner 
described in section 2.2.6.6. Confocal imaging was performed using the system 
described in section 2.2.6.3. 
 
6.2.11 Association of FITC-chitosan with Calu-3 and Caco-2 layers 
Caco-2 and Calu-3 cells were cultured on filters until confluence. In addition to 
normally employed AIC conditions, Calu-3 cells in this instance were also cultured 
using LCC conditions. Culture medium was removed and replaced with HBSS for 
equilibration (for approximately 30 min). Apical HBSS was then removed and 
replaced with a solution of FITC-chitosan (0.003% w/v in HBSS, pH 6.0). Cells were 
incubated with FITC-chitosan for 2 hours, following which chitosan solution was 
removed and cells washed with PBS extensively (at least 5 times in an attempt to 
remove the applied chitosan). Cells were then fixed with paraformaldehyde for 5-10 
min and processed for confocal imaging in the manner described previously (section 
2.2.6.5). 
 
6.2.12 Effect of chitosan on the permeability of investigational antibodies  
Antibody permeability experiments were conducted on confluent Calu-3 layers, 
equilibrated in HBSS for approximately 45 min. UCB antibodies, mA33γ1 Fab (6.52 
mg/ml), mA33γ1 Fab-diPEG (10.3 mg/ml), hCTM01γ4 antibody (3.67 mg/ml) and 
hCTM01γ4 Fab (5.64 mg/ml), all diluted in HBSS (pH 6.0), were applied to the apical 
side of the cell layers, with chitosan, which was used at a final apical concentration of 
0.003% w/v (in HBSS, pH 6.0). Antibody permeability was established by sampling 
the basolateral solution (HBSS) periodically. Sampled volumes were replaced with 
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fresh HBSS. Apical-to-basolateral translocation of the antibodies across the cell layers 
without the addition of chitosan was used as a control experiment; antibodies were 
applied at the same concentration and pH as above. Antibodies were quantified by 
HPLC (see section 2.2.7.2 for the method) in all cases.  
 
6.3 Results 
6.3.1 Chitosan NP characterisation  
Following the initial screening experiments, the optimised preparation conditions 
(initial concentrations of chitosan and the polyphosphate salt) were identified as a 
final chitosan hydrochloride concentration of 1.5 mg/ml and a final TPP concentration 
of 1.8 mg/ml. Under these conditions, the NPs formed had a mean radius of 339±66 
nm (Figure 6.1) and a surface potential of +11.3±2.7 mV, as measured in HBSS (pH 
6.0). The final NPs suspension, after the removal of excess free chitosan, following 
the procedure described in the methods section, contained 0.56 ± 0.06 mg/ml of 
chitosan (in the form of NPs), as determined by the colorimetric assay.  
 
 
 
 
 
 
Figure 6.1. Dynamic Light Scattering (DLS) measurement of the size distribution of chitosan NPs 
re-suspended in HBSS (at pH 6.0). The result represents a mean of ten measurements, performed at 
25¡C. 
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6.3.2 Cell toxicity studies  
6.3.2.1 MTS assay 
The effect of chitosan NPs and chitosan solution on the relative metabolic activity of 
Calu-3 cells is shown in Figure 6.2. NP suspensions containing 0.0015% and 0.003% 
w/v chitosan, show no significant suppressive effect on Calu-3 metabolic activity, 
while NP suspensions containing chitosan concentrations greater than 0.006% w/v all 
exhibit significant reductions (>50%) in relative metabolic activity in a concentration-
dependent manner. It should be noted that chitosan solutions at two highest 
concentrations (0.0125% and 0.025% w/v) exhibit significantly higher suppressive 
effect than corresponding NP concentrations, while for the lower three concentrations 
(0.006%, 0.003% and 0.0015% w/v), although the reduction in metabolic activity 
appears higher for chitosan solution, this difference is not statistically significant. 
According to this study, one can assign 0.003% w/v as the highest chitosan 
concentration, for both solution and NPs, exhibiting no statistically significant 
suppression on metabolic activity, as determined by the MTS assay.  
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Figure 6.2. Effect of chitosan NPs ('NP') and chitosan solution ('Sol') on the metabolic activity of 
Calu-3 cells, measured by the MTS assay following a 2-hour incubation of the cells with chitosan 
samples. Results expressed as % metabolic aactivity relative to controls (HBSS and Triton X-100), 
calculated according to the method described in section 2.2.5.3 and presented as the mean ± SD 
(n=5). * denotes statistically different effect between chitosan solution and NPs.  
 
The recovery of cells following the application of chitosan NPs and solution was also 
tested (Figure 6.3) by conducting the MTS assay 13 hours following the exposure of 
cells to chitosan. Although the data variability is higher than in Figure 6.2, it can 
nevertheless be noticed that in this cell recovery experiment, chitosan NP suspensions 
were typically associated with higher cell metabolic activity, relative to chitosan 
solutions of the corresponding concentration. Namely, for chitosan NPs statistically 
higher relative metabolic activity was observed for 0.003 and 0.0015% w/v tested 
concentrations, compared to chitosan solution. 
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Figure 6.3. Long term effect of chitosan NPs and chitosan solution on the metabolic activity of 
Calu-3 cells, measured by the MTS assay 13 hours following the incubation of cells with chitosan 
samples. Results expressed as % relative metabolic activity calculated according to the method 
described in section 2.2.5.3 and presented as the mean ± SD (n=5). 
 
6.3.2.2 LDH assay 
Figure 6.4 shows the effect of chitosan NPs and chitosan solution on relative LDH 
release. The release of LDH from cells is generally considered as an indication of 
plasma membrane disruption. In essence, a concentration dependent LDH release 
(signifying membrane toxicity) was found for both chitosan NPs and chitosan solution 
(apart from the highest concentrations of chitosan solution). Application of NP 
suspension equivalent to chitosan concentration of 0.003% w/v, identified using the 
MTS assay as the highest concentration that did not affect cell metabolic activity, 
caused a 10% increase in LDH release, whereas chitosan solution of the same 
concentration showed an increase of 11%. Both these values are significantly different 
to the HBSS control, indicating some extent of membrane disruption, however there 
is no statistically significant difference between chitosan NPs and solution (p=0.33). 
Applying higher concentrations, the membrane toxicity gradually increased for both 
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systems, reaching approximately 37% and 45% of LDH release (relative to the 
positive control) with NPs (at 0.025% w/v) and solution (at 0.0125% w/v), 
respectively. At the higher concentrations of NPs and solution, namely 0.006% and 
0.0125% w/v, there was a statistically significant difference between NPs and 
solutions (p=0.043 and p=0.004 for 0.006% w/v and 0.0125% w/v, respectively), 
whereby at the same chitosan concentration solutions showed higher membrane 
toxicity.   
 
Figure 6.4. Effect of chitosan NPs and solution on LDH release following a 2-hour incubation of 
Calu-3 cells with chitosan samples. Results expressed as relative LDH release calculated using the 
equation shown in section 2.2.5.4 and presented as the mean ± SD (n=4). 
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6.3.3 Effect of chitosan NPs and solution on TEER 
6.3.3.1 Effect on Calu-3 layers 
The effect of chitosan NPs and chitosan solutions of two different concentrations 
(0.003% and 0.006% w/v) on the TEER of Calu-3 layers is presented in Figure 6.5 
(6.5a and 6.5b for chitosan NPs and chitosan solution, respectively). Both profiles 
exhibit a typical pattern of a steep decrease in TEER to less than 10% of the baseline 
value for all the samples applied. TEER remained low (in the region <10% of the 
baseline figure) for the duration of cell incubation with the samples (2 hours). The 
largest recorded decrease in TEER was, however, significantly (statistical 
significance) larger for chitosan solution than for the NPs. 
 
Reversibility of TEER following the removal of chitosan formulations from the cells 
was found to be concentration dependent, whereby the higher concentration of 
chitosan NPs and solution (0.006% w/v) was associated with an irreversible lowering 
of the TEER (Figure 6.5). Measured 20 hours after subjecting the cell layers to 
chitosan incubation, the TEER values were in the order of 10% and 5% of the 
baseline figure, respectively. TEER values for 0.003% w/v NP suspension showed a 
high level of recovery (to 92% of the baseline value) in the same time period (6.5a). 
Regarding chitosan solution, the concentration of 0.003% w/v again showed recovery, 
with TEER reaching 84% of the baseline value (6.5b). An interesting point to note is 
that the lower concentration (0.003% w/v chitosan) produced an initial TEER 
reduction similar in magnitude to that observed with the higher concentration (0.006% 
w/v) of both NPs and solution, which were associated with no recovery in TEER.  
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a) 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
Figure 6.5. Effect of chitosan NPs (a) and solution (b) on Calu-3 layer TEER. Chitosan NPs and 
chitosan solutions were used at concentrations 0.003% w/v and 0.006% w/v. Time 0 hrs represents 
baseline TEER (i.e. TEER in HBSS, prior to application of chitosan samples). Arrows indicate 
chitosan sample removal and replacement with culture medium. Results presented as the mean ± SD 
(n=3) 
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6.3.3.2 Effect on Caco-2 monolayers 
In order to determine whether the TEER-reducing effect of chitosan NPs was 
reproducible in a different cell line that also forms electrically tight polarised layers, 
this effect was tested on intestinal Caco-2 cells. Figure 6.6 shows that the application 
of chitosan NPs to Caco-2 monolayers was again associated with a decrease in TEER 
and that the extent of this reduction, similarly to Calu-3 cells, was large (to >80% of 
the baseline value). TEER recovery was again dependent upon the NP concentration. 
However, importantly, in Caco-2 cells a complete TEER recovery (tested 22 hours 
after a 2 hour incubation of cells with chitosan NPs) was observed with a 0.0125% 
w/v chitosan concentration of NPs. This is a four times higher concentration of 
material than the chitosan NP concentration exhibiting a reversible TEER reduction in 
Calu-3 cells. Furthermore, a partial TEER recovery was also evident with higher NP 
concentrations (to 64%, 53% and 29% of the baseline value with NP concentrations 
containing chitosan concentrations of 0.025%, 0.05% and 0.1% w/v, respectively). 
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Figure 6.6. Effect of chitosan NPs on Caco-2 monolayer TEER. Chitosan NPs were applied to cells 
at concentrations 0.1%, 0.05%, 0.025% and 0.0125% w/v. Time 0 hrs represents baseline TEER (i.e. 
TEER in HBSS, prior to application of chitosan NPs). Arrow indicates sample removal and 
replacement with culture medium. Results presented as the mean ± SD (n=3). 
 
6.3.4 Permeability experiments 
6.3.4.1 Effect of chitosan NPs and solution on FD permeability: Calu-3 cells 
The permeability study was conducted to compare suspension of chitosan NPs and a 
corresponding solution containing 0.003% w/v of chitosan. The selection was based 
on (i) the low toxicity of this chitosan concentration, as determined by the MTS 
assays, and (ii) the finding that this was the highest chitosan concentration that 
showed reversibility in TEER versus time profile, for both formulations. FD4 and 
FD10 were used as macromolecular tracers and the effect of chitosan NPs and 
solution of the equivalent concentration on their permeability was compared (Figure 
6.7). The data clearly demonstrate that chitosan NPs significantly enhance the 
permeability of both FD4 and FD10, relative to the control. The extent of this effect is 
apparently dependent on the MW of the FD; the permeability of FD4 was 7.6-fold 
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higher than the control, while there was a 6.5-fold increase in the permeability of 
FD10, as compared to the control. Chitosan solution appears more efficient in 
improving the permeability of both FD4 and FD10, with a 10.1-fold improvement in 
permeability across the cells observed for both FDs, relative to their respective 
controls. However the difference between chitosan NPs and solution for the effect on 
FD4 transport was found to be statistically insignificant (p=0.074), though the data 
obtained are highly variable. In contrast, the improvement in FD10 permeability 
achieved with chitosan solution is significantly (p=0.018) higher than for the NPs. 
The data therefore clearly show that in the presence of chitosan NPs, FDs (coexisting 
in the same solution and not incorporated within the NPs) exhibit paracellular 
translocation across the Calu-3 layers and that this translocation is dependent upon 
their molecular size. 
 
Figure 6.7. Effect of chitosan NPs and solution (0.003% w/v) on the permeability of FD4 and FD10 
across Calu-3 layers. Control represents FD4 and FD10 permeability (in HBSS) without the 
presence of chitosan NPs or chitosan solution. Permeability expressed as apparent permeability 
coefficient (Papp), calculated using the equation in section 2.2.4. Results presented as the mean ± SD 
(n=4).  
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6.3.4.2 FD4 permeability with chitosan NPs: Caco-2 cells 
Permeability-enhancing effect of chitosan NPs was also tested on Caco-2 monolayers 
for the purpose of corroboration. In presence of chitosan NPs at 0.0125% w/v, FD4 
was found to traverse the Caco-2 monolayers significantly more readily compared to 
control (FD4 applied in absence on chitosan NPs), with the calculated Papp values 
amounting to 3.72x10
-7
 cm/s in control monolayers and 26.2x10
-7
 cm/s when applied 
in combination with chitosan NP, producing a 7-fold improvement in FD4 
permeability. The data are shown in Figure 6.8. 
 
Figure 6.8. Effect of chitosan NP on FD4 permeability across Caco-2 monolayers. NP suspensions 
containing an equivalent of 0.0125% w/v chitosan were used. Control represents FD4 permeability 
(in HBSS) without the presence of chitosan NPs. Permeability expressed as apparent permeability 
coefficient (Papp), calculated using the equation in section 2.2.4. Results presented as the mean ±SD 
(n=3). 
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6.3.7 Effect of FITC-chitosan on TJ modulation  
Changes in measurable indications of TJ modulation, namely TEER and paracellular 
permeability, observed following the application of FITC-chitosan to confluent Calu-
3 layers are illustrated in Figure 6.9. The purpose of conducting these experiments 
was to determine whether chemical conjugation of FITC affected the TJ opening 
properties of chitosan. Application of FITC-chitosan to Calu-3 layers was associated 
with an immediate and drastic reduction in TEER, to levels <10% of the baseline 
value (6.9a). The decrease in TEER was fully reversible, with TEER value measured 
24 hrs following the application of FITC-chitosan to the cells reaching approximately 
99% of the baseline value. It must be noted that the TEER pattern seen with FITC-
chitosan was similar to that observed with unlabeled chitosan solution. This is 
especially the case when considering the extent of TEER reduction achieved. TEER 
recovery on the other hand was more apparent with the labelled chitosan. The 
similarity in effect extends to FD4 permeability (6.9b), with FITC-chitosan showing a 
similar level of FD4 permeability enhancement (11-fold compared to control) as 
unlabeled chitosan (10-fold).  
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a) 
 
 
 
 
 
 
 
 
b) 
 
Figure 6.9. Effect of FITC-chitosan on TJ modulation of Calu-3 layers. a) Changes in TEER 
following the application of 0.003% w/v FITC-chitosan, expressed as % of the baseline value; b) 
FD4 permeability in the presence of 0.003% w/v FITC-chitosan and in HBSS (pH 6.0; control). 
Results are expressed apparent permeability coefficient (Papp), calculated using the equation in 
section 2.2.4 and presented as the mean ± SD (n=3). 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
P
a
p
p
 (
x
1
0
­8
) 
c
m
/
s 
Control 
FITC‐chitosan 
0 
20 
40 
60 
80 
100 
120 
0  5  10  15  20  25 
T
E
E
R
 (
%
 o
f 
b
a
se
li
n
e
 v
a
lu
e
) 
Time (hours) 
Chapter 6                             Permeability Enhancement with Chitosan Solution and Nanoparticles 
 202 
6.3.8 Association of FITC-chitosan NPs with Calu-3 layers 
The association of FITC-chitosan NPs with a confluent Calu-3 layer, following 
incubation and extensive cell washing, is shown in Figure 6.10. Green fluorescence, 
arising from FITC-labelled chitosan NPs is distributed throughout the imaged area of 
the cell layer. In some regions the fluorescence is concentrated, forming larger 
aggregates, while in other regions, punctate fluorescence indicating nano-sized 
species (NPs), could be observed. In some regions (arrow) the fluorescence appears to 
follow the contour of cells on the apical surface. With respect to NP fluorescence 
distribution across the vertical axis of the cell layer, NPs were mainly observed on the 
apical side of the cells (marked A), with some NP fluorescence also observed deeper, 
within the level of the cell nuclei and closer to the basolateral surface of the cells 
(marked B). 
 
 
 
 
 
 
 
 
 
Figure 6.10. Association of FITC-chitosan NPs with filter-cultured Calu-3 cells. Green: FITC-
labelled NPs; and Blue: DAPI-labelled cell nuclei. Apical side of the cells is marked with A, whereas 
basolateral side is marked with B. 
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6.3.9 Effect of chitosan NPs and solution on ZO-1 distribution 
Structural changes at the level of the cellular TJs resulting from the application of 
chitosan as NPs and solution are shown in Figure 6.11. A continuous ring of 
fluorescence, arising from ZO-1 staining, at cell-cell contacts is clearly visible in the 
control cell layer (6.11a). Fluorescence at the point of contact between the cells can 
also be seen in the cell layer incubated with chitosan NPs (6.11b) and solution 
(6.11c). However, in comparison to the control cell layer, a considerable loss in 
continued fluorescence is clearly apparent, with observation of discontinuous 
pericellular rings of fluorescence for both, chitosan NPs and chitosan solution.  
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  a)             b)       c) 
  
Figure 6.11. Effect of chitosan NPs and solution on distribution of ZO-1 TJ protein in Calu-3 layers. a) ZO-1 staining in a control layer not subjected to chitosan 
incubation (white line represents a scale bar of 10 µm), b) ZO-1 staining in cells incubated with NPs of 0.003% w/v chitosan (white line represents a scale bar of 10 µm), 
and c) ZO-1 distribution in a cell layer incubated with chitosan solution of 0.003% w/v. ZO-1 immunostaining was performed in the same way (see section 2.2.6.6) for all 
conditions. 
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6.3.10 Association of FITC-chitosan with Calu-3 and Caco-2 layers 
Figure 6.12 shows the association of FITC-chitosan with Calu-3 layers cultured using 
AIC and LCC conditions and Caco-2 monolayers. In Calu-3 cells grown using AIC 
(6.12a), green fluorescence was in some regions observed as continuous 'rings' around 
individual cells. Areas of intense green fluorescence were also observed. Green 
fluorescence surrounding individual cells were also apparent in Calu-3 cells cultured 
using LCC (6.12b). However, in contrast to AIC conditions, areas of bright 
fluorescence were not observed in Calu-3 cells grown using LCC. FITC-chitosan 
fluorescence was distributed around the cells in the Caco-2 monolayer (6.12c) 
although this pattern of fluorescence distribution was somewhat less apparent than in 
Calu-3 cells (cultured using both AIC and LCC conditions).  
 
Chapter 6                             Permeability Enhancement with Chitosan Solution and Nanoparticles 
 206
a) AIC Calu-3 cells 
   i)           ii)            iii) 
 
 
 
 
 
 
 
b) LCC Calu-3 cells  
   i)          ii)             iii) 
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c) Caco-2 cells 
  i)           ii)            iii) 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12. Association of FITC-chitosan with confluent Calu-3 and Caco-2 layers. a) Calu-3 cells cultured using AIC conditions, b) Calu-3 cells grown using LCC, and 
c) Caco-2 cells. FITC-chitosan was applied to confluent cell layers at 0.003% w/v and incubated with the cells for 2 hours. i) Blue channel: Cell nuclei stained with 
DAPI, ii) Green channel: FITC-chitosan, and iii) Overlay images.  
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6.3.11 Effect of chitosan on the permeability of investigational antibodies 
Table 6.1 shows the effect of chitosan on the permeability of four investigational 
antibodies (property of UCB). It is important to note that the HPLC method used to 
quantify the antibodies suffered from limited detection sensitivity. Consequently, any 
low basolateral levels of antibodies could not be detected. In control cell layers where 
the transport of antibodies was tested in the absence of chitosan, none of the applied 
proteins (an antibody and three Fabs) were detected (marked by 'ND' in Table 6.1) in 
the basolateral solution, i.e. if any antibody translocation occurred, it was below the 
detection limit. (The detection limits for the antibodies were 1.95 µg/ml for hCTM01 
antibody, 2.3 µg/ml for hCTM01 Fab, 1.7 µg/ml for mA33γ1 Fab and 15 µg/ml for 
A33γ1 Fab-diPEG.) On the other hand, application of the antibodies to the cell layers 
in combination with chitosan led to the detection of hCTM01 Fab (0.26% of the 
applied amount) and mA33γ1 Fab (0.49% of the applied amount) in the basolateral 
solution, while the whole antibody (hCTM01γ4), and the PEGylated antibody 
fragment (A33γ1 Fab-diPEG) were not detected after the incubation period with the 
cell layers. 
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Permeability (% of apical) 
Name Type MW 
Control Chitosan 
hCTM01 antibody 
Whole 
Antibody 
147033 ND ND 
hCTM01 Fab Fab 95815 ND 0.26±0.167 
mA33γ1 Fab Fab 24725 ND 0.49±0.022 
mA33γ1 Fab-
diPEG 
PEGylated Fab 64725 ND ND 
 
Table 6.1. Effect of chitosan solution (0.003% w/v) on the permeability of therapeutic antibodies and 
antibody fragments. Types of antibodies (i.e. whole antibody or fragment) and their MW is also given. 
Permeability is expressed as % relative to the applied amount. 'ND' means none detected. Data 
presented as the mean ± SD (n=3).  
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6.4 Discussion 
The mucoadhesive and TJ opening functionalities of chitosan have especially been 
exploited in formulation of nasal macromolecular therapeutics, including peptides and 
proteins (18). In addition to the well-documented TJ opening and mucoadhesive 
properties of chitosan solutions (8, 9), it has been suggested that chitosan NPs, and 
NPs of other materials, may improve mucosal absorption by traversing the epithelial 
barriers. The concept of using nano-sized carriers to transport drugs across the 
epithelial layers, however remains controversial (10). The in vivo transport of 150-200 
nm polylethylene glycol coated polylactide/glycolide NPs in the absence of any 
permeability enhancer was suggested by Vila et al. (12), although no evidence was 
shown of in vitro NP translocation, or indeed of a systemic effect of insulin in vivo, 
from insulin-chitosan complex NPs following nasal administration (19). It has also 
been suggested that a paracellular transport of NPs larger than 20 nm is not feasible 
due to a maximal widening of the intercellular spaces of about 15 nm (20). The 
efficacy of mucosal absorption of macromolecules using chitosan NPs as a carrier 
system has in general been shown to be inferior compared to that obtained with 
chitosan solution or chitosan powder formulations (6, 10). While a limited number of 
studies have reported opening of TJs by chitosan NPs, a large proportion of 
investigations, as will be discussed later, have shown no such effects. 
 
The present work provides a comparison between the effect of chitosan NPs and 
solution on TJ opening, whereby the paracellular translocation of model therapeutic 
macromolecules across the mucosal surfaces is investigated. In this study the 
hydrophilic FDs (FD4 and FD10), serving as models for therapeutic 
biomacromolecules, were not incorporated within the interior of the chitosan NPs, but 
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applied to cells in conjunction with the chitosan solution and the NP suspension. This 
work therefore mimics a possible situation where the therapeutic macromolecule is 
released from, and resides at the mucosal surface alongside the NPs. FDs (FD4 and 
FD10) are transported across a cell layer predominantly via the paracellular route, but 
due to their large size the extent of this transport is limited. However their paracellular 
transport would be improved if the chitosan formulations exhibited a TJ-opening 
effect. The present experimental design eliminated the need to consider a contribution 
of possible transcellular transport of chitosan NPs on the overall translocation of 
macromolecules across the epithelial cell layer. Even if transcellular transport of 
chitosan NPs did occur, this would not contribute to the apical-to-basolateral 
translocation of the FDs. 
 
Chitosan NPs were in this work prepared by the ionic gelation method, under 
relatively mild preparation conditions, which would enable incorporation of different 
therapeutic molecules (including labile protein macromolecules) within the interior of 
the NPs. Previous studies have incorporated several biomolecules, in addition to 
peptides and proteins, including tetanus toxoid (21) and siRNA (22) into similarly 
fabricated NPs. The concentrations of chitosan and TPP established as optimal for the 
production of NPs in this experiment are comparable to those reported previously 
(23), with the final chitosan and TPP concentrations in the order of 1Ð3 mg/ml and 
0.2Ð1.0 mg/ml, respectively. The optimal chitosan:TPP ratio on a weight-to-weight 
basis in this study was found to be 4.0, which is again comparable to the above 
studies. The zeta potential of the chitosan NPs was, as expected, positive, under 
experimental conditions used in the measurements, which is believed to be important 
for maintaining the mucoadhesive and TJ-opening properties of chitosan (24). It 
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should be noted that the preparation of chitosan NPs was based on the interaction 
between positively charged chitosan groups and the negatively charged TPP, where a 
balanced ratio of the two compounds is needed to ensure both sufficient cross-linking 
and also NP charge stabilization and surface presence of excess charge. It was ensured 
by centrifuging and repeated washing of the NPs that no free chitosan was present in 
the NP formulations, which could have biased the results. In previous studies by other 
research groups it has often not been clear whether free chitosan was present in the 
formulations and hence these studies are not directly comparable with this work. 
 
Systematic studies on cell toxicity (using two different cell toxicity assays, MTS and 
LDH, and in addition assessment of cell layer integrity through measurement of 
TEER) were conducted in this work to compare the effects of chitosan NPs with 
corresponding concentrations of chitosan solutions. From these studies the 
concentration of chitosan (in nanoparticulate and solution form) with minimal toxic 
effects and a reversible decrease in cell layer TEER was chosen. Performing such a 
selection was considered necessary in order to ensure that the observed effects on 
TEER and permeability were due to TJ opening and a resulting increased access to the 
paracellular route, and not because of cell toxicity and compromised cell layer 
integrity.  
 
MTS and LDH assays are two commonly used methods of determining cell toxicity. 
A reduction in metabolic activity is an early indication of cellular damage (25). On 
the other hand, the LDH assay indicates plasma membrane damage (26). Changes in 
metabolic activity are superior indicators of early cell injury, whereas membrane 
effects indicate more serious damage, leading to cell death (27). In this work, both 
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MTS and LDH assays were used to test two different indicators of cell toxicity and 
also for corroboration.  
 
It is interesting to note that the effect of chitosan solution and NPs towards the 
metabolic activity of Calu-3 cells was similar (Figure 6.2), despite the fact that 
chitosan is presented to the cells in different forms. The reasons behind observation of 
this phenomenon are, at the present point, unclear. A similar finding was described 
with application of chitosan solution and chitosan NPs produced by the same method 
as in our study (ionotropic gelation) to pulmonary epithelial A549 cells, as revealed 
by the MTT reduction assay (28). On the other hand, Silva et al. (29) observed a 
remarkable decrease in LDH release when chitosan was used as NP coating instead of 
a solution. 
 
The data on the membrane-disruptive effects of chitosan NPs, as determined by the 
LDH assay, indicates that even at chitosan concentration of as low as 0.003% w/v, 
chitosan NPs exhibit some degree of membrane disruption. A similar effect is 
observed with chitosan solution of an equivalent concentration. Although there are a 
large number of reported studies on the permeability-promoting effect of chitosan, 
very few of these studies incorporated the LDH membrane toxicity test. In the above-
mentioned study by Silva et al. (29) it was found that the application of chitosan 
solutions (MW 150 kDa and degree of deacetylation near 85%) to Caco-2 cells was 
associated with dose-dependent and significant membrane toxicity. The 
concentrations of chitosan used in these studies were 0.1%, 0.25% and 0.5% w/v. In 
another study, a 30 min exposure of Caco-2 monolayers with chitosan hydrochloride, 
used at concentrations 0.005%, 0.01% and 0.5% w/v, resulted in a slight increase in 
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extracellular LDH activity. However, when cells were allowed to recover for 8 hours 
or 24 hours following the incubation with 0.005 or 0.01% w/v concentrations of 
chitosan, the LDH activity at these time points was similar to control, suggesting cell 
membrane recovery (30). Schipper et al. (31) found a dose-dependent effect on 
intracellular dehydrogenase release from Caco-2 cells when exposed to chitosans 
having a low degree of acetylation (<35%). 
 
It should be noted that the concentrations of chitosan, either in solution or NP form, 
used in this study (0.003 and 0.006% w/v) were significantly lower than those 
typically reported in the literature. Reports on the toxicity of chitosan on Calu-3 cells 
are sparse, despite chitosan being studied extensively as a mucoadhesive and 
absorption-enhancing agent. It has been reported that application of chitosan solution 
at a concentration of 1.5% (w/v) reduced the metabolic activity of Calu-3 cells to 
around 68% compared to control (32). Chitosan NPs prepared by a similar ionic 
gelation method, as used in the present study, were shown to induce a reduction in the 
viability of A549 cells (human alveolar epithelial carcinoma) to approximately 70% at 
a concentration of around 1 mg/ml (0.1% w/v) (28). The same authors also reported 
that chitosan, delivered as microparticles, induced pro-inflammatory responses in rat 
lungs (33). However, other studies have reported low toxicity of chitosan solution and 
NPs in respiratory cell lines (3, 9). In a recent publication, the authors noted that 
chitosan/cyclodextrin ('hybrid') NPs exhibited a significantly lower cytotoxicity than 
those based on chitosan only (34), whereby the IC50 values (NP dose causing a 50% 
reduction in cell viability) were 3-fold higher for chitosan/cyclodextrin-containing 
NPs compared to the chitosan-only NPs. However, it should be emphasized that direct 
comparisons between these studies, and also with the present work, are problematic 
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due to the variabilities in the experimental parameters, including the use of different 
cytotoxicity assays, cell lines, different conditions employed, different chitosan forms, 
molecular weights and suppliers, and finally, differences in chitosan formulations.   
 
Polycations are generally considered to be cytotoxic (35). Kissel et al. (26) studied the 
toxicity of TMC and they propose that, its cytotoxic effects arise from an interaction 
with anionic components (sialic acid) of the glycoproteins on the surface of epithelial 
cells, which is also applicable to most cationic macromolecules such as protamine and 
polylysine. The authors found a MW effect on toxicity, with an increase in cytotoxicity 
as a function of MW.  
 
Regarding the discrepancies in the tolerability of chitosan between different cell lines, 
the present work clearly demonstrates a significant difference in two cell lines, Caco-
2 and Calu-3. Reversibility in TEER (indicating cell layer recovery) was seen in 
Caco-2 cells following NP application containing significantly higher concentrations 
of chitosan (0.0125% w/v) compared to that used in Calu-3 cells (0.003% w/v). This 
indicates a cell specific toxicity and emphasizes the importance of using a relevant 
cell culture model.  
 
The TEER data in this study demonstrates that chitosan in nanoparticulate form, as 
per production method described, maintains its intrinsic capacity to open the cellular 
TJs. Application of chitosan NPs or chitosan solution to Calu-3 layers was shown to 
be associated with a dramatic decrease in TEER for both NPs and solution, whereby 
the effect of NP formulation is comparable, although somewhat reduced, to chitosan 
solution of a corresponding concentration. Our results are in discrepancy with a study 
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by Ma and Lim (14) where soluble chitosan was more effective at disrupting the 
intercellular TJ than chitosan NPs. This was explained by the possibility of a less 
effective interaction of chitosan NPs with the cellular proteins because of their TPP-
crosslinked chains (14). Furthermore, in a recent publication investigating the effect 
of chitosan-TPP NPs incorporated into mannitol microspheres on TJ modulation of 
Calu-3 layers, the authors did not observe any effects (on TEER and permeability) for 
the maximum NP concentration tested (1.3 mg/ml of NPs in the formulation, 
corresponding to chitosan amount of 150 µg) (3). Discrepancy in the capacity to 
induce TJ opening between chitosan solution and NPs has also been explained by a 
restriction in the movement of the chitosan chains in the nanoparticulate form, 
hindering the contact of these chains with the plasma membranes and TJs (36).  
 
Another recent study on the effect of chitosan solution and NP formulations on TEER 
of Caco-2 monolayers showed that, in comparison to the free-soluble polymers, NPs 
based on chitosan and its quaternized derivatives (prepared by the ionic gelation 
method as used in this study), had a much lower effect on decreasing the TEER (15). 
The authors explained the finding by the reduced available amount of positive charge 
(charge density) at the surface of the NPs, compared to the soluble form of chitosan. 
 
In the present study an equivalent amount of chitosan in the nanoparticulate form 
(devoid of free chitosan) to that in the solution form was applied and therefore the 
argument that there would be a reduced exposure of positive charge in the NPs in 
comparison to the solution would stand. The TJ modulating effects of chitosan were 
shown to be mediated by its cationic charges in a study by Schipper et al. (24), where 
the authors demonstrate an inhibition of permeation-enhancing effect of chitosan by 
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addition of the highly negatively charged heparin. The same group also showed that 
chitosans with a lower degree of deacetylation, and therefore with less free positively 
charged amino groups, had a lower absorption promoting effect (31).  
 
The present study uses mucus producing Calu-3 cell layers. The presence of mucus 
would be expected to promote association of chitosan NPs, as well as chitosan from 
solution, with the cells. Behrens et al. (11) demonstrated a strong association of 
chitosan NPs (prepared by the same method as in the present study) with mucus-
secreting MTX-E12 cells (58%), an effect that was less apparent with non-mucus 
producing Caco-2 cells (7.8%). Their study further showed that the largest fraction of 
NPs was bound to mucus and that removal of the mucus layer prior to incubation of 
cells with NPs led to a 14% decrease of NP association with the cells.  
 
The strong mucoadhesive properties of chitosan coated-poly(isobutylcyanoacrylate) 
NPs have also been suggested by Bravo-Osuna et al. (37). However, in this study, the 
authors argue that the mucoadhesive properties of chitosan-coated NPs lead to their 
immobilization in the mucus layer, and in doing so, hamper their diffusion within the 
layer, reaching the vicinity of the TJ proteins, which the authors consider to be a 
prerequisite for a TJ-modulating effect. This theory was provided as an explanation 
for their finding that chitosan-coated NPs were ineffective in opening of the TJs and 
improving the paracellular permeability. 
 
The ability of chitosan-coated nanoparticles to open the TJs has previously been 
attributed to their calcium biding property (37). In fact, poly(isobutyl cyanoacrylate) 
core-shell NPs coated with chitosan were shown to possess a higher capacity to bind 
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calcium than the solution, which the authors explained by an improvement in the 
accessibility of binding sites of chitosan on the NP surface (38). This results in a 
higher calcium-depleting capacity of NPs compared to solution. However, despite the 
widely-acknowledged role of calcium in maintaining the TJ integrity and therefore the 
barrier property of the epithelium (39, 40), previous work (see Chapter 5) showed that 
a reduction of apical calcium levels in Calu-3 and Caco-2 layers led to a limited effect 
on TJ opening with a reversible TEER decrease and a modest increase in FD4 
permeability (41). 
 
In our study, confocal imaging of filter-cultured Calu-3 cells incubated with NPs 
formulated with FITC-labelled chitosan showed NP distribution throughout the 
viewed area of the cell layer. The widespread observation of chitosan NPs on the 
apical side of the cell layer, even after extensive washing of the cells, indicates a 
strong association of the NPs with the cell layer possibly arising due to mucoadhesion 
and/or bioadhesion, which is in agreement with the above study. However, in our 
study, chitosan NPs appear to reach the apical cell membrane level, with some 
evidence of NP uptake, as judged from observations of vertical (Z-sections) 
distribution of fluorescence in Figure 6.10. This suggests a close proximity of the NPs 
to the apical cell membrane and cellular TJs, enabling an interaction of chitosan with 
the TJ proteins and the resulting TJ opening effect, which was clearly demonstrated in 
this work. 
 
Determination of structural changes in cellular TJs following the incubation of the 
cells with chitosan formulations (NPs and solution) revealed that chitosan NPs 
produced a change in the distribution of ZO-1 protein that was similar to that 
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observed with chitosan solution, if not greater (Figure 6.11). Importantly, this 
experiment showed that the TEER-reducing and permeability-enhancing effects of 
chitosan NPs do indeed result from an effect on TJs and, to the best of our knowledge, 
no previous studies in the literature had reported such structural changes in TJs with 
chitosan NPs. 
 
Owing to the bioadhesive nature of chitosan NPs, which is demonstrated in this work, 
any TJ-opening effect that the NPs may have is therefore likely to be relatively 
sustainable. Provided that the therapeutic molecule is present in the vicinity (for 
example released from the drug-incorporated NPs), the mucoadhesive and TJ-opening 
effect of chitosan NPs would be expected to result in an improvement of its 
permeability across the mucosal surface.  
 
Experiments evaluating the apical-to-basolateral translocation of FDs across the Calu-
3 layers showed that chitosan NPs, devoid of free chitosan, significantly enhanced 
their permeability. In the case of the smaller penetrant macromolecule, FD4, the 
increase in permeability seen with chitosan NPs was similar to that observed with 
chitosan solution of corresponding concentration. For FD10, a significantly higher 
apparent permeability was seen with chitosan solution compared to NPs. Factors 
accounting for this observation are not clearly apparent at the present moment, 
especially considering that chitosan NPs produced clearly obvious changes in ZO-1 
(TJ protein) distribution similar to, or more pronounced than chitosan solution (Figure 
6.11).  
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Work described in this chapter therefore clearly demonstrates that chitosan NPs, 
devoid of free chitosan, reversibly open the TJs and enhance macromolecular 
permeability across the Calu-3 layers, without inducing irreversible toxicity to the 
cells at the optimized concentration used. Furthermore, the data shows that chitosan 
NPs have a permeability-increasing effect similar to chitosan solution for a 4 kDa 
macromolecular solute and somewhat inferior effect for a 10 kDa macromolecule. 
Although the work shows there is no improvement in permeability-enhancement of 
chitosan NPs compared to chitosan solution, it may be still advantageous to deliver 
proteins therapeutics through the mucosal surfaces by incorporating them within the 
NPs with the aim to provide protection from enzymatic degradation, prolong the 
presence time at the mucosa and achieve a controlled drug release.   
 
Mucoadhesive chitosan would be expected to associate with mucus, which is present 
on Calu-3 layers. In fact, based on the data obtained by confocal imaging of Calu-3 
and Caco-2 layers following their incubation with FITC-labeled chitosan, there is 
evidence of occurrence of this phenomenon. Fluorescence was clearly apparent in all 
cell layers incubated with FITC-chitosan, even after an extensive washing step 
following the exposure of the cells with fluorescent chitosan. However, larger and 
brighter areas of fluorescence, indicating a greater content of fluorescent material, 
was seen in Calu-3 cells cultured under conditions that facilitate mucus production 
(AIC) (42) compared to Calu-3 cells cultured using LCC and Caco-2 cells (Figure 
6.12). It is possible that the presence of mucus in Calu-3 cell layers cultured using 
AIC leads to a greater retainment of chitosan on the apical surface of the cell layer. 
Note that to demonstrate that chemical conjugation of FITC to chitosan does not alter 
the effects of chitosan on cellular TJs, it was shown that application of FITC-chitosan 
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to Calu-3 layers leads to a reversible decrease in TEER and an increase in FD4 
permeability across the cells (Figure 6.9); these effects were very similar to those 
encountered with unlabeled chitosan.  
 
Considering its well-established permeation-enhancing effect, which was also 
demonstrated in our work, chitosan (as solution) was evaluated whether it improves 
the transport of very large MW proteins (antibodies) across the Calu-3 layers. More 
specifically, the tested biomolecules (supplied by UCB) consisted of investigational 
therapeutic antibodies or antibody fragments (one of which was PEGylated). 
Although the technique used to quantify the antibodies suffered from a poor 
sensitivity, two out of four tested antibodies were detected in the basolateral solution, 
suggesting their translocation across the cell layers. These included the antibody 
fragments (Fabs) hCTMO1 and mA33γ1 Fab. In the case of the latter molecule 
(mA33γ1 Fab), its detection is not surprising considering its MW of approximately 25 
kDa (lowest MW out of the tested molecules). A lower level of transport across the 
cell layers was observed with the higher molar mass hCTMO1γ4 (approximately 96 
kDa), suggesting a MW effect, which was also seen with FDs. It is apparent from 
section 6.3.11 that the permeability of antibodies/fragments was expressed as % 
amount relative to the apically-applied amount; this is because the apparent 
permeability coefficient (Papp) values could not be calculated due to the lack of 
sufficient detection points of the materials over time (the tested compounds were not 
detected in the basolateral solution in the first 2 hours of the sampling period). 
Furthermore, it was not possible to calculate the permeability enhancement ratios as 
antibody permeability values in the control experiment could not be established. 
Nevertheless, the findings suggest that chitosan facilitated the translocation of two 
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antibody fragments across the Calu-3 layers, with the extent of this translocation 
depending on the MW of the tested molecule.  
 
6.5 Conclusion 
This work demonstrated that chitosan NPs, formulated using an ionic gelation 
method, exhibited similar effects on cellular toxicity and TJs to chitosan solution, as 
tested on Calu-3 layers. When applied at a concentration associated with limited 
toxicity, chitosan NPs reversibly opened the cellular TJs, as demonstrated by a sharp 
and reversible decrease in cell layer TEER and an increase in the permeability of two 
FDs. Chitosan NPs displayed TJ opening effects of an almost similar magnitude to 
chitosan solution. Furthermore, the similarity in TJ effect between NPs and chitosan 
solution was demonstrated through the changes that the two formulations of chitosan 
produced in the distribution of ZO-1 TJ protein. The mucoadhesive nature of chitosan 
solution and NPs was evident through imaging of mucus producing cell layers 
incubated with FITC-labelled chitosan (NPs or solution). The permeability enhancing 
property of chitosan (solution) was confirmed when testing its effect on the 
translocation of investigational antibody fragments across the Calu-3 layers, with 
evidence that the improvement in permeability is dependent on the MW of the tested 
solute. While there was no improvement in the permeability with chitosan NPs 
compared to solution, the former provide the potential for drug incorporation with the 
possibility of providing controlled drug release and protection from enzymatic 
degradation. 
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Chapter 7 
The potential of IgG transcytosis pathway for 
mucosal protein and nanoparticle delivery  
 
7.1 Introduction 
While it is potentially feasible to achieve mucosal absorption of smaller peptides and 
proteins by inducing transient opening of the epithelial tight junctions (TJs), this 
strategy is inefficient for larger protein therapeutics such as antibodies (MW 
approximately 150 kDa) (1), or delivery systems based on nano-sized carriers larger 
than 20 nm (2). It is also important to remember that the surface area defined by the 
TJs (i.e. the paracellular route), represents only a small proportion of the overall 
surface area of the epithelia that is potentially accessible to the mucosally-
administered drug (3). Indeed, in the gut this amounts to around 1% of the overall 
area (4). Transcytosis would potentially overcome this problem. Furthermore, unlike 
paracellular transport, receptor-mediated transcytosis is specific (5) to molecules 
(ligands) that are able to recognize and bind to receptors involved in the process, 
making this pathway selective to ligands or ligand-coupled therapeutic molecules or 
carrier systems. Therefore receptor-mediated transcytosis is potentially an attractive 
route for mucosal absorption of protein therapeutics. 
 
IgG has long been known to be actively transferred from mother to offspring, 
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confering short-term passive immunity (6, 7). Its transport is carried out by the 
neonatal Fc receptor (FcRn) (8, 9). The FcRn is a potential candidate for mucosal 
delivery of therapeutic proteins, because it is expressed in several organs and tissues, 
including the placenta (10), lung (11), kidney (12) and intestine (13) in which it is 
involved in IgG transport. Exression of FcRn in epithelia is thought to play an 
important role in the function of IgG in immune surveillance and host defense at 
mucosal surfaces (14). 
 
FcRn-mediated transport pathway across the lung epithelium may potentially be a 
useful route to deliver biological agents. Recent studies attempting to achieve 
pulmonary delivery of erythropoietin and follicle-stimulating hormone (FSH) in non-
human primates through this route proved promising (15, 16). These studies indicated 
that delivery of Fc-fusion proteins (therapeutic proteins conjugated to the Fc domain 
of IgG) to the upper airway results in an Fc-dependent, saturable uptake of these 
proteins into the systemic circulation (15-19). Furthermore, alveolar epithelial cells 
have also been shown to transcytose IgG in vitro (20). Therefore, considering that the 
surface area of the alveolar epithelium is much larger compared to the upper airway 
epithelium, the alveolar surface may contribute considerably to the amount of IgG 
absorbed through the pulmonary route (21).  
 
IgG is taken into epithelial cells from the external milieu by pinocytosis through 
formation of coated vesicles by invagination of the plasma membrane (22-24). Some 
binding of IgG to FcRn may occur at the plasma membrane (25), though it is more 
likely that binding predominantly takes place intracellularly as there is evidence that 
the majority of FcRn appears to be localized within acidic endosomal vesicles within 
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the cell, with little FcRn being detectable at the cell surface (26). Rather than fusing 
with the degradative lysosomes, the vesicles containing IgG bound to FcRn pass 
through the epithelial cell in the apical to basolateral direction, eventually releasing 
intact IgG to the interstitial space. This process is predominantly unidirectional in a 
physiological setting, being driven by a strong pH dependence of the binding of IgG 
to FcRn (as will be discussed below), and the pH gradient between the luminal and 
serosal sides of the epithelial cells.  
 
The Fc portion of IgG binds with high affinity to FcRn, with a 1:2 stoichiometry (21, 
27), at an acidic environment of the endosome (pH<6.5) (21), but not at a 
physiological pH (7.4) (8, 28, 29). The strict pH dependence of the FcRnÐFc 
interaction is mediated by the titration of histidine residues in the CH2ÐCH3 hinge 
region of IgG and their subsequent interaction with acidic residues on the surface of 
FcRn (21). The neutral (to slightly alkaline) pH found in the interstitial space enables 
the release of IgG from FcRn after fusion of the IgG-containing transport vesicles 
with the plasma membrane at the basolateral side of epithelial cells (18). Passage of 
IgG into the circulation is likely to occur largely through the paracellular route 
because of the absence of TJs between endothelial cells (30). 
 
Work described in this chapter investigated the transport of IgG across Calu-3 layers. 
Furthermore, this work assessed the potential of the IgG/FcRn transcytotic pathway 
for cellular uptake and transcellular transport of nanoparticles (NPs), which to the best 
of our knowledge has not been attempted previously. The use of Calu-3 cells for the 
purpose of this work was possible as this cell line has been shown to express FcRn 
(11). Initial work examined FcRn expression in Calu-3 cells (to confirm previous 
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reported findings), followed by characterisation of IgG transport across the cell layers. 
Uptake and transport of model NPs across the cell layers was then investigated by 
adsorbing IgG, or Fc portion of IgG, onto the surface of NPs. Certain studies were 
repeated in Caco-2 monolayers for the purpose of comparison. 
 
7.2 Methods 
7.2.1 Immunostaining for FcRn 
Filter-cultured Calu-3 cells in the form of polarised layers were fixed in 
parafomaldehyde, washed with PBS and permeabilized by incubating with Triton X-
100 (0.1% v/v in PBS) for approximately 10 min. Cells were washed again with PBS 
and incubated for 1 hour with BSA in PBS (1% w/v). Goat, anti-human FcRn primary 
antibody was diluted to 10 µg/ml in 1% BSA/PBS and incubated with the cells for 30-
60 min at room temperature. Cells were then washed extensively with PBS (5x) and 
treated with donkey, anti-goat TRITC-IgG (secondary antibody, diluted according to 
supplier's instructions in 1% BSA/PBS) for 30-60 min. Thereafter, cells were washed 
extensively with PBS and filters excised and mounted on a glass slide (using the 
DAPI-containing ProLong¨ Gold antifade mounting medium) for confocal imaging, 
which was performed using the confocal system described in section 2.2.6.3.  
 
Calu-3 cells cultured on filters under LCC conditions and Caco-2 cell monolayers 
were also immunostained for FcRn (and thereafter imaged using CLSM). This was 
conducted in the same manner as above. 
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7.2.2 Association of FITC-IgG with cell layers  
7.2.2.1 Effect of pH on FITC-IgG association with cells 
Calu-3 cells, as confluent layers, were serum starved by incubating with HBSS for 1 
hour. To ensure maximal removal of the residual bovine IgG (bIgG, present in FBS, 
used to supplement the culture medium), HBSS was replaced (in both, apical and 
basolateral compartment) twice during the serum-starving period (at 15 min and 30 
min). FITC-IgG (human, 5 µg/ml) was applied to the apical side at pH 6.0 or 7.4 (in 
MES- or HEPES-buffered HBSS, respectively). Following a 3-hour incubation of the 
cells with FITC-IgG, 100 µl volumes were removed from the apical side of the cell 
layers and transferred to a black 96-well plate for fluorescence measurements. FITC-
IgG was quantified by fluorescence (485 nm excitation, 535 nm emission; using an 
MFX microtiter plate fluorometer from Dynex Technologies, USA) through pre-
constructed calibration curves. Note that to account for pH sensitivity of FITC, in 
cases where FITC-IgG was applied at pH 6.0, the calibration curves were constructed 
by serially diluting FITC-IgG in HBSS at pH 6.0. 
 
7.2.2.2 Association of FITC-IgG with cells: competition with unlabelled IgG  
A solution of human FITC-IgG (5 µg/ml) and human IgG (referred to as 'IgG' in this 
thesis, 20 µg/ml) in HBSS (pH 6.0) was added to confluent cell layers and cells 
incubated for 3 hours. Apical solutions were then sampled (by removing 100 µl 
volumes) and transferred into a black 96-well plate. FITC-IgG was quantified by 
fluorescence in the manner described in the preceding section. 
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7.2.2.3 Cell uptake of FITC-IgG: effect of pH and competition with unlabelled IgG  
Cell uptake of FITC-IgG was assessed on the same confluent Calu-3 layers used in 
the preceding two experiments (section 7.2.3.2 and 7.2.3.3). As described above, cell 
layers were incubated with FITC-IgG (5 µg/ml) at pH 6.0 or pH 7.4 for 3 hours. 
Additionally, some cell layers were incubated with a solution containing a 
combination of FITC-IgG (5 µg/ml) and unlabelled IgG (20 µg/ml), at pH 6.0. After 
sampling of the apical solution for the purpose of FITC-IgG quantitation in 
experiments detailed in the preceding two sections, the apical solution was aspirated 
and cells washed with PBS extensively (5x). Cells were then permeabilised with 
Triton X-100 (0.1% v/v), which also produced cell detachment from the filters. Cells 
were collected from the filters, transferred into microcentrifuge tubes and centrifuged 
(13,000 rpm) to form cell pellets. The supernatants were transferred into a black 96-
well plate following which FITC-IgG was quantified by fluorescence as before (see 
section 7.2.2.1). Note that the calibration curve used to quantify FITC-IgG was in this 
instance constructed by measuring the fluorescence of known concentrations of FITC-
IgG progressively diluted in a solution of Triton X-100, 0.1% v/v in HBSS. 
 
7.2.3 IgG transport experiments  
7.2.3.1 IgG transport across Calu-3 layers 
Culture medium was removed from confluent cell layers and cells washed with PBS. 
Cells were then serum starved by incubating with HBSS (pH 6.0 and 7.4 on the apical 
and basolateral side, respectively) for 1 hour prior to the transport experiments. In an 
attempt to remove the residual bIgG present in FBS, HBSS was replaced twice during 
the serum-starving period as described in section 7.2.2.1. 1 µg/ml of IgG (human) was 
applied on the apical side of the cells and IgG transport across the cell layers was 
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measured for the duration of two hours by regular sampling of the basolateral solution 
(with replacement of the sampled volumes). HBSS (pH 6.0 and pH 7.4, on the apical 
and basolateral side, respectively) was used as the transport medium. IgG was 
quantified by ELISA, in the manner detailed in section 2.2.7.1. 
 
7.2.3.2 Transport saturation  
IgG was applied to the apical side of serum-starved Calu-3 layers at the following 
concentrations: 50 ng/ml, 500 ng/ml and 5 µg/ml (in HBSS, pH 6.0). Its apical-to-
basolateral translocation was determined by quantifying IgG present in the basolateral 
medium (HBSS) at different time intervals (every 30 min). However, in contrast to 
the experiment above, transport was assessed over 3 hours and the basolateral solution 
was completely exchanged at each sampling interval. IgG was quantified by ELISA, 
as described in section 2.2.7.1. 
 
7.2.3.3 Receptor competition  
IgG (1 µg/ml) was added to the apical side of confluent (serum-starved) Calu-3 layers 
in conjunction with rabbit IgG (rIgG, 50 µg/ml), both in HBSS at pH 6.0. The 
basolateral medium (HBSS) was then sampled regularly (every 30 min) over 2 hours 
(with replacement of the sampled volumes). (Human) IgG specific ELISA was then 
conducted on the sampled solutions, as described in section 2.2.7.1.  
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7.2.3.4 IgG transport across Caco-2 monolayers 
Caco-2 cells were cultured on filters for 21-23 days as per protocol detailed before 
(section 2.2.1). Apical-to-basolateral IgG transport experiment was conducted in the 
same way as for Calu-3 cells (described in Section 7.2.3.1). 
 
7.2.4 Adsorption of IgG or Fc to NPs 
FITC-IgG was adsorbed on the surface of sulfate-modified, polystyrene NPs of 30 nm 
diameter (Red, Sigma). To achieve this, the stock suspension of NPs (containing 2.5% 
w/v solid) was diluted in 1:50 in distilled water (sterile filtered). The use of HBSS or 
PBS for dilution of NPs was not appropriate due to the colloidal instability 
(coagulation) of the NPs in these buffers. The resulting diluted NP suspension was 
added to FITC-IgG stock solution (10 mg/ml in 0.01 M PBS). An overall amount of 
FITC-IgG used per 1 ml of diluted NP solution was 1 mg (equivalent to 50 mg FITC-
IgG per 1 ml of 2.5% w/v stock NP suspension). NPs were incubated with IgG at 
room temperature for 3 hours, with gentle magnetic stirring. The suspension was then 
centrifuged at 14,000 rpm for 30 min. The supernatant was removed and the NP pellet 
re-suspended in HBSS (pH 6.0), the volume of which was equal to the volume of 
removed supernatant. 
 
The amount of IgG added to the NPs was selected based on the hypothetical number 
of IgG molecules adsorbing on the surface of one NP, which was calculated by, 
firstly, determining the number of NPs in 1 ml of the stock solution using the equation 
provided by the manufacturer (Sigma):  
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  NPn =           = 1.692 x 10
15 
 
(NPn is NP number, S is % solids in NP stock solution, and d is the diameter, µm.) 
 
Thereafter, the surface area of one NP was determined using this equation:  
 
SA=4πr2= 2827.43 nm2 
 
(SA is the surface area and r is the NP radius.) 
 
Based on the literature data (31), the minimal molecular area of the native ÔTÕ-shaped 
IgG in the adsorbed closely-packed monolayer, calculated from X-ray diffraction 
data, should be approximately 7100 2 when the molecules are attached to the surface 
by the ÔlegÕ (Fc fragment) or by the ÔcapÕ (Ôend-onÕ disposition), approximately 4200 
2 at the Ôside-onÕ disposition, and approximately 12100 2 at the flat disposition. 
Therefore, a theoretical estimate (range) of the number of IgG molecules adsorbing 
per one NP can be calculated in the following way:  
 
 
AC = between       and              = 23-67  
 
 
(AC is adsorption capacity in terms of number of IgG molecules per 1 NP.) 
 
The number of IgG molecules adsorbed on the surface of NPs present in 1 ml of NP 
suspension (undiluted 2.5% w/v stock) was calculated to be between 3.892x1016 and 
1.134x1017 (ACxNPn), amounting to a range between 6.463x10
-8 M and 1.883x10-7 M 
6.03"10
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" S
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(calculated using Avogadro's constant) or between approximately 9.7 mg and 
approximately 28.2 mg. The higher ratio of 50 mg per 1 ml of NP suspension 
(undiluted stock containing 2.5% w/v solid) was used to ensure maximal NP surface 
coverage.   
 
FITC-Fc or (unlabelled) Fc fragment of IgG (Jackson Immunoresearch, USA) were 
adsorbed on three types of fluorescent polystyrene NPs: red, sulfate modified, 30 nm 
diameter NPs (used above, Sigma), yellow-green (YG), 20 nm, sulfate modified 
(FluoSpheres¨, Invitrogen) and YG, 50 nm, carboxy-modified (Fluoresbrite¨, 
Polysciences Europe). Additionally, Fc was also adsorbed on non-fluorescent, 
carboxy-modified NPs of 50 nm (Polybead¨, Polysciences Europe). The adsorption 
was performed by incubating the NPs, which were diluted 1 in 20 in distilled water 
(sterile filtered) with Fc in a similar way as for IgG, described above, with the 
following exceptions. 20 mg of Fc (in PBS) was used per 1 ml of 2% w/v and 2.5% 
w/v solid NP stock suspension, for FluoSpheres¨ and Fluoresbrite¨ NPs, respectively. 
This amounted to approximately 5.3 and 13.2 molecules of Fc per one 20 nm (sulfate-
modified) and 50 nm (carboxy-modified) NP, respectively, as calculated by 
determining the number of NPs per 1 ml (using manufacturer's information, in a 
similar way to above) and the number of individual Fc molecules (by employing 
Avogadro's constant). The amount of Fc used for coating of the NPs was probably 
lower than the adsorption capacity of NPs. However, this was done intentionally in 
order to achieve sub-total decoration of the NP surfaces, leaving exposed surface 
charges in an attempt to maximise the colloidal stability (charge repulsion) of NPs. 
Consequently, the decision was made not to centrifuge the NP suspensions following 
the incubation with Fc solution to remove the excess of free (not adsorbed) Fc as no 
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significant amount of free Fc was expected. Omitting the centrifugation step was 
considered advantageous as to prevent NP aggregation, which was noted following 
centrifugation of IgG-coated NPs. After incubation with Fc, the resulting suspension 
was diluted (1 in 5) in HBSS (pH 6.0) to achieve an overall dilution of 1 in 100 for all 
NP stock suspensions; NPs were applied to cells at this concentration. 
 
Note that protein-adsorbed NPs were applied to cells in HBSS (pH 6.0) in all cases. A 
control experiment, which potentially indicates successful adsorption of Fc onto the 
NP surface, was in some cases performed by adding HBSS to ÔuncoatedÕ NP 
suspension (of the same concentration), with evident immediate aggregation. Out of 
the different NPs used in this work, colloidal stability in HBSS in the absence of Fc 
was only apparent with those having a carboxy-modified surface (as judged by 
observation of visually transparent solution following the addition of HBSS to NPs).  
 
7.2.4.1 Nanoparticle size characterisation 
The mean diameter and size distribution of NPs after their incubation with IgG or Fc 
was determined by Dynamic Light Scattering (DLS) using a Viskotec system. 
Protein-adsorbed NPs were analysed by DLS suspended in HBSS at pH 6.0 (to 
replicate the conditions in which NPs were applied to the cells). The results represent 
the mean of ten measurements, performed at 25¡C. 
 
7.2.5 Confocal microscopy analysis of cellular uptake of IgG- or Fc-NPs 
7.2.5.1 Cell uptake of IgG-adsorbed NPs  
Confluent cell layers were serum-starved (in the way described in section 7.2.3.1) for 
1 hour. HBSS was then removed from the apical side of the layers and replaced with 
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IgG-adsorbed NP suspension (red, 30 nm, sulfate-modified) in HBSS (pH 6.0). The 
incubation with NPs continued for 2 hours. NP suspension was then removed and 
cells washed extensively (5x) with PBS. Cells were then fixed with 4% 
paraformaldehyde and processed for confocal imaging (in the way described in 
section 2.2.6.5). Confocal imaging was performed using the Leica system described in 
section 2.2.6.3. 
 
7.2.5.2 Cell uptake of Fc-adsorbed NPs  
The method detailed in section 7.2.5.1 for the uptake of IgG-coated NPs was 
followed, i.e. FITC-Fc- or Fc-adsorbed NPs, were applied to confluent, serum-starved 
cell layers (in HBSS, pH 6.0) for 2 hours. Cells were then washed (with PBS, 5x) and 
fixed with paraformaldehyde as before. Fixed cells were either processed for confocal 
imaging (as described in section 2.2.6.5) or in some cases, stained for ZO-1 TJ protein 
(following the method detailed in section 2.2.6.6) prior to processing for confocal 
microscopy. YG, Fc-adsorbed NPs were used in addition to red NPs (both sulfate 
modified). Adsorption of Fc on NPs was conducted according to the method 
described in section 7.2.4. 
 
7.2.5.3 LysoTracker
¨
 staining  
Fc-adsorbed NPs (YG, sulfate modified), prepared as described in section 7.2.4 were 
applied to the cells in a similar manner as in the preceding section, but in combination 
with the LysoTracker¨ probe. The concentration of the probe in the apical solution 
(containing NPs in HBSS, pH 6.0) was 100 nM. (A higher than the manufacturer's 
recommended concentration of 50-75 nM was used due to the lack of observed 
staining with the recommended concentration range). Cells were incubated with the 
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NPs and the LysoTracker¨ probe for 2 hours. The apical solution was thereafter 
removed and cells washed extensively with PBS. Cells were fixed with 
paraformaldehyde and processed for confocal imaging as described in section 2.2.6.5. 
Cell samples were imaged by CLSM using the system described in section 2.2.6.3. 
 
7.2.6 Cell uptake of Fc-NPs: measurement of NP fluorescence  
7.2.6.1 Cell uptake of Fc-NPs, comparison with unmodified NPs, and effect of IgG  
YG, carboxy-modified NPs were used for the purpose of this experiment due to their 
colloidal stability in HBSS in the absence of Fc (see section 7.2.4). Fc-adsorbed and 
unmodified (non-coated) NPs were applied to confluent, serum-starved cell layers. 
Additionally, Fc-NPs were applied to cell layers in the presence of soluble, 'free' IgG 
(5 µg/ml, added separately prior to the application of Fc-NPs). NP concentration was 
identical in all three situations. Cells were incubated with NPs for 3 hours, following 
which apical solutions were removed and cells extensively washed with PBS. Triton 
X-100 (0.1 v/v in PBS) was then applied to the cells for approximately 10 min. 
Application of Triton X-100 resulted in cell membrane permeabilisation and cell 
detachment from the filters. Cells were collected, transferred into microcentrifuge 
tubes and centrifuged at 13,000 rpm for 5 min. 100 µl of the supernatant from each 
pelleted cell layer was transferred to a 96-well plate for fluorescence determination. 
Cell uptake of NPs was quantified by fluorescence (485 nm excitation, 535 nm 
emission) using an MFX microtiter plate fluorometer (Dynex Technologies, USA), 
through preconstructed calibration curves. NP solution applied to cells was 
progressively diluted in a solution of 0.1% v/v Triton X-100 in HBSS and the 
resulting curve (a mean of three) was used to quantify NP uptake in terms of % 
relative to the applied amount.  
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7.2.6.2 Effect of non-fluorescent Fc-NPs on cell uptake of fluorescent Fc-NPs  
Fluorescent (YG) and non-fluorescent NPs (both carboxy-modified, 50 nm) were used 
for the purpose of this experiment. Adsorption of Fc to NPs was conducted in the 
same manner for both, fluorescent and non-fluorescent NPs, as described in section 
7.2.4. Confluent cell layers were serum-starved for 1 hour before the experiment as 
described in section 7.2.3.1 and NP suspensions (in HBSS, pH 6.0) were applied to 
the apical side of the cell layers. Fluorescent Fc-NPs (i.e. Fc adsorbed on fluorescent 
NPs) were applied to the cells either on their own or with non-fluorescent Fc-NPs 
(used at a 5-fold higher concentration than fluorescent Fc-NPs). The concentration of 
fluorescent Fc-NPs was kept identical in both scenarios. The incubation lasted for 3 
hours at usual cell culture conditions (37¡C/5%CO2), following which the apical 
solution was aspirated and cell layers washed. Cells were then permeabilised and 
detached from filters with Triton X-100, pelleted by centrifugation and the 
supernatant collected. NP uptake was quantified by measuring the fluorescence of the 
supernatant using the method described in section 7.2.6.1. NP uptake is expressed as 
% relative to the applied amount, as determined through calibration curves in the 
manner detailed in section 7.2.6.1. 
 
7.2.7 Fc-coated NP transport across the cell layers 
7.2.7.1 Transport of Fc-NPs and unmodified NPs 
YG, carboxy-modified NPs were used in this experiment. Transport of Fc-NP 
(prepared as described in section 7.2.4) across the Calu-3 layers was determined 
simultaneously to NP uptake (section 7.2.6.1). Following the application of NPs on 
the apical side of the cell layers (as detailed in section 7.2.6.1), the basolateral 
solution was sampled regularly for 3 hours (with replacement of the sampled 
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volumes). NPs were quantified in the sampled basolateral solutions by fluorescence 
(see section 3.2.4); the extent of transport is expressed as % relative to the applied 
amount. 
 
7.2.7.2 Effect of IgG on Fc-NP transport 
YG, sulfate-modified, Fc-NPs (prepared as described in Section 7.2.4) were applied to 
the apical side of the cell layers and incubated with the cells for 3 hours. In some 
cases NPs were added to the cells in combination with soluble IgG (5 µg/ml, added 
separately prior to the application of Fc-NPs). Cells were incubated with NPs for three 
hours, after which the basolateral medium was collected and transferred into a black 
96-well plate. The presence of NPs in the basolateral medium was determined and 
quantified (relatively to the NP amount applied apically) through measurement of 
fluorescence (485 nm excitation, 535 nm emission) using an MFX microtiter plate 
fluorometer, based on calibration curves of known concentrations of Fc-NPs serially 
diluted in HBSS. 
 
7.2.7.3 Effect of non-fluorescent Fc-NPs on transport of fluorescent Fc-NPs 
Fluorescent (YG) and non-fluorescent NPs (both carboxy-modified, 50 nm) were used 
for the purpose of this experiment. The transport of fluorescent Fc-NPs (prepared as 
described in section 7.2.4) across the cell layers was established in the same 
experiment as their uptake (as described in section 7.2.6.2). Following NP application 
to the apical side of the cell layers (as detailed in section 7.2.6.2), their transport 
across the layers was determined by sampling the basolateral medium (100 µl 
volumes) every 30 min for 3 hours (with replacement of the sampled volume with 
fresh HBSS). NP transport was determined by measuring the fluorescence of the 
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sampled basolateral solutions using preconstructed calibration curves (as described in 
the preceding section) and is expressed as % relative to the applied amount. 
 
7.2.7.4 Co-adsorption of Fc and an investigational therapeutic protein on the NPs 
and transport across the cell layers 
Carboxy-modified (YG) NPs (50 nm in diameter) were coated with Fc only (as 
described in section 7.2.4) or with equal amounts (20 mg protein per 1 ml of 2.5% 
w/v NP stock suspension) of Fc and an investigational therapeutic antibody fragment 
(Fab), hCTM01 (supplied by UCB, Slough), for 3 hours. Fc-NPs, hCTM01-Fc-NPs 
and unmodified NPs were applied on the apical surface of confluent, serum-starved 
Calu-3 layers. Apical-to-basolateral NP transport was determined by sampling the 
basolateral solution at regular intervals and fluorescence measurement of these 
solutions (as described in section 7.2.7.2). 
 
7.2.7.5 Association of NPs with filter (Transwell
¨
) plastic 
Following the measurement of NP transport in the preceding section (7.2.7.4) cells 
were detached from the filters by incubation with Triton X-100. The filters were then 
excised from the Transwell¨ and the fluorescence associated with the filters was 
assessed by lysis of the NPs with 50% acetone to release the entrapped fluorochrome 
(32) followed by fluorescence measurement (485 nm excitation, 535 nm emission). 
NPs associated with the filters are expressed as % relative to the applied amount, 
calculated through calibration curves (constructed in 50% acetone).  
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7.3 Results  
7.3.1 Immunostaining for FcRn 
Figure 7.1 shows confocal micrographs of Calu-3 cell layers cultured under AIC (7.1 
a and b) or LCC conditions (7.1c). Intensive punctate red fluorescence was observed 
in cells treated with both, primary (anti-FcRn) and TRITC-labelled secondary 
antibody (7.1a and 7.1b). Red fluorescence was observed in the region around the cell 
nuclei (cytosol), apparent from the micrographs as large blue areas (DAPI-stained) 
and also across the vertical axis (7.1b), implying that the receptor is distributed on 
both apical and basolateral sides of the cells. Considerably less fluorescence was 
observed in Calu-3 cells cultured using LCC (7.1c) and no red fluorescence was 
detected in control cells (grown using AIC) treated with the secondary (TRITC-
labelled) antibody only (Figure 7.1d).  
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 a) 
Figure 7.1. Immunostaining for FcRn in filter-cultured Calu-3 cells. a) AIC Calu-3 cells subjected to incubation with goat, anti-human FcRn (primary) 
antibody and donkey, anti-goat TRITC-IgG (secondary antibody); i) Blue channel: cell nuclei stained with DAPI, i) Red channel: TRITC fluorescence, and iii) 
Overlay image (Blue and Red channel). b) Three dimensional image of a Calu-3 cell layer cultured under AIC, showing vertical ('z-axis') on the bottom and the 
right hand side. c) Calu-3 cells cultured using LCC conditions. d) Calu-3 cells (AIC) incubated with donkey, anti-goat TRITC-IgG (secondary antibody) only. 
 b) c) d) 
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Similar results were obtained with confluent Caco-2 cells cultured as monolayers 
(Figure 7.2). Again, red fluorescence due to donkey, anti-goat TRITC-IgG, was 
distributed in the regions around the nuclei. This fluorescence was only observed in 
cells incubated with both, primary and secondary antibodies (7.2a ii and iii); in 
control cells where incubation with the primary antibody was omitted (i.e. cells were 
exposed to donkey, anti-goat TRITC-IgG only) no red fluorescence was detected 
(Figure 7.2b). 
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a) 
b) 
Figure 7.2. Immunostaining for FcRn in filter-cultured Caco-2 cells. a) Cells subjected to incubation 
with goat, anti-human FcRn (primary) antibody and donkey, anti-goat TRITC-IgG (secondary 
antibody); i) Blue channel: cell nuclei stained with DAPI, ii) Red channel: TRITC fluorescence, and 
iii) Overlay image (Blue and Red channels). b) Control cells incubated with donkey, anti-goat TRITC-
IgG (secondary antibody) only.  
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7.3.2 Association of FITC-IgG with cell layers  
7.3.2.1 Effect of pH on FITC-IgG association with cells  
Levels of cell-associated FITC-IgG following its incubation with Calu-3 layers in 
either a slightly acidic or physiological pH (6.0 and 7.4, respectively) for 3 hours are 
shown in Figure 7.3. Approximately 76% of the applied dose of FITC-IgG was 
present in the apical solution 3 hours after its application at pH 6.0, compared to 87% 
following its application to cells at pH 7.4; this difference was statistically sigificant 
(p=0.04). 
 
Figure 7.3. Effect of pH on association of FITC-IgG with Calu-3 layers. Cell association presented 
as amount of FITC-IgG in the apical solution following its incubation with the cells at pH 6.0 or 7.4 
for 3 hours. Results expressed as % of the amount applied initially (5 µg/ml, equating to 2.5 µg). 
Data presented as the mean ± SD (n=3). 
 
7.3.3.2 Association of FITC-IgG with cells: competition with unlabelled IgG  
Incubation of FITC-IgG with the cells in the presence of unlabelled IgG (at pH 6.0) 
resulted in significantly higher (p=0.015) levels of FITC-IgG (93% of the applied 
amount) being detected in the removed apical solution at the end of incubation period 
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compared to application of FITC-IgG on its own (76% of the added amount, shown in 
the previous section), as illustrated in Figure 7.4.  
 
Figure 7.4. Effect of unlabelled IgG on association of FITC-IgG with Calu-3 layers. Cell association 
presented as amount of FITC-IgG in the apical solution following its incubation with the cells (at 
pH 6.0) on its own (5 µg/ml, equating to 2.5 µg) or in the presence of unlabelled IgG (20 µg/ml or 10 
µg) for 3 hours. Results shown as % of the amount applied initially. Data presented as the mean ± 
SD (n=3). 
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7.3.2.3 Cell uptake of FITC-IgG: effect of pH and competition with unlabelled IgG  
Figure 7.5 shows the uptake of FITC-IgG by Calu-3 cells in different experimental 
situations. Although it is apparent from the figure that cell uptake was lower 
following the application of IgG to cells at pH 7.4 compared to pH 6.0, this difference 
was not statistically significant (p=0.09). On the other hand, application of unlabelled 
IgG (4x higher amount compared to FITC-IgG; pH 6.0) resulted in suppression of 
cellular uptake of FITC-IgG by approximately 19%; the difference was statistically 
significant compared to the uptake of FITC-IgG at pH 6.0 (p=0.007) and pH 7.4 
(p=0.004).  
 
Figure 7.5. Effect of pH and unlabelled IgG on cell uptake of FITC-IgG. Cells were incubated with 
samples for 3 hours. The amount of unlabelled IgG applied to the cells (at pH 6.0) was 4x higher 
than FITC-IgG (10 µg and 2.5 µg, respectively). Uptake expressed as % of the amount applied 
apically. Data presented as the mean ± SD (n=3).  
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7.3.3 IgG transport experiments 
7.3.3.1 IgG transport across Calu-3 layers 
Figure 7.6 shows the amount of IgG present in the basolateral solution at different 
times following its addition on the apical surface of the layers. There was an increase 
in basolateral IgG levels from approximately 4 ng (at time 0 min, prior apical addition 
of IgG) to 51 ng (at time 60 min). Thereafter, a plateau was observed, with the 
basolateral IgG amount remaining somewhat stable (51-52 ng) from 60 min to 120 
min.  
 
Figure 7.6. Apical-to-basolateral transport of IgG across Calu-3 layers. Transport presented as IgG 
amount (ng) in the basolateral solution at different time intervals following addition of 1 µg/ml (500 
ng) of IgG to the apical surface of the cells at pH 6.0. Data presented as the mean ± SD (n=4).  
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7.3.3.2 Transport saturation 
Cumulative amounts of IgG present in the basolateral solution following its addition 
at varying concentrations (50 ng/ml, 500 ng/ml and 5 µg/ml) on the apical side of the 
cell layers are shown in Figure 7.7. It is worth pointing out here that in the current 
experiment, the basolateral solution was replaced completely at each IgG sampling 
point (every 30 min), as opposed to sampling 100 µl volumes, performed in the 
previous experiment. Another important point to highlight is that the experiments 
described here and in the next section (7.3.3.3) were conducted on Calu-3 cells of a 
different batch and higher passage numbers (passage 43-44) than cells used in work 
described in other sections of this chapter (passage 21-27). Cumulative basolateral 
IgG amount in Figure 7.7 followed a similar pattern at all added concentrations, but 
basolateral IgG levels were lower (at all time intervals) for application of 50 ng/ml 
IgG as compared to application at higher concentrations of 500 ng/ml and 5 µg/ml 
(the difference in basolateral IgG amount between 50 ng/ml and 500 ng/ml 
application, measured at 180 min, was statistically significant; p=0.025). It is 
interesting to note that basolateral IgG levels measured following the apical addition 
at 5 µg/ml were similar to those obtained with 500 ng/ml, indicating no further 
increase in IgG transport with increasing apical concentration.  
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Figure 7.7. Apical-to-basolateral transport of IgG across Calu-3 layers: transport saturation. 
Transport presented as IgG amount (ng) present in the basolateral solution at different time 
intervals following its application (on the apical side of Calu-3 layers) at 50 ng/ml, 500 ng/ml and 5 
µg/ml. Basolateral solution was replaced completely every 30 min (at each IgG sampling interval).  
Results are shown as the mean ± SE (n=3). 
 
7.3.3.3 Receptor competition 
Figure 7.8 shows the pattern in basolateral IgG amount following its application to the 
cell layers on its own or in conjunction with rabbit IgG (rIgG; applied at 50x higher 
concentration than IgG). Basolateral IgG levels increased with time (from 
approximately 3 ng to 11 ng) after its application on its own. Co-addition of rIgG 
resulted in a considerably lower increase in the basolateral levels of IgG (from 
approximately 1.2 ng to 2.6 ng), with similar levels seen at all time intervals.  
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Figure 7.8. Apical-to-basolateral transport of IgG across Calu-3 layers: receptor competition. 
Transport presented as IgG amount (ng) present in the basolateral solution at different time 
intervals following its application (on the apical side of confluent Calu-3 layers) in the presence or 
absence of rabbit IgG (rIgG). IgG was applied apically at 1 µg/ml, whereas rIgG was applied at 50 
µg/ml (both in HBSS, pH 6.0). Results are shown as the mean ±SE (n=3).  
 
7.3.3.4 IgG transport across Caco-2 monolayers 
The application of IgG to Caco-2 monolayers resulted in a small increase in 
basolateral IgG levels with time from approximately 0.7 ng to 2.7 ng (Figure 7.9).  
0 
2 
4 
6 
8 
10 
12 
14 
0  20  40  60  80  100  120  140 
B
a
so
la
te
r
a
l 
Ig
G
 a
m
o
u
n
t 
(n
g
) 
Time (min) 
IgG 
IgG + rIgG 
Chapter 7  The potential of IgG transcytosis pathway for mucosal drug and nanoparticle delivery  
 
 253 
 
 
Figure 7.9. Apical-to-basolateral transport of IgG across Caco-2 monolayers. Transport presented as 
IgG amount (ng) present in the basolateral solution following its addition to the apical side of Caco-
2 cell monolayers. IgG was applied at 1 µg/ml in HBSS (pH 6.0). Data presented as the mean ± SD 
(n=4).  
 
7.3.4 Adsorption of IgG or Fc to NPs 
7.3.4.1 Nanoparticle size characterisation 
Figure 7.10 shows DLS size characterisation of NPs (red, sulfate-modified NPs of 30 
nm nominal diameter) before their incubation with IgG or Fc (i.e. unmodified) and 
following adsorption of IgG or Fc. For uncoated NPs (7.10a), the most abundant 
(approximately 90%) particle population had average hydrodynamic radii of 
approximately 21 nm (i.e. average diameters of 42 nm). Larger particulates in the 
micron range (suggesting aggregation and/or presence of other particulate material in 
the analysed sample) were also observed. With IgG-adsorbed NPs (7.10b), about 88% 
of particle populations had average radii of 220 nm (equivalent to 440 nm diameter), 
with NP populations of other sizes, namely those with mean radii of about 26 nm and 
larger micron-sized particles, also observed to a lesser extent. Finally, DLS analysis 
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of Fc-adsorbed NPs revealed that particle populations of two sizes were present in the 
samples; 2.4% of these had average radii of approximately 19 nm (diameter 38 nm), 
while the majority (around 98%) were NPs with mean radii of approximately 60 nm 
(diameter 120 nm). 
 
a) 
 
 
 
 
 
 
 
b) 
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c) 
 
 
 
 
 
 
 
Figure 7.10. Size characterisation of unmodified (a), IgG-adsorbed (b) and Fc-adsorbed NPs (c) by 
Dynamic Light Scattering (DLS). Tables show information on mean sizes (radii) and size 
distributions of detected NP populations. The result represents the mean of ten measurements, 
performed in HBSS (pH 6.0) at 25¡C. 
 
7.3.5 Confocal microscopy analysis of cellular uptake of IgG- or Fc-NPs 
7.3.5.Cell uptake of IgG-adsorbed NPs 
Figure 7.11 shows confocal micrographs of Calu-3 cells (as confluent filter-cultured 
layers) incubated with IgG-adsorbed NPs. The micrographs reveal the presence of 
green fluorescence (green channel) resulting from FITC-IgG and red fluorescence 
(red channel) from fluorescent latex NPs. Furthermore, green and red fluorescence 
was observed to occur at the same locations - i.e. to co-localise.  
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  i)     ii)              iii)         iv) 
 
 
 
 
 
 
 
Figure 7.11. Uptake of FITC-IgG-adsorbed NPs by Calu-3 cells. i) Blue channel: DAPI-labelled cell nuclei, ii) Green channel: FITC-IgG, iii) Red channel: fluorescently 
labelled (red) polystyrene NPs, and iv) Overlay image (all channels).  
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7.3.5.2 Cell uptake of Fc-adsorbed NPs  
Confocal microscopy analysis of cellular internalization of Fc-adsorbed NPs is shown 
in Figure 7.12. Red, FITC-Fc-immobilised NPs can clearly be seen associated with 
the cells (7.12a). Similarly to IgG-adsorbed NPs, it is clear from the micrographs that 
green and red fluorescence (due to FITC-Fc and red NPs, respectively) was observed 
at the same areas, indicating Fc-association with the NPs. Furthermore, Fc-adsorbed 
NPs (non-fluorescent Fc) were seen in the interior of the cells (7.12b), with 
distribution of NPs throughout the vertical z-axis of the cells (7.12b ii) and some even 
seen at the level of the filter (seen as continuous blue fluorescence on the bottom/right 
hand side of the micrograph). Figure 7.12c shows the uptake of YG Fc-NPs (non-
fluorescent Fc) in cells that were subsequently stained for the TJ protein, ZO-1. 
Again, punctate fluorescence from the NPs was clearly apparent within the cells, at 
the level above and below the TJs (c iii). Note that both red and YG NPs were sulfate 
modified and Fc-adsorption was performed in the same way. It is apparent from 
Figure 7.12 that with Fc-NPs, punctate fluorescence of smaller dimensions was 
observed compared to IgG-NPs (Figure 7.11).  
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c)  i              ii                        iii
Figure 7.12. Uptake of Fc-adsorbed NPs by Calu-3 cells. a) Uptake of red (sulfate-modified) NPs coated with FITC-Fc; i) Blue channel: DAPI-labelled cell nuclei, ii) 
Green channel: FITC-Fc, iii) Red channel: red polystyrene NPs, and iv) Overlay image (all channels). b) Uptake of red Fc-NPs. i: Single section (approximately 
midway between apical surface and the filter plastic), and ii: Three dimensional image showing vertical axis where A is the apical side and B is the basolateral side of 
the cells. c) Uptake of Yellow-Green Fc-NPs. i: Single section showing blue channel (DAPI-stained cell nuclei), green channel (YG NPs), red channel (secondary, 
TRITC-labelled antibody directed towards primary, anti ZO-1 antibody) and overlay image, ii: same as i, but higher magnification, and iii: three dimensional image 
showing vertical axis (right hand side and bottom of the micrograph), where A is apical side and B is basolateral side of the cells. 
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7.3.5.3 LysoTracker
¨
 staining  
Cellular localisation of Fc-NPs following their incubation with filter-cultured Calu-3 
cells in the form of a confluent layer in the presence of the lysosomal marker, 
Lysotracker¨ Red, is shown in Figure 7.13. Again, Fc-NPs were observed in the 
interior of the cells, as suggested by the presence of green fluorescence across the 
vertical cross-sections, with a somewhat more prominent distribution of fluorescence 
on the apical side. The presence of red staining due to the Lysotracker¨ probe was 
relatively weak, despite its use at higher than recommended concentrations (see 
section 7.2.5.3) and observation of this phenomenon was repeatable. Although very 
low staining level is apparent, with the exception of one area (marked by the white 
box), red fluorescence did not co-localise with green fluorescence due to Fc-NPs.  
 
 
 
 
 
 
 
 
 
Figure 7.13. Confocal microscopy micrograph showing cellular distribution of Fc-NPs and 
lysosomal probe, Lysotracker
¨
. NPs and Lysotracker
¨
 (100 nM) were incubated with confluent 
Calu-3 layers for 2 hours. Green fluorescence is due to YG NPs (Fc-adsorbed) and Red fluorescence 
is due to the Lysotracker
¨ 
red probe. White box shows a region where green and red fluorescence co-
localised. A is the apical side and B is the basolateral side of the cells. 
B A 
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7.3.6 Cell uptake of Fc-NPs: measurement of NP fluorescence 
7.3.6.1 Cell uptake of Fc-NPs, comparison with unmodified NPs, and effect of IgG  
The extent of Fc-NP internalization by Calu-3 cells following an incubation period of 
three hours is shown in Figure 7.14. A comparison is made with the uptake of NPs in 
the presence of ÔfreeÕ IgG. Furthermore, the level of unmodified NP uptake is also 
depicted in the figure. Approximately 12% of the applied Fc-NPs were taken up by 
the cells. In contrast, when Fc-NPs were added in combination with IgG, there was a 
decrease in uptake of Fc-coated NPs to approximately 8% of the applied amount 
(though this decrease lies just outside of the 95% significance, with p=0.06). Finally, 
the internalization of unmodified NPs by cells was the lowest, with approximately 5% 
of the applied NPs observed in the supernatants of lysed cells. This value was 
statistically lower than those obtained with Fc-NPs when applied both on their own 
and with IgG (p=0.042 and 0.02, respectively). 
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Figure 7.14. Cell uptake of Fc-NPs, Fc-NPs in the presence of IgG (5 µg/ml) and unmodified NPs 
(all in HBSS, pH 6.0). 50 nm carboxy-modified (YG) NPs (coated or non-coated with IgG) were 
used, which were incubated with Calu-3 layers for 3 hours. NP uptake is expressed as % relative to 
the applied amount. Data presented as the mean ± SD (n=4). 
 
7.3.6.2 Effect of non-fluorescent Fc-NPs on cell uptake of fluorescent Fc-NPs 
Application of non-fluorescently labelled Fc-NPs in combination with the labelled Fc-
NPs was associated with a reduction in cellular uptake of fluorescent Fc-NPs (Figure 
7.15). Approximately 18% of the applied Fc-NPs were taken up by cells following 
their application on the apical side of the cell layers. In contrast, when fluorescent Fc-
NPs were added in conjunction with non-labelled NPs (Fc-adsorbed), their uptake was 
significantly (p=0.02) lower (approximately halved to about 9% of the applied 
amount).  
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Figure 7.15. Effect of non-fluorescently labelled Fc-NPs on cellular uptake of labelled (fluorescent) 
Fc-NPs. Non-labelled NPs were used at a 5-fold higher concentration compared to labelled NPs. 
Labelled and non-labelled NPs were carboxy-modified and of an identical nominal diameter (50 
nm). Adsorption of Fc was conducted in the manner described in section 7.2.4 for both types of NPs. 
NPs were incubated with Calu-3 layers for 3 hours. NP uptake is expressed as % relative to the 
applied amount. Data presented as the mean ± SD (n=3). 
 
7.3.7 Fc-coated NP transport across cell layers 
7.3.7.1 Transport of Fc-NPs and unmodified NPs 
Figure 7.16 illustrates the apical-to-basolateral translocation of Fc-immobilised NPs 
(Fc-NPs) and unmodified NPs. A dramatic difference in the extent of NP transport 
between Fc-NPs and unmodified NPs can be noted from the figure. While there was a 
gradual build up of NPs in the basolateral solution in both cases, this increase was 
considerably steeper in the case of Fc-NPs compared to unmodified NPs, with 
basolateral NP levels reaching final values (at 180 min) of approximately 1.1% and 
0.3%, respectively (which were significantly different; p=0.0004). 
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Figure 7.16. Apical-to-basolateral transport of Fc-adsorbed (Fc-NP) and unmodified NPs ('NP') 
across Calu-3 layers. Carboxy-modified NPs were used and NPs were applied to cells at an identical 
concentration in both cases. The presence of NPs in the basolateral solution was measured every 30 
min for 180 min. NP transport is expressed as % relative to the applied amount. Data presented as 
the mean ± SD (n=3). 
 
7.3.7.2 Effect of IgG on Fc-NP transport 
The influence of IgG presence on the extent of apical-to-basolateral transport of Fc-
NPs is shown in Figure 7.17. Rather than measuring the transport over time as in the 
preceding experiment (section 7.2.7.1), in this instance the basolateral solution was 
only sampled once following a 3-hour incubation of cells with the NPs. In this 
experiment, approximately 3.6% of the apically added Fc-NPs were found in the 
basolateral solution at the end of the incubation period. The extent of Fc-NP transport 
that occurred in the presence of free IgG was significantly lower (approximately 
1.5%; p=0.04). 
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Figure 7.17. Effect of IgG on apical-to-basolateral transport of Fc-NPs across the Calu-3 layers. 
IgG applied at 5 µg/ml. The presence of NPs (YG, sulfate modified) in the basolateral solution was 
measured at time 180 min. NP transport is expressed as % relative to the applied amount. Data 
presented as the mean ± SD (n=3). 
 
7.3.7.3 Effect of non-fluorescent Fc-NPs on transport of fluorescent Fc-NPs 
Similarly to the uptake experiment, co-application of non-fluorescent Fc-NPs with 
fluorescent Fc-NPs led to a reduction of apical-to-basolateral movement of the latter 
(Figure 7.18). While there was an increase in relative amount of NPs found 
basolaterally over time in both cases, higher fluorescence values (and therefore NP 
amounts) over time were observed when Fc-NPs were applied per se compared to co-
application. For example, this difference at time 180 min was statistically significant 
(p=0.024). 
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Figure 7.18. Apical-to-basolateral transport of Fc-NPs (fluorescent) across Calu-3 layers in the 
absence and presence of unlabelled Fc-NPs. Non-labelled NPs were used at a 5-fold higher 
concentration compared to labelled NPs. Labelled and non-labelled NPs were carboxy-modified and 
of an identical nominal diameter (50 nm). Adsorption of Fc was conducted in the manner described 
in section 7.2.4 for both types of NPs. Fluorescent NPs in the basolateral solution were quantified 
every 30 min for 180 min (3 hours). NP transport is expressed as % relative to the applied amount. 
Data presented as the mean ± SD (n=3). 
 
 
7.3.7.4 Co-adsorption of Fc and an investigational therapeutic protein on the NPs 
and transport across the cell layers 
Figure 7.19 displays the data on transport of ÔcoatedÕ and uncoated NPs across the 
Calu-3 layers; NPs were either coated with Fc, or with Fc and an investigational 
therapeutic antibody fragment (Fab, 'CTM01'). Both systems were seen to traverse the 
cell layers to a similar extent, with 7.4% and 7.8% of the applied NPs being detected 
in the basolateral solution at 180 min for Fc-NPs and CTM01-Fc-NPs, respectively. 
In contrast, the transport of NPs coated with the therapeutic antibody fragment only 
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(CTM01-NP) was significantly lower, with approximately 3.6% of the apically 
applied NPs translocating across the cell layers.  
 
Figure 7.19. Transport of differently coated NPs (carboxy-modified) across the Calu-3 layers. NPs 
were coated with a therapeutic antibody fragment (Fab), CTM01, with Fc, or with both, CTM01 and 
Fc. The basolateral solution was tested for fluorescence (NP presence) at different time intervals 
(every 30 min) for 180 min. NP transport is expressed as % relative to the applied amount. Data 
presented as the mean ± SD (n=3). 
 
7.3.7.5 Association of NPs with filter (Transwell
¨
) plastic 
Association of NPs with the filters, following their apical-to-basolateral transport 
across the cell layers, for the systems investigated in the experiment above (section 
7.3.7.4) is illustrated in Figure 7.20. It is apparent from the figure that approximately 
7% of apically applied NPs coated with the therapeutic Fab (CTM01) were associated 
with the filters. For NPs co-adsorbed with CTM01 and Fc and those with Fc only, the 
values were similar at 11 and 12%, respectively. While the difference in relative NP 
amount that was associated with the filters lies just outside statistical significance for 
CTM01-NPs and CTM01-Fc-NPs (p=0.051) the difference in values for CTM01-NPs 
and Fc-NPs is statistically significant (p=0.023).  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
0  50  100  150  200 
B
a
s
o
la
te
r
a
l 
N
P
 a
m
o
u
n
t 
(%
 o
f 
a
p
p
li
e
d
 a
p
ic
a
ll
y
) 
Time (min) 
CTM01‐NP 
CTM01‐Fc‐NP 
Fc‐NP 
Chapter 7  The potential of IgG transcytosis pathway for mucosal drug and nanoparticle delivery  
 
 269 
 
Figure 7.20. Association of differently coated NPs with filter plastic (of the Transwell
¨
 system) 
following their transport across the Calu-3 layers. NPs were coated with the therapeutic antibody 
fragment (Fab), CTM01, with Fc, or with both, CTM01 and Fc. Coated NPs were applied to cells at 
an identical concentration in all cases. Filters were excised and NPs lysed with 50% acetone to 
release the entrapped fluorochrome. The extent of NP association with the filters is expressed as % 
relative to the applied amount. Data presented as the mean ± SD (n=3). 
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7.4 Discussion 
The enhancement of mucosal absorption through reversible opening of epithelial TJs 
is more efficacious with relatively small therapeutic proteins such as peptides. Indeed, 
it is apparent from the literature discussed in Chapter 1 (sections 1.5.1.3 and 1.5.1.4) 
that most studies attempting to improve mucosal absorption through TJ modulation 
incorported peptides having a relatively low MW, including octreotide (1 kDa), 
buserelin (1.3 kDa) and salmon calcitonin (approximately 3.4 kDa). With larger 
proteins such as antibodies, the use of this strategy becomes rather inefficient. 
Miyamoto and co-workers (1) studied the effect of poly-L-arginine (TJ-opening 
absorption enhancer), on nasal absorption of FITC-dextrans (FDs) with average MWs 
ranging from 4.3 to 167 kDa in rats and showed that the extent of absorption 
enhancement was dependent upon the MW. Consequently, the bioavailability was seen 
to decrease exponentially with the increasing MW of FDs. Based on the relationship 
between the achieved bioavailability and the MW of FDs, the authors of this study 
propose that the maximal MW of protein drugs exhibiting efficient absorption with the 
paracellular permeability enhancer, poly-L-arginine, is about 20 kDa, assuming a 10% 
lower limit of bioavailability for developing a potent nasal delivery system. However, 
it must be noted that there are very few reported studies in the literature addressing 
the capacity of the paracellular route as a function of the MW of the therapeutic, 
following opening of the cellular TJs. Our work utilising chitosan in an attempt to 
improve the permeability of antibodies across Calu-3 layers (Chapter 6) found that 
chitosan exhibited a limited effect on antibody permeability. As argued previously 
(section 7.1), an alternative to paracellular transport would be to deliver large MW 
protein therapeutics through the transcellular route. 
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Work detailed in this chapter hence investigated the potential of the IgG/FcRn 
transcytotic pathway for mucosal delivery of large macromolecules (antibodies) and 
NPs, as a potential drug carrier system. This pathway has been investigated in some 
detail by other groups, as will be discussed later, and its potential for use in the field 
of mucosal delivery of macromolecules has, to some extent, been proven. Indeed, the 
IgG/FcRn transcytotic transmucosal pathway has been exploited commercially; the 
drug delivery technology of Syntonix Pharmaceuticals relied on construction of 
therapeutic proteins conjugated to the Fc domain of IgG ('Fc-fusion proteins') (33), 
the potential of which was demonstrated in phase I clinical studies (as will be 
discussed later).  
 
As for any transport route, the usefulness of the IgG/FcRn transcytotic pathway for 
delivery of therapeutic biologicals is highly dependent on its capacity and therefore 
the amount of the therapeutic that it can transport. To this end, while some researches 
are demonstratrating the potential of the FcRn/IgG pathway for mucosal delivery of 
macromolecules (as will be disussed later) others have argued that this route is 
associated with a limited capacity (34). Furthermore, to the best of our knowledge, 
there are no studies reported in the literature that investigated potential of the 
IgG/FcRn transport pathway for cellular uptake and transport of NPs across epithelial 
cells or mucosal surfaces. This work attempted to address these points. 
 
As mentioned earlier, endogenous FcRn expression in Calu-3 cells has been shown 
previously by applying Western blotting analysis (11). It should be however noted 
that this is the sole published work showing this information. In the present work, 
FcRn expression in Calu-3, as well as in Caco-2 cells, was demonstrated by 
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immunofluorescence. Confocal micrographs of the cells cultured as polarised layers 
imaged following the FcRn staining procedure revealed abundant distribution of 
fluorescence throughout the cell cytoplasm. Interestingly, considerably lower 
flourescence was clearly apparent in cells cultured under LCC conditions, 
demonstrating the importance of appropriate culture conditions. The absence of 
fluorescence in the control (cells treated with the secondary antibody only) is strongly 
suggestive that the fluorescence seen following the applied imunofluorescence 
procedure, is is due to FcRn and is a clear indication of receptor expression.  
 
FcRn immunostaining in filter-cultured Caco-2 cells was performed for corroboration, 
as, unlike Calu-3 cells, FcRn expression in the Caco-2 cell line has been demonstrated 
previously in a number of studies (14, 35, 36). The pattern of fluorescence, indicating 
FcRn presence, in Caco-2 cells appeared similar to that seen in Calu-3 cells. However, 
the comparison of the level of FcRn expression in the two cell lines was not possible 
due to the qualitative nature of the immunostaining/confocal technique.  
 
In primates, FcRn is expressed predominantly in the upper airway epithelium as 
demonstrated by Spiekermann et al (11). In this study the lungs of adult humans and 
non-human primates (cynomologus macaque) were examined for expression of FcRn 
and found that total cell lysates obtained from lungs of both species contained a 45-
kDa glycosylated protein consistent with human FcRn, as assessed by SDS-PAGE 
and Western blotting. When lung tissue samples were visualized by 
immunohistochemistry, FcRn was found localized predominantly at the apical region 
of bronchial epithelial cells lining the large and small airways. Furthermore, cell 
lysates prepared from the Calu-3 cell line (used in this thesis) and BEAS-2B (another 
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human bronchial epithelial cell line) also contained FcRn.  
 
To assess the pH-dependence of IgG binding to FcRn, FITC-IgG was incubated with 
confluent cell layers at a slightly acidic or physiological environment (pH 6.0 and 7.4, 
respectively). Determination of the levels of FITC-IgG in the apical solution at the 
end of the incubation interval revealed a difference in apical FITC-IgG amount, 
relative to that applied, depending on the pH (76% versus 87% at pH 6.0 and 7.4, 
respectively). Such a disappearance of FITC-IgG from the apical solution following 
its incubation with the cells could have been a result of its transcellular transport, cell 
uptake, its binding to FcRn (present at both the cell interior and cell surface), and/or a 
combination of all these processes. Although this experiment did not provide 
information with regards to the fate of FITC-IgG following its application, data 
suggests that one or more of the above-mentioned possible processes causing IgG 
removal are likely to be significantly more efficient at pH 6.0. While IgG binding to 
FcRn present within the acidic compartments (following its internalisation) is unlikely 
to be affected by the pH of the apical solution, IgG binding to FcRn present at the cell 
surface is facilitated at pH 6.0, possibly accounting for the observed difference 
discussed above. Detection of higher levels of FITC-IgG in the apical solution 
following its incubation with the cells in the presence of unlabelled IgG compared to 
levels observed after FITC-IgG application on its own, suggests that the uptake, 
transport and/or receptor binding (processes discussed above) occur through 
mechanisms specific to IgG.  
 
Although the disappearance of IgG from the apical solution was seen to be pH-
dependent, as discussed above, its cell uptake was not affected by pH (the difference 
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in uptake between pH 7.4 and 6.0 was not statistically significant). On the other hand, 
suppression of cellular uptake of FITC-IgG by unlabelled IgG (Figure 7.5) again 
indicated that FITC-IgG internalised through an IgG-specific pathway.  
 
Findings similar to ours have also been published by Sato et al. (36). Their work 
demonstrated that the binding of FITC-labelled human IgG to the membrane surface 
of Caco-2 cells increased as the pH of incubation buffer decreased. Recently the work 
by Stirling et al. (37), which used the porcine kidney cell line, IB-RS2 (expressing 
FcRn with a high homology to human FcRn), also demonstrated that there was little 
binding of porcine IgG at pH 7.8, but binding was clearly evident at pH 6.0.  
 
Periodic measurement of IgG levels in the basolateral solution following its 
application on the apical surface of the cell layers revealed that IgG traversed the 
Calu-3 layers. A pattern of an initial increase in basolateral IgG level, followed by a 
plateau was typically observed in experiments where the basolateral solution was 
sampled at regular intervals. Observation of this phenomenon can possibly be 
attributed to transport saturation with time and/or the property of IgG to traverse the 
epithelial cell layers in a bidirectional manner, as documented previously (14).  
 
An important point to note is the presence of bovine IgG (bIgG) in the cell culture 
serum, which could have potentially interferred with IgG uptake/transport studies in 
our work. However, extensive cell washing and serum starving prior to IgG uptake 
and transport experiments was undertaken to ensure its maximal removal. 
Furthermore, human FcRn does not bind significantly to bIgG (38). Therefore, taking 
both factors into account, one would assume that the potential for its interference in 
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IgG transport and uptake experiments in the present study was very low. Also, the 
quantification method used in the present experiments was specific to (human) IgG, 
therefore permitting the experimental setup used in this work.  
 
Apical-to-basolateral IgG transport data demonstrate that the process is saturable, as 
following IgG application on the apical surface of the cell layers at varying 
concentrations the increases in the apical IgG concentration beyond a certain level did 
not produce an increase in basolateral IgG amount (Figure 7.7). Such transport 
saturation with an increasing concentration of the ligand indicates a receptor-mediated 
process; this phenomenon would not be exhibited by a non-specific mode of transport, 
such as passive paracellular movement.  
 
To further confirm that IgG transport in Calu-3 layers is receptor-mediated, rabbit IgG 
(rIgG) was used in the transport experiment. rIgG has previously been shown to 
possess an ability to bind to human FcRn (38). However the analytical method used to 
quantify IgG in the transport experiment was specific to human IgG only and could 
not detect rIgG. Therefore, the rIgG in effect acted as a competitive inhibitor. 
Importantly, data from this experiment showed that co-application of excess rIgG 
with (human) IgG suppressed the apical-to-basolateral transport of the latter, 
suggesting again that the transport of (human) IgG across the Calu-3 cell layers is 
indeed mediated by FcRn.  
 
The difference in the amount of IgG transported across the Calu-3 cell layers between 
different experiments (namely the experiment detailed in section 7.3.3.1 with those in 
sections 7.3.3.2 and 7.3.3.3) must be noticed. The reasons for the observed 
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discrepancy (approximately 4.8-fold) are not clear at the present moment. What can 
be highlighted as a potential cause is that the cells used in the experiments described 
in the former section were of a considerably lower passage number (passage 23) and 
of a different batch compared to those in the latter sections (passages 43-44). 
 
An interesting finding was encountered following the comparison of IgG transport in 
Calu-3 and Caco-2 cells. In the monolayers of the Caco-2 cell line, the maximal level 
of IgG found in the basolateral solution following its addition on the apical side was 
markedly lower compared to those measured in Calu-3 layers. This is particularly 
interesting considering that Calu-3 cells used in the studies were grown under AIC 
conditions where the presence of mucus may have potentially presented a barrier to 
IgG transport, compared to non-mucus producing Caco-2 cells. It may be possible that 
the observed inter-cell line difference in IgG transport is a result of variations in the 
extent of FcRn expression in the two cell lines. 
 
At this point it is worth mentioning that experiments comparing the transport of 
FITC-dextrans across Calu-3 and Caco-2 cell layers (section 3.3.3.5) found that the 
extent of permeability of these compounds was notably lower across the Calu-3 as 
compared to Caco-2 cells, hence demonstrating a less restrictive paracellular barrier in 
Caco-2 monolayers (compared to Calu-3 cells). With the receptor-mediated 
transcellular transport of IgG on the other hand, the opposite appears to be the case 
(i.e. higher rate of IgG transport across Calu-3 than Caco-2 monolayers), which is 
further evidence that IgG translocation across the cell layers could not have arisen 
from its movement through the paracellular pathway. 
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While the mechanism of IgG transcytosis in epithelial cells (which was briefly 
discussed in Chapter 1) was not the focus of our work, it is worth highlighting that 
recent studies have attempted to elucidate the intracellular mechanisms involved in 
IgG trafficking in epithelial cells. For example, Sato et al. (36) investigated the effects 
of endocytosis inhibitors on internalization of human IgG by Caco-2 cells and showed 
that IgG uptake was significantly inhibited by a mixture of metabolic inhibitors 
(sodium azide and 2-deoxyglucose). However, the uptake of FITC-IgG at pH 6.0 was 
not inhibited by clathrin-dependent endocytosis inhibitors (phenylarsine oxide and 
chlorpromazine) and caveolin-dependent endocytosis inhibitors (nystatin and 
indomethacin). In contrast, macropinocytosis inhibitors such as cytochalasin B and 5-
(N-ethyl-N-isopropyl) amiloride significantly decreased its uptake. This study 
therefore showed that FcRn-mediated internalization of IgG in human intestine most 
likely occurs by a process other than clathrin- and caveolin-dependent mechanisms. In 
another recently-published study, Tzaban et al. (39) showed that in polarized cells 
FcRn is sorted by the recycling endosomes (RE) into distinct recycling and 
transcytotic pathways in a strongly polarized manner. The authors observed that FcRn 
localizes to the RE, and that MyoVb and Rab25 regulate a sorting step that specifies 
transcytosis for FcRn in both directions without affecting their recycling.  
 
Perhaps the most clinically relevant study investigating the prospect of delivering 
protein therapeutics via the IgG/FcRn pathway is that by Dumont et al. (17) In this 
study, the authors investigated whether FcRn can mediate the absorption of Fc-fusion 
proteins through the lung by administering erythropoietin fused to Fc (EpoFc, MW 
112 kDa) to 22 healthy male volunteers. EpoFc was deposited into the central lung at 
doses of 3, 10 or 30 µg/kg. A dose-dependent absorption through the lungs was seen, 
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wich achieved maximal serum concentrations of 0.2, 1.2 and 7.1 ng/ml, respectively. 
Furthermore, Low et al. (16) tested the absorption of FSHÐFc fusion proteins (MW 
94.5-128 kDa) following the pulmonary delivery in four cynomolgus monkeys. The 
authors demonstrated maximum serum concentrations of FSHÐFc fusion proteins 
between 69 and 131 ng/ml.  
 
FcRn-mediated delivery of protein therapeutics has however been criticised in the 
literature for its low delivery capacity, with Sakagami and co-workers arguing that 
this strategy is promising for pulmonary delivery of highly potent proteins only (34). 
Indeed when one considers the above-mentioned studies in humans and non-human 
primates, it can be noticed that maximal serum concentrations achieved were 
approximately 7 ng/ml and approximately 130 ng/ml for Epo and FSH (Fc 
constructs), respectively. However, most biologics in the market, including the 
immunoglobulin-based therapeutic molecules, require plasma concentrations in mg 
range, as exemplified by the following tumor necrosis factor (TNF) antagonists. 
Infliximab [Remicade, a chimeric (human-murine) monoclonal IgG1], which is used 
in the treatment of Crohn's disease and rheumatoid arthritis requires plasma trough 
concentrations above 1 µg/ml for a clinical response (40). The pharmacokinetic data 
of Adalimumab (Humiraª, a recombinant human monoclonal IgG1 used in 
rheumatoid arthritis and psoriasis) and Etanercept (Enbrel¨, a dimeric fusion protein 
consisting of the extracellular ligand-binding portion of the human TNF receptor, 
linked to the Fc portion of human IgG1) indicated average steady state therapeutic 
plasma concentrations of 5.5±2.5 mg/L and 1.78-1.88 mg/L, respectively (41). 
Therefore, if the use of the IgG/FcRn pathway is to be considered for pulmonary 
delivery of currently marketed biologics, and those requiring similar plasma 
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concentrations for clinical response, there is indeed a necessity for an improvement in 
absorption capacity.  
 
Assessment of IgG transport across the Calu-3 layers in this work indicated a 
transport capacity ranging from 9-45 ng per cm2 per hour [estimated by dividing the 
amount of IgG transported in 1 hour by the cell layer area (1.1 cm2)]. Assuming that 
IgG absorption across the bronchial mucosa in vivo occurs to a similar extent (in 
terms of amount per surface area per time) and with a surface area of human bronchi 
of 1300 cm2 (42) one could extrapolate that an absorption capacity of approximately 
12 µg-59 µg per hour is potentially achievable through the FcRn pathway in vivo. 
However, one must exercise caution with this hypothetical projection. Drug transport 
across the pulmonary mucosal surfaces in vivo, where factors not present in the 
epithelial cell layer model (e.g. mucociliary clearance, extracellular tissue, etc.) will 
undoubtedly play a role in the transport process, is more than likely to be different to 
that across the epithelial cell culture models. Furthermore, it is not clear whether 
FcRn expression in vivo in cells lining the bronchial tubes is similar in extent to Calu-
3 cells and whether regions of the lung other than bronchi also contribute towards 
FcRn-mediated transepithelial transport. Finally, in the in vitro experiments presented 
in this thesis, IgG was in contact with the cell layers and therefore available for 
transport for a relatively long period of time (2-3 hours). However, this scenario is 
unlikely to occur in vivo, where a functional mucociliary mechanism (43) may 
potentially clear a proportion of the administered FcRn-targeted therapeutic molecule 
(if the administered formulation is entrapped within the mucus layer and less so if the 
therapeutic traverses the mucus layer in a short period of time). Nevertheless, as 
pointed out previously, in addition to the bronchial epithelium, other segments of the 
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lung may participate in FcRn-mediated transport (including alveolar epithelium with 
its huge surface area), contributing to the overall absorption. 
 
The present work investigated whether it would be potentially possible to improve the 
absorption capacity of a receptor-mediated pathway by employing nanoparticulate 
carriers. In the case of IgG/FcRn pathway, such a nanocarrier would be surface-
decorated with IgG or Fc, exploiting transport via FcRn, while the therapeutic 
macromolecules will be encapsulated (and protected) within the interior of these 
carriers. Surface adsorption of the therapeutic biologic to the nanocarrier (alongside 
IgG or Fc), providing that it does not hinder the binding of surface-adsorbed IgG (or 
Fc) to FcRn, is another possibility. The therapeutic-incorporated/adsorbed carrier 
would then be transported transmucosally through the FcRn transcytotic pathway, not 
as individual molecules, but as a number of therapeutic molecules in the NP carrier 
system.  
 
To the best of our knowledge there are no published studies investigating the potential 
of FcRn pathway for mucosal transport of NPs. Furthermore, it was not clear at the 
beginning of the study whether the association of NPs with IgG, or Fc, affects the 
transcytotic process by which FcRn normally transports free IgG. It must be 
highlighted that polystyrene NPs were used as nanocarrier models, due to the 
convenience of their availability in different sizes, different surface modifications and 
fluorophores (allowing imaging and quantification). IgG or Fc was not chemically 
conjugated to the NPs; these molecules were instead physically adsorbed on the NP 
surface, taking advantage of their ability to adsorb non-covalently and almost 
irreversibly onto the surface of polystyrene NPs (44, 45) through hydrophobic 
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interactions. Hydrophobic sorption of IgG to the NPs was assumed to occur 
randomly, as shown in previous studies for polystyrene NPs (46, 47) with 
immobilised IgG adopting random geometries, including those that potentially permit 
binding of the immobilised protein to the receptor.  
 
Characterisation of NPs for their size by dynamic light scattering (DLS) revealed that 
IgG-adsorbed NPs had mean radii of 220 nm, as compared to mean radii of 
approximately 21 nm observed for unmodified ('naked') NPs. It must be noted that the 
observed size for IgG-NPs was considerably larger than expected from the protein 
adsorption process if one would make the following assumption with regards to 
adsorption of IgG to NPs. Small angle X-ray scattering data show that the leg of the 
T-shaped IgG has a length of 58  (5.8 nm) (48). Therefore, a maximal increase in 
the diameter of NPs by 11.6 nm would be expected to occur following the 
immobilisation of IgG molecules on the surface of NPs as a single layer. Following 
the adsorption of IgG to gold nanoparticles, Khlebtsov et al. (49) found that the 
thickness of adsorbed layer of IgG was equal to 5Ð6 nm. However, in our work, the 
larger than expected change in NP diameter following the adsorption of IgG on their 
surface is, perhaps, not surprising given the tendency of IgG to aggregate in solution 
(50), which could occur before its immobilisation on the NPs, resulting in adsorption 
of large aggregated complexes, and/or after its binding to the NPs. Furthermore, 
adsorption of the weakly charged IgG on the surface of negatively charged 
polystyrene NPs may have resulted in diminished colloidal stabilisation of the NPs 
due to a reduction in surface charge repulsion.  
 
Nevertheless, adsorption of Fc fragment of IgG onto NPs instead of whole IgG 
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produced smaller NPs having mean radii of approximately 60 nm (i.e. 120 nm 
diameter) (Figure 7.10). Such a nanoparticulate system is also expected to potentially 
bind to the FcRn receptor and undergo transcytosis, as it is the Fc portion of IgG that 
bings to FcRn and is subsequently transcytosed (27). Furthermore, with a mean 
diameter of 120 nm, Fc-adsorbed NPs are probably still ameanable to cell endocytotic 
processes (51). 
 
Determination of cellular uptake of NPs by visualization through confocal microscopy 
revealed that IgG-immobilised NPs were found in the interior of the cells, suggesting 
their uptake by the cells. Furthermore, and highly important for this study, co-
localisation of fluorescence from FITC-IgG with that of red NPs was observed, 
suggesting that IgG remains associated with the NPs following their uptake by the 
cells. The confocal images further showed that IgG-NPs were largely found inside the 
cells as micron-sized structures/aggregates, in addition to smaller, nano-sized 
particles.  
 
In the case of Fc-adsorbed NPs, observed punctate fluorescence resulting following 
their application to the cells suggested that NPs in this case were smaller than IgG-
NPs (Figure 7.11), though some large complexes were also observed for Fc-NPs 
(Figure 7.12). This is in agreement with the DLS data. Fc-adsorbed polystyrene NPs 
localised within the interior of Calu-3 cells following their incubation with the cell 
layers. Importantly, and similarly to FITC-IgG-NPs, fluorescence from Fc (FITC-Fc) 
was seen to co-localise with that of the NPs (Figure 7.12a), indicating that Fc 
remained associated with the NPs within the interior of the cells. It must be pointed 
out at this stage that the fluorescence intensity of FITC-IgG or FITC-Fc would be 
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expected to decrease when present in an acidic environment (due to pH sensitivity of 
FITC), such as that within endosomes. This may be a possible explanation for the 
somewhat lower observed fluorescence in the green confocal channel (FITC-Fc) 
compared to the red channel (NPs) in the case of FITC-Fc-NPs (Figure 7.12a).  
 
Also cruically, NPs were in some cases observed uniformly throughout the vertical 
axis of the cells, including below the level of the TJs (Figure 7.12a) and at the level of 
the Transwell¨ filter (Figure 7.12b), suggesting their translocation across the cells. 
Furthermore, staining of the cells for lysosomes revealed that Fc-coated NPs generally 
did not co-localise with the lysosomes, though the result of this experiment must be 
interpreted with caution due to low observed staining.  
 
In addition to qualitative data obtained from confocal imaging, cellular uptake and 
transport of Fc-NPs across the cell layers was also quantified by measurement of NP 
fluorescence. Cellular uptake of Fc-NPs was significantly higher than that of 
unmodified NPs, suggesting that adsorption of Fc on the NP surface promotes their 
cellular uptake. Furthermore, Calu-3 uptake of Fc-NPs was inhibited by soluble 
('free') IgG, implying the likelihood that Fc-NPs were internalized by cells through an 
IgG-specific pathway. This was further confirmed by the experiment where the effect 
of non-fluorescently labelled Fc-NP on cell uptake of fluorescently labelled Fc-NPs 
was tested. This experiment was conducted to induce competitive receptor inhibition 
by presenting the competing ligand to the cells in the same manner as the tested 
ligand. Data obtained clearly showed that non-labelled Fc-NPs significantly reduced 
the uptake of traceable (fluorescently-labelled) Fc-NPs, suggesting that Fc-NP 
internalisation is a saturable process.  
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In agreement with the uptake data, Fc-immobilised NPs were seen to traverse the cell 
layers in a larger extent than unmodified NPs, suggesting that, in addition to 
promoting their cellular uptake, coating of NPs with Fc facilitates their transport 
across the cell layers. Inhibition of Fc-NP transport across the cell layer barriers by 
soluble IgG and by non-labelled Fc-NPs indicates the involvement of the IgG 
transport pathway in the transepithelial movement of Fc-NPs and that this transport is 
saturable.  
 
Final experiments tested the effect of NP coating with an investigational therapeutic 
antibody fragment (Fab, CTM01), with or without Fc, on their transport across the 
cell layers. This was done to determine whether coating of NPs with a protein other 
than Fc facilitates their transport across the cells and also to test the potential of the 
Fc-NP carrier system to transport therapeutic macromolecules across the epithelial 
barriers. It was found that co-adsorbing the therapeutic Fab with Fc on the surface of 
NPs significantly improved their transport across the cell layers to levels very similar 
to those observed with Fc-NPs. In contrast, NPs coated with the Fab only were seen to 
traverse the cell layer barriers in a considerably less efficient fashion. Furthermore, 
testing the filter plastic for the presence of NPs (after the transport study) revealed 
that Fc-adsorbed NPs associated with the filters to a significantly larger extent than 
Fab-adsorbed NPs, indicating a greater apical-to-basolateral translocation of NPs with 
surface-adsorbed Fc. 
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7.5 Conclusion 
Using the Calu-3 epithelial cell model, which is shown to express FcRn, this work 
investigated IgG transport across the cells and the potential of this route for 
transepithelial delivery of NPs. IgG was found to traverse the Calu-3 layers in a 
fashion that strongly suggested FcRn involvement. Furthermore, adsorption of Fc on 
the surface of NPs was seen to promote their cellular uptake and transport across the 
cell layers. Experiments investigating the cellular uptake and transport of Fc-NPs 
revealed data suggestive of FcRn involvement in this process. This work therefore 
shows that the IgG/FcRn transcytotic pathway offers potential for mucosal delivery of 
protein and NP-based therapeutics.  
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Chapter 8 
Summary and Future Directions 
 
8.1 Overall Summary 
Mucosal surfaces offer a potential for non-invasive delivery of biotherapeutics, 
including peptides, proteins and antibodies. However, these surfaces are naturally 
designed to limit the movement of material from the external environment (mucosal 
lumen) into the systemic circulation. A mucosally administered protein therapeutic 
has to overcome many barriers, physical and biochemical, if it is to reach the systemic 
circulation. These barriers were discussed in Chapter 1 and include mucus and the 
mucociliary clearance mechanism, protease enzymes, the inter-epithelial tight 
junctions (TJs) and the cellular membranes.  
 
Investigating mucosal drug absorption in vitro requires models of the mucosal 
surface(s) of interest. In this respect, several options exist and each system is 
associated with its advantages and drawbacks. Mucosal models based on epithelial 
cell layers minimise animal usage and are extensively used (in academia and the 
pharmaceutical industry), with a demonstrated record of in vitro-in vivo correlation 
(as discussed in Chapter 3). 
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The Calu-3 cell line was selected in this work as a model of the airway epithelium. 
One of the advantages of using the Calu-3 cell line as an in vitro mucosal model is its 
capacity to produce mucus when cultured under appropriate conditions. In this thesis, 
initial work focused on establishing and characterising the Calu-3 cell layer model. 
Data shown in Chapter 3 demonstrated that, following their growth on filters under 
air-interfaced culture (AIC) conditions, Calu-3 cells form polarised layers of closely 
packed cells exhibiting a TEER >500 Ωcm2. Cells exhibited structural features that 
resemble the native epithelium, including the TJs, the microvilli and the secretory 
granules. Cell layers presented a barrier to the permeability of FITC-dextrans (FDs, 
paracellular markers), with the magnitude of the barrier being proportional to the MW 
of the marker and larger than that observed with Caco-2 monolayers. Furthermore, 
Calu-3 layers presented a significant barrier to the movement of nanoparticles (NPs). 
 
Following characterisation of the Calu-3 layer model, several strategies were 
investigated in an attempt to improve the transport of macromolecules (FDs were 
used as macromolecular drug models) across the cell layers. The first class of 
compounds to be tested were alkylglycoside (AG) surfactants. Data obtained with 
three representative AGs, illustrated that these compounds exhibited severe toxicity 
(shown by three different toxicity assays) towards Calu-3 cells (and also HT29 cells), 
even after their use at considerably lower concentrations than those reported in the 
literature (Chapter 4). Furthermore, data indicated that the cellular toxicity of AGs is 
possibly a result of a disruptive effect on membranes. Although the use of AGs as 
absorption enhancers has been commercialised (the drug delivery platform of Aegis 
Therapeutics is based on these compounds), it must be noted that literature 
information on their mucosal toxicity in vivo or epithelial cell lines in vitro is 
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surprisingly limited. Considering their adverse toxic effects on cells, further studies 
evaluating the absorption enhancing potential of AGs were deemed inappropriate. 
 
The experiments detailed in Chapter 5 investigated the effect of extracellular calcium 
depletion on TJ modulation. More specifically, the aim of the work presented in this 
part of the thesis was to investigate the conditions under which exhaustion of 
extracellular calcium produces the greatest effect on TJ opening. Calcium depletion 
has long been known to induce opening of the TJs, resulting in increased transport of 
macromolecules through the paracellular route. However it is unclear from the 
literature whether this strategy can be used to improve the absorption of 
macromolecular therapeutics in the in vivo settings, where removal of extracellular 
calcium (through the mucosally administered absorption enhancer) is likely to occur 
predominantly on the luminal side. The data presented in this chapter suggested that 
depletion of calcium on the apical side produced limited TJ modulation, although with 
a more sustainable depletion the effect was somewhat more pronounced. On the other 
hand, apical and basolateral calcium removal produced large effects on TJs, but this 
scenario is probably irrelevant in an in vivo situation, making calcium depletion an 
ineffective strategy for mucosal delivery of therapeutic macromolecules. 
 
Thereafter, two formulations of chitosan, namely solution and chitosan in the form of 
NPs, were investigated for their effect on epithelial TJs and therefore their potential 
use as mucosal absorption enhancers. Observations noted in Chapter 6 demonstrated 
that chitosan NPs formulated by the ionic gelation method, at a concentration 
exhibiting low toxicity, displayed a similar TJ-opening effect to chitosan solution. 
This was shown by a similar reduction in TEER, FD4 permeability and an effect on 
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the TJ protein, ZO-1. This work therefore indicated that chitosan NPs could 
potentially be used to carry and protect fragile therapeutic macromolecules to the 
mucosal surface of interest and at the same time promote their absorption through TJ-
opening. These results are of significance as, although a large number of published 
studies on chitosan (as a mucosal absorption-promoter) exist, only a few of these 
studies have reported TJ opening by chitosan NPs.  
 
Significant progress has been made recently in understanding the function of 
epithelial TJs at the molecular level. This has enabled targeting of specific TJ 
components in an attempt to improve mucosal absorption of macromolecules. 
Examples include the study by Dutzar et al. (1), in which siRNA knock down of 
different TJ proteins was used to test the effect on permeability. However, it must be 
noted that while TJ opening appears to be an attractive strategy to facilitate mucosal 
absorption of macromolecules, caution must be advocated, as the long-term 
physiological consequences of repeated TJ-opening are unknown (2). 
 
Furthermore, while it is potentially feasible to achieve mucosal absorption of smaller 
peptides and proteins by opening the epithelial TJs (provided this does not have any 
adverse long term consequences), this strategy becomes inefficient for larger 
macromolecules such as antibodies, or for nano-sized drug carriers. Moving away 
from TJ modulation, work presented in Chapter 7 investigated the potential of a 
transcytotic pathway for mucosal delivery of macromolecules. Very few transcytotic 
pathways are known to exist in epithelial cells and endocytotic activity at the apical 
plasma membrane of epithelial cells is low, which is logical considering the crucial 
physiological role of epithelia in filtering and repelling foreign substances in order to 
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protect cells and organs (3). Of these, the IgG/FcRn pathway has been studied and 
shown potential for use in transmucosal delivery of protein therapeutics.  
 
Investigation of FcRn expression by immunofluorescence showed that Calu-3 cells 
express FcRn. IgG was shown to traverse the Calu-3 layers and studies characterizing 
this transport strongly indicated FcRn involvement in the process. In order to establish 
whether the IgG/FcRn pathway could potentially be hijacked to deliver nano-sized 
drug carriers, IgG or Fc was immobilised on the surface of model NPs and their 
cellular uptake investigated by confocal microscopy. This work revealed that IgG- or 
Fc-coated NPs were taken up by Calu-3 cells, with NPs clearly observed within the 
interior of the cells and, in some cases, at the level of the Transwell¨ filters. 
Adsorption of Fc on the surface of NPs was seen to promote their cellular uptake and 
transport across the cells, as measured by fluorescence. Characterisation of cell uptake 
and transport of Fc-NPs revealed data suggestive of FcRn involvement in this process. 
This work therefore showed that the IgG/FcRn transcytotic pathway offers potential 
for mucosal delivery of macromolecules and nanoparticulate-based therapeutics.  
 
8.2 Future directions 
The problem of overcoming the barrier presented by the mucosal surfaces in 
delivering protein therapeutics through this route is being extensively researched. The 
increase in number of macromolecular biotherapeutics on the market, will 
undoubtedly be followed by research into their mucosal delivery. Research that is 
producing a rapid expansion in biologics, is likely to increase the number of highly 
potent protein drugs, which would make good candidates for mucosal administration. 
Furthermore, research is likely to lead to reductions in the cost of pharmaceutical 
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ingredients based on biologics making routes of administration that achieve modest 
bioavailabilities (such as mucosal administration) more acceptable. Yet another point 
to make is that, in addition to the obvious advantages of improved patient 
acceptability (and therefore compliance), and reduced administration cost and risk to 
the patient, the development of drug delivery technologies for mucosal administration 
can also potentially extend the patent lifetime of drug products, providing an incentive 
to the pharmaceutical industry.  
 
In terms of early-stage research in the area of mucosal delivery of protein drugs, new 
research tools have become available which may accelerate progress within this field. 
Examples include molecular biology techniques used by some groups (mentioned 
previously) to identify TJ proteins essential in maintaining the barrier property of the 
epithelium. Another particularly exciting research strategy in the area is the use of 
phage display libraries to identify specific molecules (normally peptides) with 
inherent epithelial translocating properties.  
 
To conclude, non-invasive administration of protein therapeutics is currently far from 
being a widely available option for the patient. However, the ever-increasing number 
and use of biologics is likely to increase research into their non-invasive delivery, 
which in turn is expected to produce progress within this field. 
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